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 1 
The global burden of cancer continues to increase largely because of the aging and 
growth of the world population, alongside an increasing adoption of cancer-
causing behaviors, particularly smoking, in economically developing countries. 
Cancer causes about a quarter of all deaths in developed countries, only slightly 
less than cardiovascular diseases. The incidence started to increase early in the 
20th century owing partly to increasing longevity and reduction in deaths from 
other serious illnesses, which gives tumours more time to develop. One in three 
people will develop cancer at some time. Part of the increase is also undoubtedly 
due to environmental features of industrialized life, such as atmospheric pollution, 
smoking and diet. There are wide variations in the incidence and prevalence of 
cancer for different anatomical sites, sexes, ages, and racial, ethnic and 
geographical groups. Almost certainly, cancers form a heterogeneous group of 
diseases with multifactorial causes. Individuals may have an inherited 
predisposition, but this may never be expressed unless an appropriate combination 
of environmental triggers is met. Chemicals seem to be the chief culprits. Actually 
smoking is by far the largest single contributor, although a wide variety of 
industrial carcinogens have also been positively identified. Dietary factors are 
increasingly seen as important factors, although the specific carcinogenic 
constituents remain largely unknown. Drugs may also cause cancer in a number of 
ways. Hormones, especially the sex hormones (e.g. oestrogens), may encourage 
tumours in hormone-dependent tissues. Finally the possible contributions of 
immunological factors, trauma (e.g. local irritation) and psychosocial factors are 
unknown.
1-4 
 
Cancer is the general term for a group of disorders caused by the abnormal and 
unrestricted growth of cells. Each primary tumour derives from a single aberrant 
cell following mutation. The term neoplasm (‘new growth’) describes this 
tendency to excessive, uncontrolled growth. 
Benign tumours enlarge but do not invade surrounding tissue; they are generally  
less dangerous than malignant tumours, which invade local tissues and also spread 
to distant sites (metastasis) due to their lower adhesiveness to their basement 
membrane. Malignant tumours are predominantly carcinomas (epithelial origin, 
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e.g. adenocarcinoma), sarcomas (connective tissue, e.g. osteosarcoma) or 
leukaemias (haematological). 
During the growth phase of an organism, cell proliferation clearly exceeds cell 
death, but subsequently cell numbers remain relatively stable throughout mature 
life. However, tissues retain the ability to proliferate in response to either 
physiological demands or losses (e.g. bone marrow, gut lining) or pathological 
ones (e.g. injury). Thus, in most tissues there is a reservoir of stem cells, which 
remain dormant until their division is needed to provide either replacement stem 
cells or more functional differentiated (end) cells. Cancer involves uncontrolled 
division and impaired differentiation, and because stem cells are both 
incompletely differentiated and still capable of division, neoplasms generally 
derive from stem cells. Stem cells need a signal telling them when they have to 
divide and to stop, and the daughter cells need to know whether or not they have 
to differentiate. All these cells respond to a complex network of cytokines with 
growth stimulant or growth inhibitory properties. Some cells release autocrine 
factors that act on receptors on their own surfaces. Numerous growth factors 
specific for particular cell types are known, e.g. platelet-derived growth factor 
(PDGF), firoblast growth factor (FGF), epidermal growth factor (EGF), Vascular 
endothelial growth factor (VEGF) erythropoietin (EPO), Thrombopoietin (TPO), 
granulocyte colony stimulating factor (G-CSF). Some tumors also secrete their 
own transforming growth factors (TGF), which closely resemble EGF. Generally 
these are growth stimulants and they may be secreted in excess in some cancers. 
Other factors are growth inhibitors and are presumed deficient in cancer. 
Insensitivity to local growth control mechanisms has long been recognized as a 
characteristic feature of neoplastic tissue. This breakdown in control may involve 
abnormal secretion of growth factors, an abnormality in growth factor receptors, 
or abnormal signaling between the cell surface receptors and nuclear receptors 
coding for growth or differentiation. It is known that the genes coding for 
mitogenic proteins or their receptors can become expressed inappropriately 
(amplified). They are known as cellular oncogenes.. Human oncogenes are 
normally present but repressed. When activated for proliferation, they code for 
growth factors, or growth factor receptors, or other mitogenic promoters. These 
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factors are essential for a cell’s entry into the cell cycle and movement through it 
as a prelude to cell division. The expression of oncogenes is strictly controlled and 
turned off when no further growth is required. Besides ‘anti-oncogenes’ (tumour 
suppressor genes) may be expressed to control excessive cell growth.  A 
neoplastic transformation may result in abnormal proliferation by different 
mechanisms: a carcinogen may cause the inappropriate expression of a human 
oncogene, often by mutation of a controlling gene such as a repressor gene; viral 
oncogenes might mimic activated human oncogenes or an anti-oncogene (or 
tumour suppressor gene) may malfunction through mutation, permitting 
neoplastic transformation. 
The most common forms of cancer occur in epithelial tissues The epithelial 
tissues are separated from the underlying connective tissue, blood and lymphatic 
vessels and nerves by a basement membrane. Neoplastic epithelium tends to show 
structural differences when compared with the normal architecture of the tissue 
within which the tumor originated. The architecture of neoplastic tissue is not 
organized and neoplastic cells are distinguished from normal cells by a loss of a 
cellular differentiation.  
Cells are well differentiated if they have a similar morphology to the cells that are 
generally present in the origin tissue and maintain physiological functions. The 
reduction in differentiation is an important feature of malignat neoplasm, and it is 
referred to as anaplasia, characterized by morphologic and functional changes at 
cellular level. The cells and their nuclei show also variation in size and shape, 
which is called pleomorphism. Neoplastic cells generally have large amounts of 
dark staining DNA that take up an exceptionally large proportion of the total 
volume of the cell. These neoplastic cells may also show evidence of frequent cell 
divisions, indicating rapid cellular proliferation. Evidence for cellular proliferation 
might include the presence of large nucleoli and large numbers of mitoses.
 
Microscopic studies of cells also show evident changes in the cellular 
cytoskeleton, which is generally composed of actin fibers. The cytoskeleton is a 
three dimensional network of this filamentous protein that fills the space between 
organelles and gives shape and structure to cells. These actin cables are connected 
to receptors on the cell surface, which in turn anchor the cell to the intracellular 
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matrix. In cancer cells, these actin cables are either lost or become disorganized 
and the cancer cells lose their adherence to the intracellular matrix.  
Neoplasms, as above described, are classified as either benign or malignant based 
on a number of important characteristics.  Benign neoplasms are usually well 
differentiated, they tend to be self-contained and have definite margins.  
Malignant neoplasm, that range from well differentiated to poorly differentiated, 
are more invasive. They expand in a very disorganized way, their margin is 
indistinct and they cause considerable disruption to the surronding environment. 
This process is aided by the secretion of proteases (proteolytic enzymes such as 
matrix metalloproteinase) from tumour cells, which facilitate their passage 
through basement membranes and into the extracellular matrix of local connective 
tissue.  
Benign neoplasms tend to grow at a relatively slow pace and may take years to 
develop into a significant mass. Malignant tumors generally tend to grow faster, 
with growth rates inversely correlated with the degree of differentiation. A 
measure of tumor growth is the “Doubling time”, that is the amount of time that 
the tumor needs to double its mass. Benign tumors usually have long doubling 
times, whereas the doubling time for malignancies can be quite short. Benign 
tumors, which are encapsulated by connective tissue, tend to remain confined 
within the tissue of origin. Malignant tumor may gain the ability to penetrate the 
basement membrane, a thin layer of mucopolysaccharides and proteins that covers 
a surface, lines a cavity, or divides a space or organ. This ability to penetrate the 
basement membrane leads to local invasion and destruction of adjacent tissues. 
Migration of neoplastic cells away from the primary tumour to distant sites is the 
key stage in malignancy. Almost all mortality from cancer is associated with 
metastatic deposits. Metastasis can occur through a number of mechanisms, 
including the direct extension of tumor into various natural body cavities, such as 
the peritoneal cavity. The most common mechanism of metastasis is the 
penetration of nearby lymph nodes and blood vassels and, in this way, the tumor 
can move to other vital organs. 
 There are two important stages: 1) the primary cell mass loses adhesion and 
escape 2) the cell arrests at a distant site. The most important cell adhesion 
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molecules (CAMs) are cell surface-transmembrane molecules known as 
cadhedrins. They participate in the maintenance of proper cell-cell contacts. 
Cadherins act as both receptors and ligands. They also play a fundamental role in 
maintaining the integrity of multicellular structures. Reduced activity of these 
molecules, owing to gene down-regulation, allows some cells to escape. 
Migrating cells then become trapped by other adhesion receptors called integrins, 
which are normally involved in localizing cells who take part in defence 
mechanisms, e.g. leucocytes. Integrins are the major group of proteins mediating 
adhesive interactions between cells and ECM (extracellular matrix) proteins.  
Metastases usually grow considerably faster than their parent primary tumour, 
partly because they are smaller and thus better perfused. In patients who have 
been exposed to previous chemotherapy they also tend to be more chemoresistant. 
The metastatic cancer cells spread all over the body by invading new blood 
vessels formed by tumor angiogenesis or by entering existing blood and lymphatic 
vessels. The metastatic cells enter and leave the circulatory system by excreting a 
number of substances that break the vessel wall.
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Current therapies
5-8 
The current therapy for the treatment of cancer includes: 
 Surgery ( excision of primary tumour ). 
 Radiotherapy. 
 Pharmacotherapy (cytotoxic chemotherapy, endocrine therapy, 
biological therapy, immunotherapy, gene therapy). 
Surgery may be used to help to diagnose some cancers. The surgeon removes a 
small piece of tissue, which is used to confirm the diagnosis of cancer and to find 
out about the type of cancer. This is called biopsy. The sample is then examined 
in laboratory. Surgery is usually the most appropriate treatment for solid tumors 
which remain localized. Where possible, surgery is used to remove the tumour 
and surrounding tissues that may contain cancer cells. However, surgery may 
inadvertently facilitate metastatic spread, displacing tumour cells and liberating 
them into the local circulation or lymph.  
Radiotherapy is suitable as primary therapy in some local tumours when surgery 
is inappropriate or it can be used in association with surgery or pharmacotherapy. 
There are two different types of radiotherapy: there is an external radiotherapy, 
that uses high energy x-rays, and an internal radiotherapy, given by radioactive 
materials placed within the body. The first type consists in the use of high-energy 
ionizing radiations, the second one consists in the systemic administration of 
radioisotopes. Radiotherapy works by destroying cancer cells in the area that is 
treated. Although normal cells can also be damaged by radiotherapy, they can 
usually repair themselves. Radiotherapy can cure some cancers and can also 
reduce the chance of a cancer coming back after surgery. It may also be used to 
control a cancer or improve the symptoms of it.  
Pharmacotherapy is based on the systemic administration of drugs treating both 
the localized and the metastatic tumors. Pharmacotherapy disrupts the way cancer 
cells grow and divide but it can also affect normal cells. Generally 
pharmacotherapy is combined with other treatments (surgery, radiotherapy..). 
The ideal antineoplastic drug would have completely selective toxicity for 
neoplastic cells. Unfortunately, save for one minor exception, human neoplastic 
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cells do not differ in any qualitative biochemical way from normal cells. The 
pharmaceutical research is always trying  to identify new drugs which are able to 
act selectively on the injured tissues. For this reason differences between normal 
and neoplastic tissues have to be carefully exploited. For example we know that 
neoplastic tissues have different growth parameters, which are amenable to 
cytotoxic intervention; we have understood that the growth of some neoplasms is 
sensitive to natural hormones and other growth factors and that some cell signal 
transduction pathways are activated to a different (greater or lesser) degree in 
neoplastic cells. Moreover the comprehension that genomic expression may be 
inappropriate in neoplastic cells, made cancer cells to be the targets for gene 
therapy and biological agents that interfere with gene expression. Finally 
neoplastic cells may express a different immunological phenotype, making them a 
target for immunological agents. 
It is usual to distinguish the traditional relatively unselective cytotoxic agents, 
which act on nucleoproteins within the nucleus, from newer biological agents that 
act primarily on cell signaling and cytokines within the cytoplasm or on the cell 
surface. The former kill cells, hence the name cytotoxic; the latter tend to be 
cytostatic, inhibiting further growth but not necessarily killing the cell. 
 
-Cytotoxic Chemotherapy 
The cytotoxic therapy is based on the principle that tumours are often more 
sensitive to agents that interfere with the biochemistry of cell division (a greater 
proportion of neoplastic cells being affected than those in normal tissue) and that 
tumour tissues usually do not recover as rapidly as normal tissues from such 
interference. There are two important aspects of the action of the cytotoxic drugs: 
the biochemical mode of action (pharmacological classification) and the cell cycle 
phase or phases when they are active (cytokinetic classification). The most of 
cytotoxic drugs act within the nucleus to kill cells by interfering with the 
production or structure of nucleic acid, or occasionally protein. Cell death 
following exposure to cytotoxic action (and to radiation) is due to the triggering of 
apoptosis. 
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- Biological Therapies 
 Biological therapies are treatments that act on processes in cells and consist in the 
administration of living organs, substances derived from living organs, synthetic 
substances or substances produced by the organism itself, to stimulate and 
reactivate the immune system, so that it can be able to attack cancer cells. These 
therapies may stop cancer cells from dividing and growing or seek out cancer 
cells and kill them. Following discoveries in molecular biology about the control 
of cell cycle events it became clear that certain signaling pathways controlling 
growth and differentiation were excessively activated in various tumours.  
Although these pathways are part of normal cell growth and they are present in all 
dividing cells including the bone marrow, they are relatively more prominent in 
neoplastic cells. Cell cycle is a finely controlled mechanism, made of different 
steps. When a gene that regulates the cycle undergoes a mutation, the cell can 
grow in an unrestrained way and, if repairing systems don’t run, daughter cells 
will proliferate in a not controlled way and give way to tumor. Many of the agents 
developed are humanized monoclonal antibodies aimed to act at specific elements 
of these signalling processes. Other characteristics of tumours, such as their 
propensity to migrate and to encourage neovascularization, are also controlled by 
similar signalling mechanisms. 
 
- Endocrine Therapy  
The growth of certain tissues, especially the sex organs, is hormone-dependent; 
actually hormones play an analogous role to growth factors in cellular growth. By 
manipulating hormone levels, the growth of tumours derived from such organs 
can be reduced, proving that they are still sufficiently differentiated to respond. 
The effect is cytostatic, suppressing further growth rather than killing cells. Thus, 
although endocrine therapy can rarely be curative, it can provide valuable 
remissions or can be combined with other treatments to improve their 
effectiveness. 
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- Immunotherapy 
A neoplastic transformation involves genetic changes. This change in the 
genotype may lead tumour cells to differ immunologically from normal cells. For 
example, they may express abnormal or ‘nonself’ surface antigens or fail to 
express ‘self’ antigens. For this reason many potential tumours may normally be 
aborted by immune mechanisms. The immune system could be manipulated either 
by active stimulation or by developing immunoactive substances such as 
antibodies or immune cells specific for tumour cells.  
 
- Gene therapy 
Gene therapy is the use of Dna as a pharmaceutical agent to treat disease. The 
most common form of gene therapy is based on the use of Dna that encodes a 
functional, therapeutic gene to replace a mutated one or Dna that encodes a 
therapeutic protein drug to provide treatment. Another different approach to gene 
therapy includes the inactivation, or “knocking out,” of a mutated gene that is 
functioning improperly. 
 Dna that encodes a therapeutic protein is packaged within a “vector”, which is 
used to release Dna inside cells. Gene therapy is designed to modify cancer cells 
at molecular level. Cancer is one of the first areas of application of this rapidly 
developing technology. Cells are being experimentally implanted with a variety of 
different genes, based on the observation that neoplastic cells may have escaped 
immunosurveillance, as mutation has prevented them from expressing 
histocompatibility (HLA) antigens. Some tumour cells are implanted (transfected) 
with appropriate HLA gene sequences and then injected into the patient, to enable 
a specific immune response to be mounted against the tumour phenotype. More 
direct genetic manipulation involves either inserting normal tumour suppressor 
genes or disabling the oncogene responsible for the tumour.  
The biology of human gene therapy remains complex and many techniques need 
further development. Many diseases and their strict genetic link need to be 
understood more fully before gene therapy can be used appropriately. The public 
policy debate surrounding the possible use of genetically engineered material in 
human subjects has been equally complex. Although the technology is still in its 
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infancy, it has been used with some success. Scientific breakthroughs continue to 
move gene therapy toward mainstream medicine. 
 
The lack of biochemical specificity is one of the majors drawbacks with cytotoxic 
chemotherapy but the development of drug resistance is equally important. In 
general, resistance is due either to extracellular circumstances that limit drug 
access to the tumour, or to intracellular pharmacological or biochemical factors 
that antagonize cytotoxic action. Recent studies on the p53 gene have suggested 
that treatment resistance may in some cases be associated with defects in this 
gene, possibly because cytotoxic drug-induced apoptosis is prevented. Resistance 
to a range of structurally unrelated cytotoxic agents, multiple drugs resistance 
(MDR), is quite common and is an extremely serious constraint on chemotherapy. 
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Role of kinase proteins in cancer 
 Kinase proteins (PKs) represent a wide family of homologous enzymes, both 
transmembranous and cytoplasmic, that catalyze the transfer of the γ-phosphate 
group from ATP to a hydroxy group of selected target protein substrates.
 
This 
covalent post-translational modification is a pivotal component of normal cellular 
communication and maintenance of homeostasis.
9  
PKs can be divided in two principal classes: Tyrosine kinases (TKs) and Serin-
Threonin kinases (STKs). The first ones catalyze the transfer of the phosphate 
group to the phenolic group of a tyrosine, STKs phosphorylate the alcoholic group 
of a serine or threonine. 
Phosphorylation/ de-phosphorylation are the more common post-translational 
modifications and the more potent mechanism for signalling transduction and 
enzymatic regulation.  
Phosphorylation can regulate the activity of a protein in different ways. For 
example it can lead to the obstruction of the ligand binding site, it can change the 
protein conformation or it can create new binding sites because a ligand can need 
a phosphorylated residue to bind to a specific site.    
Kinases are key regulators of almost all cellular processes, they control the 
activity, localization and overall function of many proteins, they are essential in 
signal transduction and coordination of complex biological functions such as 
growth, differentiation, metabolism and apoptosis, in response to external and 
internal stimuli. Recent advances have demonstrated the role of tyrosine kinases 
in the pathophysiology of cancer. Though their activity is tightly regulated in 
normal cells, they may acquire transforming functions due to mutation(s), 
overexpression and autocrine or paracrine stimulation, leading to malignancy.
 
For 
this reason   kinase proteins represent a valid target in the therapy against cancer. 
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Tyrosine Kinase Receptors (RTKs) 
 
Under physiological conditions, tyrosine phosphorylation represent a fundamental 
signal transduction mechanism that proceeds hierarchically in an ordered 
sequence of protein interactions, ensuring cross-talk between cells and regulating 
key aspects of cell life such as proliferation, differentiation, metabolism, and 
apoptosis.
10  
Receptor tyrosine kinases have been shown not only to be key 
regulators of normal cellular processes but also to have a critical role in the 
development and progression of many types of cancer. 
Approximately 518 genes that codify for PKs, 358 STKs and 90 TK receptors, 
have been identified. Tyrosine kinases are primarily classified as receptor tyrosine 
kinase (RTK) e.g. EGFR, PDGFR, FGFR, and non-receptor tyrosine kinase 
(NRTK) e.g. SRC, ABL, FAK and Janus kinase. Among the 90 genes that codify 
for TKs, 58 codify for receptor TKs and 32 codify for non-receptor TKs. RTKs  
transduce signals from both outside and inside the cell and function as relay points 
for signaling pathways inside the cells. NRTKs are found in the cytoplasm, they 
lack the extracellular domain with the ligand binding site and the transmembrane 
segment, however they have domains that regulate interactions between proteins. 
These interaction domains are called Src homology 2 (SH2) and 3 (SH3). SH2 
domain is characterized by about 100 residues that can interact with 
phosphorylated tyrosines in a very specific way. 
The receptor tyrosine kinases are not only cell surface transmembrane receptors, 
but also enzymes having kinase activity. Among the transmembrane receptor type, 
depending on their different structural features, approximately 20 RTK classes 
have been identified (Figure 1).
11
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Figure 1. Human Receptors Tyrosine Kinase.
11 
 
 
All RTKs have a similar molecular architecture. The structural organization of the 
receptor tyrosine kinase exhibits an extracellular domain, organized into seven 
immunoglobulin (Ig)-like fold; a single pass transmembrane hydrophobic helix 
and a cytoplasmic region that contains the protein tyrosine kinase domain (TKD)  
plus additional carboxy (C-) terminal and juxtamembrane regulatory regions, and 
an activation loop. The kinase domain has regulatory sequence both on the N and 
C terminal end.  The overall topology of RTKs, their mechanism of activation and 
key components of the intracellular signaling pathways are highly conserved in 
evolution.  
 
Mechanism of receptor activation
 
The molecular mechanisms that lead to activation of RTKs are similar for almost 
all the members of the different families but markedly differs in details.  
Tyrosine kinases are enzymes that selectively phosphorylate tyrosine residues in 
different substrates. Receptor tyrosine kinases are activated by ligand binding to 
their extracellular domain. Ligands are extracellular signal molecules (e.g. EGF, 
PDGF etc) that induce receptor dimerization (except Insulin receptor). It is 
important to note that a subset of RTKs forms oligomers even in the absence of an 
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activating ligand.
12,13
 Whether the ‘inactive’ state is monomeric or oligomeric, 
activation of the receptor still requires the bound ligand to stabilize a specific 
relationship between individual receptor molecules in an ‘active’ dimer or 
oligomer. Binding of VEGF occurs to the N-terminal part of the extracellular 
domain of the receptor, and can take place in cis, e.g. by freely diffusible VEGF 
or by presentation of VEGF through co-receptors expressed on the same cell as 
the VEGFR, or in trans, e.g. by presentation through co-receptors expressed on 
adjacent cells. 
Different ligands employ different strategies by which they achieve the stable 
dimeric conformation. One ligand may bind with two receptor molecules to form 
1:2 ligand: receptor complex e.g. growth hormone and growth hormone receptor, 
while in other cases two ligands bind simultaneously to two receptors (2:2 ligand 
receptor complex) and provides the simplest mechanism of receptor dimerization 
e.g. VEGF and VEGFR. Dimerization is stabilized by contact points between 
receptor extracellular domains. Sometimes the complex has to be better stabilized 
by accessory molecules, such as heparin sulfate proteoglycans (HSPG).
 
Ligand-induced dimerization of the extracellular regions of RTKs leads to the 
activation of the intracellular tyrosine kinase domain (TKD) through different 
mechanisms. All TKDs presents a minor lobe (N-lobe),with the function to link 
ATP, allowing γ-phosphate transfer, and a larger lobe (C-lobe), which properly 
orients the γ-phosphate and allows protein substrate interactions. Crystal 
structures of the activated forms of TKDs of RTKs are all very similar while the 
structures of inactive TKDs differ substantially from receptor to receptor, and this 
variation reflects the diversity in their regulatory mechanisms.
14,15
 Each TKD is 
uniquely cis-autoinhibited by a set of intramolecular interactions, that occlude the 
active site, blocking access of ATP and/or protein substrates.
16
 Release of cis-
autoinhibition and subsequent ligand-induced receptor dimerization, is the key 
event that triggers RTK activation and it occurs through an auto-phosphorilation 
process: auto-phosphorylation of the activation loop,
14,15
 of key tyrosines in the 
juxtamembrane region
17,18,
 in the C-terminal tail,
19
 or also trans-phosphorylation 
between dimers,
20
 disrupt the cis-autoinhibitory configuration so that TKD can 
adopt the characteristic active configuration. Therefore, after the dimerization, a 
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region of the cytoplasmatic domain, that generally obstructs the active site, moves 
outward, and this event opens the binding site to the target proteins. 
Once the TKD is activated, additional tyrosines are then autophosphorylated in 
other parts of the cytoplasmic region of most RTKs in a precise order. The 
resulting phosphotyrosines serve as specific sites for the assembly of downstream 
signaling molecules that are recruited to the receptor and activated in response to 
ligand stimulation.
21,22
 These molecules contain Src homology-2 (SH2) or 
phosphotyrosine-binding (PTB) domains, that specifically bind to 
phosphotyrosine and start different signaling cascades. The molecules containing 
SH2 domains have another specific domain that binds to specific regions of target 
proteins. One important example of this cascade is the RTK-Grb2-Sos-Ras/MAP 
kinase pathway. In this case the molecule containing SH2 domain is called Grb2 
(Growth factor receptor-bound protein 2) and this one binds to a region of a 
specific protein called SOS (Son-of-sevenless), that is rich of the aminoacid 
Proline and is a GTP-GDP exchange factor. SOS protein catalyses the activation 
of RAS protein, which can bind to and phosphorylate RAF, that continues the 
cascade activating MEK. Finally this one leads to the activation of MAP kinases, 
that lead to mitosis and cell division.  
Therefore, with multiple phosphotyrosines in most receptors and the involvement 
of numerous docking proteins, activated RTKs clearly can influence a large 
number of different signaling pathways and can lead to the activation or 
repression of various subsets of genes and thus define the biological response to 
signals. An activated RTK can be thought of as a node in a complex signaling 
network that transmits information from the exterior to the interior of the cell. 
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Vascular Endothelial Growth Factors (VEFGs) 
family 
 
The VEGF family and its receptors play an integral role in angiogenesis, 
lymphangiogenesis, and vasculogenesis. There are five structurally related 
mammalian VEGF ligands (VEGF or VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
and placental growth factor; PlGF). Moreover, alternative splicing of their 
corresponding pre-mRNAs generates multiple isoforms of VEGF, VEGF-B, and 
PlGF.
23,24
 The variants bind differently to both VEGFRs and co-receptors and 
therefore induce different biological responses.  
The VEGFs are produced by many different cell types and typically act locally, in 
a paracrine manner. However, VEGFA is produced above all in endothelial cells 
and may act in an autocrine manner on VEGFRs expressed in the same cell.
25
 
All VEGF isoforms are hydrophilic and freely diffusible in simple buffered 
solutions. However, some isoforms contain heparan sulfate proteoglycan-binding 
domains that limit their diffusibility in vivo because of their affinity for anionic 
proteoglycans located on the plasma membrane of cells and in the extracellular 
matrix.
26
 Their release is mediated by extracellular proteases including plasmin 
and matrix metalloproteases.
27
 
VEGFs are five homodimeric glycoproteins containing a cystine knot motif that is 
essential for establishing the tertiary structure
 
(Figure 2).
28
 
VEGF binds to the second immunoglobulin domain of VEGFR1 and the second 
and third immunoglobulin domains of VEGFR2.  
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Figure 2. Structure of a VEGF molecule.  
 
 
VEGF-A 
In the 1980s the structure of VEGF-A was described and different molecular 
weights (34 to 46 kDa) of VEGF were determined, probably because of partial 
proteolysis, different degrees of N-glycosylation or production of isoforms related 
to alternative splicing of pre-mRNAs. 
X-ray crystallographic structure of human VEGF-A showed an antiparallel 
homodimer covalently linked by two disulfide bridges, with three other disulfide 
bridges for each monomer.
29
 The receptor-binding sites are located at each pole of  
the dimer. VEGFs are related to the PDGF family of growth factors, with 
intrachain and interchain disulfide bonds between eight cysteine residues in 
conserved positions. The VEGFs preferentially form homodimers, although 
VEGFA and PLGF heterodimers have been identified. 
VEGF-A, which contains a N linkage glycosylation site, consists of nine isoforms 
that result from alternative splicing of pre-mRNA transcribed from a single gene 
containing eight exons.
30 
Alternative splicing of several of the VEGF family members gives rise to 
isoforms with different biological activities. The human isoforms of VEGF-A are 
denoted VEGFA121, VEGFA145, VEGFA165, VEGFA189 and VEGFA206. 
The mouse isoforms are one amino-acid residue shorter than the corresponding 
human isoform, and they are denoted VEGFA120 and so forth. The activities of 
the VEGFA isoforms are dictated by their different abilities to interact with 
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VEGFR co-receptors, such as neuropilin and HSPGs. For example VEGFA165 is 
a co-receptor-binding form and mediates pro-angiogenic responses, whereas 
VEGFA121 does not interact with co-receptors and may exert anti-angiogenic 
effects. Another splice variant of VEGFA, known as VEGF165b, has been 
proposed to negatively regulate VEGFR activity. 
VEGF-A, which can bind both to VEGFR1 and VEGFR2 (figura 3), is a mitogen 
and survival factor for vascular endothelial cells, especially during 
embryogenesis, and it is fundamental for organization of the vasculature. It also 
promotes vascular endothelial cells and monocyte motility, and selectively and 
reversibly permeabilizes the endothelium to plasma and plasma proteins, without 
leading to injury.
31,32 
 
Gene targeted mice lacking expression of different VEGF ligands have 
demonstrated the critical role of VEGFs in the vessel function. The most striking 
effects are seen for VEGF-A, where embryos succumb already when one allele is 
deleted.
33,34
 Experiments with VEGF-A null mice, which die at embryonic Day 
8.5, exhibit impaired vasculogenesis and blood-island formation indicating that 
VEGF-A participates in the earliest stages of embryonic vasculogenesis. VEGF-A 
mRNA and protein are expressed in many tissues and organs (especially lung, 
adrenal, heart, and kidney) but also in a wide variety of human malignancies. For 
this reason it can represent an important anti-cancer target.  
 
VEGF-B 
VEGF-B consists of two isoforms that result from alternative splicing of pre-
mRNA synthesized from a single gene containing seven exons.
35 
VEGF-B186 is 
freely diffusible while VEGF-B167, the predominant isoform, binds to heparan 
sulfate proteoglycan and is not freely diffusible in vivo. Both VEGF-B isoforms 
exist as disulfide-linked homodimers. The highest levels of VEGF-B transcripts 
occur in brain, heart, kidney, and testes but it is also expressed in several human 
neoplasms.
36 
The function of VEGF-B is unclear: it seems to be required for 
normal heart function in adults but is not required for cardiovascular development 
or for angiogenesis. However, its expression in human tumors and its ability to 
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activate VEGFR1 and the co-receptor neuropilin-1 indicates that VEGF-B 
represents a potential anti-cancer target.
37 
 
VEGF-C 
VEGF-C is synthesized as a pre-pro-protein that undergoes intricate proteolytic 
processing to generate the mature form of the growth factor, which exists as a 
homodimer lacking inter-subunit disulfide bonds. Human adult heart, ovary, 
placenta, skeletal muscle, and small intestine contain high levels of VEGF-C 
mRNA, but modest amounts were also found in other tissues.
38
 The fully 
processed form of VEGF-C binds to both VEGFR2 and VEGFR3 and participates 
in lymphangiogenesis - the formation of new lymphatic vessels from pre-existing 
ones - during embryogenesis and in the maintenance of differentiated lymphatic 
endothelium in adults.
39 
About half of VEGF-C null mice die between embryonic 
days 15.5 and 17.5 and none survives gestation, indicating the essential nature of 
this factor. VEGF-C is indispensable for embryonic lymphangiogenesis, while 
blood vessels develop normally in VEGF-C null mice. Moreover, VEGF-C is 
expressed by a significant fraction of human tumors, making it a potential anti-
cancer target.
40 
 
VEGF-D 
Like VEGF-C, VEGF-D is synthesized as a pre-pro-protein that undergoes 
intricate proteolytic processing to generate the mature form of the growth factor. 
Mature VEGF-D is a non-covalent homodimer and binds to both VEGFR2 and 
VEGFR3.
41
 In contrast to VEGF-C null mice, VEGF-D null mice are viable and 
exhibit normal lymphangiogenesis during development and normal lymphatics in 
mature animals thus suggesting that VEGF-C and perhaps other factors can 
substitute for VEGF-D.
42 
Adult colon, heart, lung, skeletal muscle, and small 
intestine contain high levels of VEGF-D transcripts and it also results up-
regulated in several tumors, representing a potential anti-cancer target.
43-45 
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PlGF 
Placental growth factor is a homodimeric glycoprotein that shares 42% amino 
acid sequence identity with VEGF allowing the same inter- and intra-subunit 
disulfide bonds. The PlGF gene contains seven exons and expresses four isoforms 
(PlGF-131, -152, -203, and -224).
46,47
 PlGF isoform transcripts occur primarily in 
placenta but they could also be found in other healthy or tumoral tissues.
48-50
 PIGF 
is a multitasking cytokine that stimulates angiogenesis by direct or indirect 
mechanisms, and also activates bone-marrow derived endothelial progenitor and 
myeloid cells, as well as stromal cells, to create a nurturing soil for tumor cells, in 
addition to activating tumor cells. PlGF
 
null mice are viable and fertile, but they 
exhibit diminished vascularization of the retina and the corpus luteum.
51
 
 
 
Figure 3: Binding of different VEGFs to VEGFRs. 
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Regulation of VEGF gene expression  
VEGF gene expression is regulated by many factors including the hypoxia-
inducible transcription factor (HIF), growth factors, hormones, oncogenes and 
tumor suppressor genes. 
Because vessels supply oxygen, endothelial cells are equipped with oxygen 
sensors and hypoxia-inducible factor-2α (HIF-2α), which allow the vessels to re-
adjust their shape to optimize blood flow. The expression of VEGF increases 
when the oxygen concentration is low and it can be considered as an adaptive 
response to hypoxia because increased VEFG production promotes angiogenesis, 
which leads to increased red blood cells and oxygen delivery. 
In particular hypoxia increases gene expression of VEGF-A, VEGF-C and PIGF, 
that are importantly implicated in angiogenesis. 
Oncogenes are other factors that can increase VEGF gene expression. Mutations 
which transform proto-oncogenes to oncogenes occur in a variety of cancers 
because they can lead to an enhancement of pro-angiogenic signaling and a 
decrease of anti-angiogenic signaling. A common example is the mutation of Ras 
proto-oncogene. Ras is able to activate the Raf-Mek-Erk Map kinases cascade that 
ends with the increased expression of VEGF promoting angiogenesis and 
supporting tumor growth. 
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Vascular Endothelial Growth Factor Receptors 
(VEFGRs) 
 
The VEGFs bind to three different but structurally related VEGF receptors 
tyrosine kinases, VEGFR-1, VEGFR-2 and VEGFR-3, which are transmembrane 
tyrosine kinases (TKs). In addition, a number of co-receptors that lack intrinsic 
catalytic activity bind VEGFs and modulate the effects of VEGFRs. Such co-
receptors include integrins, neuropilins (Neuropilin-1 and -2) and heparan sulfate 
proteoglycans (HSPG), that are found on the plasma membrane and in the 
extracellular matrix. The five VEGFs present different affinities to the three 
VEGFRs, initiating homo- and hetero-dimer formation (Figure 4 and Table 1).
52
 
 
 
 
 
 
Figure 4. VEGF binding specificities and VEGFR signalling complexes. 
Schematic outline of the five VEGFs, VEGFA, VEGFB, VEGFC, VEGFD and PlGF, binding with 
different affinities to three VEGFRs, initiating VEGFR homo- and hetero-dimer formation. JMD, 
juxtamembrane domain; KID, kinase insert domain; TMD, transmembrane domain; TKD1, ATP-
binding domain; TKD2, phosphotransferase domain. 
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Receptor VEGFR1 VEGFR2 VEGFR3 
Neuropilin-
1 
Neuropilin-2 
Ligands VEGF, VEGF-B, PlGF VEGF, VEGF-
C, VEGF-D 
VEGF-C, 
VEGF-D 
VEGF, PlGF, 
VEGF-B, 
VEGF-C, 
VEGF-D 
VEGF, VEGF-C, 
VEGF-D 
Functions Vasculogenesis, 
Angiogenesis and 
monocyte/macrophage 
motility 
Vasculogenesis, 
Angiogenesis, 
vascular 
permeability and 
endothelial cell 
motility 
Vascular 
and 
lymphatic 
development 
and 
maintenance 
Vascular 
maturation, 
branching, 
heart 
development 
Lymphangiogenesis 
 
Table 1. VEGF receptors, ligands and functions. 
 
 
VEGFR-1 (Flt-1) is critical for hematopoietic cell development, VEGFR-2 
(human KDR or murine Flk-1) for vascular endothelial cell development, and 
VEGFR-3 (Flt-4) for lymphatic endothelial cell development. The expression 
ofVEGFR-3 is associated with the dissemination of tumor cells to regional lymph 
nodes.
53
 
VEGF receptor protein-tyrosine kinases consist of an approximately 750-amino-
acid-residue extracellular domain, which is organized into seven immunoglobulin 
(Ig)-like fold (in VEGFR3, the fifth Ig domain is replaced by a disulfide bridge). 
The extracellular part is followed by a single transmembrane segment. The 
intracellular portion of the receptor is constituted by a juxtamembrane (JM) 
segment, a TK domain, which is divided into proximal and distal kinase domains, 
by an insert domain of about 70 aminoacid residues, and a carboxy-terminal tail 
(Figure 5a-b and 6).
54 
Structural and functional studies have yielded insights into 
how the distinct domains contribute to VEGFR activity. The crystal structure of 
part of the extracellular domain of VEGFR1, alone and in complex with a ligand, 
shows that the Ig domain-2 constitutes the ligand-binding site on the receptor. 
In addition, biochemical analyses showed that the Ig domain-3 in VEGFR2 is 
important for the determination of ligand-binding specificity. 
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Figure 5a. Schematic representation of VEGER structure. 
 
 
 
 
 
Figure 5b 
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Figure 6. Organization of the VEGF receptor protein–tyrosine kinases. Numbers on the right of 
each receptor correspond to human tyrosine residue phosphorylation sites.  
 
 
Although the VEGFRs are primarily expressed in the vascular system, more 
sensitive methodologies combined with improved reagent quality have allowed 
the detection of VEGFR expression in non-endothelial cells.  
However, genetic models imply that the most important function of 
VEGF/VEGFRs is in the vascular system. 
 
These enzymes catalyze the following reaction: 
MgATP
1-
 + Protein-OH → Protein-OPO3
2-
 +MgADP + H
+
 
where -OH is a hydroxyl group of a tyrosine 
 
The binding of VEGFs to VEGFRs induces receptor dimerization, causing 
modification in the intracellular domain conformation.
 
These conformational 
changes lead to the exposure of the ATP-binding site, followed by ATP binding 
and auto- or transphosphorylation on specific tyrosine residues on the receptor 
dimers and on downstream signal transducer proteins.
55 
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This mechanism leads to the initiation of typical receptor signal transduction 
cascades, which activate several downstream enzymatic pathways. Tyrosine 
phosphorylation on VEGFRs is tightly regulated both by internalization and 
degradation and by dephosphorylation through different protein tyrosine 
phospatases.
56 
The biological and pathological roles of VEGFRs have been extensively studied 
and continue to be investigated. 
For example VEGFRs seem to be fundamental for their ability to transduce 
signals that form the vascular tube and for their pivotal role in regulating vascular 
permeability. 
 
 
VEGFR1 structure, expression and signaling 
VEGFR-1 (Flt-1, fms-like tyrosyl kinase-1, where fms refers to feline 
McDonough sarcoma virus) is a 180-185 KDa glycoprotein activated by the 
binding of VEGF-A, VEGF-B and PIGF. 
VEGFR1 has higher affinity for VEGF than VEGFR2 (15 pM vs.750 pM). Six 
residues in the C-terminal tail of VEGFR1 have been identified as 
phosphorylation sites (figure 6). 
57
 
Although both VEGF and PlGF activate VEGFR1, the phosphorylation sites are 
different. For example, Autiero and colleagues found that VEGF stimulates 
VEGFR1 Tyr1213 phosphorylation whereas PlGF stimulates Tyr1309 
phosphorylation;
58 
these results indicate that they activate this receptor differently 
and exert distinct biological effects. 
Even though VEGF stimulates VEGFR1 phosphorylation, it fails to alter the gene 
expression profile of mouse primary capillary endothelial cells. In contrast, PlGF 
treatment produces changes in the expression of more than 50 genes. 
 Autiero and co-workers suggested that the mechanism responsible for these 
differences may be due to the ability of these ligands to induce different 
conformational changes in VEGFR1.
59 
However, the X-ray crystal structures of 
VEGF or PlGF bound to the second immunoglobulin-like domain of human 
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VEGFR1, fail to reveal any differences in conformation.
60 
It only indicates  that 
hydrophobic interactions stabilize the ligand−receptor dimers.61 Loops 1 and 3 are 
also required for high-affinity binding. 
VEGFR-1 is mainly expressed in vascular endothelial cells at relatively high 
levels throughout development and in the adult but is also present in non 
endothelial cells, including monocytes, macrophages, renal mesangial cells, 
vascular smooth muscle cells, and dendritic cells. VEGFR-1 has been shown to 
mediate monocyte migration, recruitment of endothelial cell progenitors, 
hematopoietic stem cell survival, and release of growth factors from liver 
endothelial cells.
62  
 
The precise role of VEGFR-1 is not still well known. Several studies imply that 
VEGFR1 is dispensable for proliferation or migration of endothelial cells in vitro. 
VEGFR1 may regulate endothelial cells via cross-talk with VEGFR2, through 
dimerization, through transphosphorylation and through regulation of receptor 
expression levels.
63
 
VEGFR1–VEGFR2 heterodimers would form as a consequence of VEGFA 
binding. 
 Moreover we have come to know that VEGFR-1 has both negative and positive 
functions in angiogenesis but it acts primarily as a modulator of the availability of 
VEGF-A (it seems to reduce the bioavailability of VEGF-A to other receptors, in 
particular VEGFR-2, which is the principal receptor in VEGF signaling). 
Importantly, VEGFR-1-dependent signaling was shown to play a role in the 
angiogenesis of certain tumors as well as in the progression of rheumatoid arthritis 
and atherosclerosis.
64,65 
VEGFR-1 is up-regulated in several tumor cell lines, 
including malignant prostate cells, pancreatic cancer cells, malignant melanoma 
cells, and lung adenocarcinoma cells.
66-69
 Importantly VEGFR-1 is involved in 
tumor metastasis.
70
 Thus, blocking the activity of VEGFR-1 has emerged as an 
antimetastasis strategy to target angiogenesis, cancer cell survival, and migration. 
VEGFR-1 and VEGFR-2 also exist in soluble secreted forms (also known as 
sFLT-1) that are involved in angiogenesis and in different human diseases. 
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 Kendall and Thomas cloned cDNAs from a human vascular endothelial cell 
library that encoded a soluble truncated form of VEGFR1.
71
 sVEGFR1, which 
contains the first six of seven extra-cellular immunoglobulin-like domains, binds 
VEGF with high affinity and inhibits its mitogenic activity for vascular 
endothelial cells. 
Excessive sVEGFR1 generated by human placenta and released into the 
circulation of the mother has been associated with the pathogenesis of pregnancy-
induced hypertension.  
High levels of soluble VEGFR have also been detected in several cancers, 
including breast, pancreatic, lung, and ovarian cancers and leukemias. On the 
other hand, administration of soluble VEGFR-1 has demonstrated antitumor 
effects, probably because the soluble receptor intercepts VEGF-A.
72
 
Fong and co-workers showed that VEGFR1 null mice die between embryonic 
days 8.5 and 9.
73 
Endothelial cells form normally in both embryonic and extra-
embryonic sites in these mice, but the cells fail to assemble into organized blood 
vessels. 
However, Hiratsuka and collaborators reported the surprising finding that mice 
expressing the VEGFR1 extracellular ligand binding and transmembrane 
segments but lacking the tyrosine kinase (TK) and its insert domain are viable and 
fertile.
74
 
The only defect noted in these mice was an inability of VEGF to stimulate 
macrophage migration. Hiratsuka and co-workers subsequently demonstrated that 
about half of the mice with a deletion of both the transmembrane segment and 
tyrosine kinase domain were embryonic lethal.
75
 These observations indicate that 
the membrane-anchored ligand-binding domain is the essential part of the receptor 
during development. These findings are consistent with the concept that the chief 
function of VEGFR1 in embryos is to sequester VEGF and modulate the 
concentration of the free ligand near the cell surface (figure 7). 
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Figure 7. VEGFR1 tyrosine phosphorylation sites and signal transduction. 
 
 
VEGFR2: structure, expression and signaling 
VEGFR-2 [also known as KDR in the human and Flk1 (fetal liver kinase-1) in the 
mouse] is a 210−230 kDa glycoprotein that binds VEGFA with a 10-fold lower 
affinity than VEGFR-1. In addition, VEGFR-2 binds proteolytically processed 
VEGFC and VEGFD. (Proteolytic processing  of the human VEGFC and D 
allows the binding to VEGFR2, however, these factors bind to VEGFR2 with 
lower affinity than to VEGFR3). 
Ligand binding involves extracellular Ig-like domains 2 and 3 of VEGFR2. 
Alternative splicing results in the generation of sVEGFR2, which is present in 
various tissues such as the skin, heart, spleen, kidney and ovary, and in plasma. 
sVEGFR2 binds VEGFC and prevents its binding to VEGFR3, consequently 
inhibiting lymphatic endothelial cell proliferation.
76,77
 
Although VEGFR2 has lower affinity for VEGF than VEGFR1, VEGFR2 
exhibits robust protein tyrosine kinase activity in response to its ligands.
78
 
Six tyrosine residues of VEGFR2 are autophosphorylated (figure 6).
79 
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Autophosphorylation of residues 1054 and 1059 within the activation loop of 
VEGFR2 leads to increased kinase activity. 
VEGFR2 is expressed most prominently in vascular endothelial cells and their 
embryonic precursors, with highest expression levels during embryonic 
vasculogenesis and angiogenesis; it has also been found in a range of non-
endothelial cells such as haemopoietic stem cells.
 
VEGFR-2 is the major regulator 
of VEGF-driven responses in endothelial cells, including permeability, 
proliferation, invasion, migration and formation of the vascular tube.   
Moreover, it is considered to be a crucial signal transducer in both physiologic, 
active angiogenesis, such as in the uterus during the reproductive cycle, and in 
pathological processes associated with neovascularization, such as cancer (figure 
8). 
Autophosphorylated VEGFR-2 is required for activation of several downstream 
pathways, usually hyperactivated in several tumors. VEGFR-2 is overexpressed in 
several malignancies, including ovarian and thyroid cancer, melanoma, and 
medulloblastoma. VEGFR-2, often in combination with VEGFR-3, is expressed at 
significantly upregulated levels in the tumor vascular endothelium of most 
common human solid tumor types. The signal intensity of both receptors is 
significantly higher in vessels associated with malignant colorectal, lung, and 
breast tumor tissues than in adjacent non tumor tissues.
 
Shalaby and colleagues reported that VEGFR2 null mice die between embryonic 
days 8.5 and 9.5 as a result of defects in the development of hematopoietic and 
endothelial precursors.
80
 
Yolk-sac blood islands were absent at 7.5 days, organized blood vessels were not 
observed in the embryo or yolk sac at any stage, and hematopoietic progenitors 
were severely reduced. These findings indicate that VEGFR2 is essential for yolk-
sac blood-island formation and vasculogenesis in the mouse embryo and are 
consistent with the concept that VEGFR2 is one of the earliest markers of 
embryonic endothelial cells (figure 8). 
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Figure 8. VEGFR2 tyrosine phosphorylation sites and signal transduction. 
 
 
VEGF induces dimerization of VEGFR2 that leads to receptor 
autophosphorylation and activation. Autophosphorylation occurs in trans: one 
kinase of the dimer catalyzes the phosphorylation of tyrosine residues in the 
second, and the second catalyzes the phosphorylation of tyrosine residues in the 
first. 
Autophosphorylation of tyrosine residues within the activation loop of the kinase 
domain stimulates catalytic activity while autophosphorylation of tyrosine 
residues at other locations generates docking sites for modular Src homology 2 
(SH2) and phosphotyrosine binding (PTB) domains that recognize 
phosphotyrosines in sequence-specific contexts.
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VEGFR3: structure, expression and signaling 
VEGFR-3 (also denoted Fms-like tyrosine kinase 4, Flt4 in the mouse) is 
synthesized as a precursor protein of 195 kDa. VEGFR-3 undergoes a proteolytic 
cleavage in the sixth immunoglobulin-like domain; the two components of the 
original chain remain linked by a disulfide bond (figure 9). 
Alternative splicing of VEGFR3 pre-mRNA in humans generates two isoforms of 
VEGFR3 that differ in their C-terminal tails.
81
 The splicing gives rise to a short 
and a long VEGFR3 isoform, but the long one is predominantly expressed.
82      
Dixelius and co-workers identified five tyrosine residues in the C-terminal tail of 
human VEGFR3 as autophosphorylation sites (figure 6).
 
VEGFR-3 is activated by the binding of VEGF-C or VEGF-D. VEGFC and 
VEGF-D undergo proteolytic processing, which increase the binding affinity to 
both VEGFR-2 and VEGFR-3. VEGFR-3 is deeply involved in the establishment 
and maintenance of the lymphatic system. Its expression in the adult seems to be 
largely restricted to lymphatic endothelial cells
83 
but its expression is induced in 
endothelial cells in conjunction with active angiogenesis, such as in tumour 
vessels, in endothelial tip cells of angiogenic sprouts, in the developing retina or 
in chronic inflammatory wounds. VEGFR-3 is also expressed in non-endothelial 
cells such as osteoblasts, neuronal progenitors, and macrophages, which indirectly 
may support angiogenesis. 
Furthermore, VEGFR-3 is strongly expressed in several human malignancies, 
including lung, cervical, breast, and colorectal cancers. Its higher levels are 
correlated with increased metastasis formation and shorter patient survival,
84
 since 
the lymphatic vessels surrounding the tumor play important roles in metastasis 
formation.
85 
It has been clearly demonstrated that inhibition of VEGFR-3 activity 
arrests tumor vascularization, leading to decreased vascular density in several 
tumor models. 
VEGF-C/VEGFR-3 play a fundamental role in the tumor microenvironment by 
promoting the formation of new lymphatic vessels from preexisting ones. VEGF-
C, produced by tumor cells, induces lymphatic endothelial destabilization, 
resulting in the endothelial sprouting and enlargement of the vessels. These 
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changes facilitate the entry of tumor cells into the lymphatics and further 
dissemination of metastasis to sentinel lymph nodes.  
Gene inactivation to eliminate expression of VEGF-C alone or combined 
delection of VEGF-C and VEGF-D results in defects mainly in lymphatic vessels, 
while blood vessels remain unaffected. Studies in vivo and in vitro demonstrate 
the importance of molecular communication between VEGFR-3 and VEGFR-2 in 
the angiogenic process, exerted e.g. via receptor heterodimerization. 
Dumont et al. showed that VEGFR-3 null mice died by embryonic day 9.5 and 
exhibited defective blood vessel development.
86
 Vasculogenesis and angiogenesis 
occurred, but large vessels became abnormally organized with defective lumens, 
leading to fluid accumulation in the pericardial cavity and cardiovascular failure. 
Thus it became clear that VEGFR-3 has an essential role in the development of 
the embryonic cardiovascular system before the emergence of the lymphatic 
vessels, where VEGFR-3 also plays a pivotal role. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. VEGFR3 tyrosine phosphorylation sites and signal transduction. 
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The activity of RTKs is regulated by the availability of ligands. A particular 
feature of VEGF-A is the dramatic upregulation of its expression levels under 
hypoxic conditions. Hypoxia allows the stabilization of hypoxia-inducible factors 
(HIFs) that bind to specific elements that are present in the promoter region of 
VEGF-A. Similarly, expression of VEGFR-1 is directly regulated by HIFs. 
VEGFR-2 is also upregulated during hypoxia, but the role of different HIFs in this 
regulation remains to be clarified. VEGFR-3 expression is upregulated in 
differentiating embryonic stem cells that are cultured in a hypoxic atmosphere. 
However, the contribution of hypoxia to regulation of VEGFR-3 expression in 
vivo is still unclear. 
 
VEGF Co-Receptors 
VEGF co-receptors are VEGF-binding cell-surface-expressed molecules that lack 
intrinsic catalytic activity, but indirectly modulate the responsiveness to VEGF 
and contribute to the final biological effect.  
 
Heparan Sulfate (HS):  
Heparan sulfate is a sulfated polysaccharide that is found on the surface of most 
cells or in the extracellular matrix as part of proteoglycans (HSPG). In this form, 
it is able to bind to a variety of protein ligands regulating a wide variety of 
biological activities. HS modulates VEGF biology in several ways, by binding not 
only VEGF ligands but also receptors and co-receptors such as Neuropilin-1 
(NRP-1). All VEGF-A isoforms except VEGF-A121 bind heparin. HS serves as a 
reservoir for growth factors, and controlled release allows formation of growth-
factor gradients.
87,88
 HS may promote tumor growth not only by increasing VEGF 
biology but also by supporting a broad spectrum of growth factor activities. 
 
Neuropilin-1 and -2  
There are two neuropilin homologues, NRP-1 and NRP-2, which are 130 kDa 
transmembrane proteins with a large extracellular component, a transmembrane 
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segment, and a small cytoplasmic tail lacking intrinsic catalytic function. 
Neuropilins are co-receptors for both the semaphorin and the VEGF family.
89
 
Semaphorins are glycoproteins with neuronal guidance functions, implicated in 
modulating the development of the nervous and vascular systems. 
One of the pertinent questions concerning the NRPs is how their binding of VEGF 
ligands affects VEGF-induced signal transduction. NRP1 contributes to VEGFR-2 
signaling in a qualitative manner, leading to enhanced migration and survival of 
endothelial cells and it has been implicated in VEGFR-2-mediated permeability. 
NRP2 mediates VEGF-C-induced lymphatic sprouting in a VEGFR-3-dependent 
manner.
90,91 
Both overexpression and disruption of NRP1 in mice lead to embryonic lethality 
at E12,5-13-5 due to either an excess of vessel formation or a range of vascular 
abnormalities, respectively. NRP2 knockout mice show normal development of 
arteries and veins but exhibit marked deviations in the development of capillaries 
and small lymphatics. 
Treatment with a neutralizing anti-NRP1 antibody reduces angiogenesis and 
vascular remodelling in vivo and has an additive effect with anti-VEGF-A 
antibody therapies in reducing tumour growth and tumour vessel organization. 
Treatment with a neutralizing anti-NRP2 antibody reduces lymphangiogenesis 
and functional lymphatics in tumours, while leaving established lymphatics 
unaffected. The reduced lymphatic function is accompanied by reduced metastatic 
spread.
92,93
 
 
Integrins:  
Integrins are transmembrane heterodimers that mediate cell matrix adhesion by 
specific binding to extracellular matrix components, such as collagen, fibronectin, 
vitronectin and laminin. VEGF induces complex formation between VEGFR-2 
and the αVβ3 integrin, which is important for VEGFR-2 activity. 
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VEGFR protein kinase core 
The VEGFR-2 protein tyrosine kinase core has the characteristic bilobed 
architecture observed in all protein kinases (figure 10). The active site is located 
in the cleft between the two lobes and consists of residues contributed by both 
lobes. 
There are two general types of conformational changes associated with protein 
kinases. The first one involves the interconversion of inactive and active states. 
Inactivation-activation involves changes in the position of the αC helix in the N-
lobe and in the conformation of the activation segment in the C-lobe. The second 
conformational change occurs in the active state as the two lobes move relative to 
each other to open and close the cleft, when the enzyme goes through its catalytic 
cycle. 
ATP and protein substrates bind to the open conformation, catalysis occurs in the 
closed conformation, and ADP and phosphorylated substrate are released during 
progression to the open state that completes the cycle. The three-dimensional 
structures of the protein kinase cores of VEGFR-1 and VEGFR-3 have not yet 
been solved crystallographically, but they are expected to be conform to the 
canonical structures of other protein kinases. 
 
 
 
Figure 10. Structure of the protein kinase catalytic core of VEGFR2. The glycine-rich loop is 
hidden by Lys868.
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The smaller N-terminal lobe has a predominantly antiparallel β-sheet structure. A 
glycine-rich (GXGXXG) ATP-phosphate binding loop occurs in each VEGF 
receptor. The larger C-terminal lobe, which is predominantly α-helical in nature, 
contains the catalytic loop and the activation segment. Hanks and colleagues 
identified 12 subdomains
94
 with conserved amino acid signatures and in particular 
the role of three amino acids was described (figure 11): 
- Lys868. In the activated enzyme, Lys868 is an invariant residue that 
forms ion pairs with the α- and β-phosphates of ATP and with Glu885 of the αC 
helix. In the inactive enzyme, which lacks ATP bound, Lys868 binds instead to an 
activation segment phosphotyrosine and is far from Glu885.  
- Asp1028. It is catalytic base in a conserved HRD (His-Arg-Asp) 
sequence and it orients the tyrosyl group of the substrate protein in a catalytically 
competent state.  
- Asp1046. It is the first residue of the activation loop in a conserved DFG 
(Asp-Phe-Gly) sequence found in the large lobe. It is part of a magnesium-binding 
loop and it binds to Mg
2+
 that in turn coordinates the β and γ phosphate groups of 
ATP; Asp1046 also binds to the α-phosphate. 
Within each lobe there is a polypeptide segment that can assume active and 
inactive orientations. In the small N-lobe, this segment is the αC helix which 
rotates and translates with respect to the rest of the lobe, making or breaking part 
of the catalytic site. In the active state, Glu885 of the αC helix forms a salt bridge 
with Lys868 of the N-lobe. C-lobe differs between active and inactive enzymes. 
In protein kinases that are in the inactive state, the activation loop is positioned to 
prevent protein substrate binding and phosphorylation of the activation segment 
stabilizes it in its active conformation.
95
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Figure 11. Diagram of the inferred interactions between the human VEGF receptor 2 protein–
tyrosine kinase catalytic core residues, ATP, and a protein substrate.  
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Anti-angiogenic cancer therapy 
 
Blood vessels deliver oxygen and nutrients to every part of the body, but also 
nourish diseases such as cancer. Over the past decade, our understanding of the 
molecular mechanism of angiogenesis has increased at an explosive rate and has 
led to the approval of the anti-angiogenic drugs for cancer. 
The formation of the vascular system is composed of two different processes: 
vasculogenesis and angiogenesis. The differences depend on when blood vessels 
form. Vasculogenesis refers to the ex-novo formation of blood-vessels from 
competent cellular precursors during embryogenesis. These precursors, called 
angioblasts, differentiate into endothelial cells (EC), which assemble into a 
vascular labyrinth. Subsequent sprouting ensures expansion of the vascular 
network, known as angiogenesis. Angiogenesis is indeed the formation of new 
blood vessels, creating new capillaries from existing vasculature. Angiogenesis is 
a normal process for organ development, that involves the migration, growth, and 
differentiation of endothelial cells during physiological processes such as 
embryogenesis, wound healing, development and homeostasis of adult tissues and 
of growth of the endometrium in the menstrual cycle. It is an essential and highly 
regulated process under physiological conditions. When a malfunction in 
controlling mechanisms of angiogenesis occurs, it may be involved in the 
development and progression of various diseases such as rheumatoid arthritis, 
ocular neovascularization, psoriasis, inflammation, tumor growth and metastasis 
(pathological angiogenesis). Vessel formation can also occur by the recruitment of 
bone-marrow-derived and/or vascular-wall-resident endothelial progenitors 
(EPCs) that differentiate into endothelial cells. 
Tissues can also become vascularized by other mechanisms. For example, pre-
existing vessels can split by a process known as intussusception, giving rise to 
daughter vessels. In other cases, vessel co-option occurs, in which tumor cells 
hijack the existing vasculature, or tumor cells can line vessels, a phenomenon 
known as vascular mimicry (figure 12). Unlike normal tissues, which use 
sprouting angiogenesis, vasculogenesis and intussusception, tumors can use all 
modes of vessel formation. 
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Figure 12. Non-sprouting forms of angiogenesis described in tumors. 
 
Generally blood vessels are composed of a single layer of simple squamous 
endothelial cells glued by a polysaccharide intercellular matrix, surrounded by 
subendothelial specialized cells, such as pericytes, which suppress endothelial cell 
proliferation and release cell-survival signals such as VEGF; these cells are 
interconnected by junctional molecules. Endothelial cells are anchored to a 
basement membrane and everything is immersed in the extracellular matrix 
(ECM), a complex of fibroblasts, macrophages and macromolecules secreted by 
the cells in the intercellular space. 
Endothelium has not only a structural function, but it is also able to produce 
chemical mediators, to control vascular permeability, coagulation and interactions 
with cells. 
In the embryo and yolk sac, early blood vessels develop by aggregation of 
angioblasts into a primitive network of simple endothelial tubes. In contrast, 
angiogenesis is the process of new blood vessel formation from pre-existing 
vascular networks by capillary sprouting. During this process, mature endothelial 
cells divide and are incorporated into new capillaries. Adult human vascular 
endothelial cells correspond to an estimated surface area of 1000m
2
, but only 1 in 
every 10,000 endothelial cells is in the cell division cycle at any one time. 
However, there is an increased rate of endothelial cell mitosis and angiogenesis 
during wound healing and tissue repair, during ovarian corpus luteum formation, 
and during the placental development establishing pregnancy.
96,97 
Angiogenesis is regulated by both endogenous activators and inhibitors (table 2) 
The body controls angiogenesis by producing a precise balance of growth and 
inhibitory factors in healthy tissues. When this balance is disturbed, the result is 
both too much or too little angiogenesis. Abnormal blood vessels growth, either 
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excessive or insufficient, is recognized as a “common denominator” underlying 
many deadly and debilitating conditions, from skin diseases, age-related blindness 
and diabetic ulcers to cardiovascular disease, stroke and cancer above all. 
 
Table 2. Selected endogenous pro- and anti-angiogenic factors. 
Endogenous pro-angiogenic factors Endogenous anti-angiogenic factors 
Acidic fibroblast growth factor (aFGF, FGF1) (A) Derived from the extracellular matrix 
Angiogenin       Anastellin 
Angiopoietin-1       Arresten 
Angiopoietin-2       Canstatin 
Basic fibroblast growth factor (bFGF, FGF2)       Chondromodulin-1 
Ephrin-A1       EFC-XV 
Ephrin-B1       Endorepellin 
Ephrin-B2       Endostatin 
Epidermal growth factor (EGF)       Fibulin fragments 
Granulocyte colony-stimulating factor (GCSF)       Thrombospondin-1 and -2 
Macrophage-granulocyte colony-stimulating factor 
(GM-CSF)       Tumstatin 
Hepatic growth factor (HGF, scatter factor) (B) Non-matrix derived factors 
Interleukin-8 (Il-8, CXCL8)       Angiostatin 
Leptin       Antithrombin III (cleaved) 
Placental growth factor (PlGF)       Hemopexin-like domain (PEX) 
Platelet-derived endothelial growth factor (PD-
EGF)       Interferon-α, -β, -γ 
Platelet-derived growth factor-A (PDGF-A)       Interleukin-1, -4, -12, -18 
Platelet-derived growth factor-B (PDGF-B)       2-Methoxyestradiol 
Transforming growth factor-α (TGF-α) 
      Pigment epithelium-derived factor 
(PEDF) 
Transforming growth factor-β (TGF-β)       Plasminogen kringle-5 
Tumor necrosis factor (TNF-α)       Platelet factor-4 
Vascular endothelial growth factor (VEGF-A)       Prolactin fragments 
VEGF-B       Prothrombin kringle-2 
VEGF-C       Semaphorin-3F 
VEGF-D       Soluble VEGFR1 
       TIMP-2 
       Troponin I 
       TrpRS 
       Vasostatin 
 
There are about 30 endogenous pro-angiogenic factors; among these molecules, 
VEGF/VEGFR family plays a fundamental role and proves to be essential in 
vasculogenesis and angiogenesis. 
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VEGF has been demonstrated to be the major contributor to angiogenesis 
increasing the number of capillaries in a given network. Binding of VEGF to 
VEGFR-2 starts the tyrosine kinase signaling cascade that triggers the production 
of factors responsible of vessel permeability, proliferation, survival, migration and 
finally differentiation into mature blood vessels. 
The delicate balance on which angiogenesis is based demonstrates that 
angiogenesis is an intricate process that involves interactions between several 
regulatory and effector molecules.  
According to a classic model, angiogenesis can be divided into a phase of 
sprouting and a phase of resolution. 
The first phase includes vasodilatation, induced by the release of NO (Nitric 
Oxide) by surrounding tissues. This is followed by an increased transcription of 
VEGF (Vascular Endothelium Growth Factor), which is the principal growth 
factor involved in angiogenesis, and an increased vascular permeability.  
Then extravascular fibrin deposition, vessel wall disassembly and enzymatic 
degradation of capillary basement membrane occur. The activation of receptors on 
endothelial cells by angiogenic factors make them produce matrix metallo 
proteinases (MMPS), a special class of enzymes which are released into the 
surrounding tissue and begin to degrade the extracellular matrix. The degradation 
of this matrix permits the migration of endothelial cells. Once activated, 
endothelial cells begin to migrate into the surrounding tissues, start to proliferate 
and evolve gradually into a mature network of blood vessels (formation of 
capillary lumen). This last process is helped by the production of PDGF-B 
(platelet Derived Growth Factor-B) which recruits pericytes and leads to the 
formation of the basement membrane around the new vessels. Pericytes are 
fundamental because they are able to produce several growth factors and 
cytokines that are important for vascular functionality. 
The phase of resolution consists of five steps: (i) inhibition of endothelial cells 
proliferation, (ii) cessation of cell migration, (iii) basement membrane 
reconstitution, (iv) junctional complex maturation, and (v) vessel wall assembly 
including recruitment and differentiation of smooth muscle cells and pericytes, 
both of which are mural cells. 
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Protease inhibitors known as tissue inhibitors of metalloproteinases (TIMPs) and 
plasminogen activator inhibitor-1 cause the deposition of a basement membrane, 
and junctions are re-established to ensure optimal flow distribution.   
Several features discriminate vessels formed during physiological processes from 
those in pathologies, and research on tumor angiogenesis has assumed 
considerable biomedical importance during the past 40 years.  
Healthy vessels are arranged in a hierarchical manner (arteries, capillaries and 
veins), whereas the tumor vasculature is disorganized and morphologically 
abnormal. Tumor vessels display partial or complete occlusions leading to poor 
blood flow. Pericytes may be more cloosely associated with tumor vessels, or may 
be completely lacking. Moreover, the vascular basement membrane may be 
discontinuous. Tumor vessels are leaky, in part due to deficient perivascular 
support, but also due to abundant expression of VEGF-A in the growing tumor. 
The leakiness leads to a build-up of interstitial pressure and impaired drug 
delivery. Indeed, as a consequence of the elevated VEGF expression, the tumour 
associated vasculature becomes abnormal and inefficient, with many blind ends, 
and it is difficult for conventional drug molecules to gain access to the tumour 
tissue.  
Recognition that a control of angiogenesis could have therapeutic value has 
indeed stimulated great interest.  
The strategy to arrest tumor vascularization as an effective treatment for all types 
of cancer was proposed in the early seventies by Judah Folkman who 
hypothesized that tumor growth is angiogenesis-dependent and that inhibition of 
angiogenesis may be a potential way to inhibit cancer progression. Since then 
tumor angiogenesis has been studied in greater detail.  
The rapid increase of blood vessel formation to support tumor growth is triggered 
by (1) oncogene-mediated tumor expression of angiogenic proteins including 
VEGF, fibroblast growth factor (FGF), platelet derived growth factor (PDGF), 
endothelial growth factor (EGF), lysophosphatic acid (LPA), and angiopoietin 
(Ang), (2) metabolic and/or mechanical stress, (3) genetic mutations, (4) immune 
response, and maybe most prominently (5) hypoxia. Tumor-angiogenesis 
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therefore depends on tumor type, site, growth and stage of disease, and 
contributes to tumor growth, invasion, and metastasis. 
Since we have understood that angiogenesis has a crucial role in cancer while it is 
absent in (most) healthy conditions, in this year a lot of efforts have been done to 
develop different approaches to inhibit proangiogenic signaling pathways. 
 
 
 
Targeting VEGF/VEGFR as anti-angiogenic 
therapy 
 
The correlation between PKs and cancer is known since 1975, when Harold 
Varmus and Michael Bishop identified the first cellular oncogene, v-src, which 
codified for a TK. A lot of RTKs, if altered, changed or over-expressed, are 
directly linked to tumor outbreak. There a genomic rearrangement can occur, with 
the creation of fusion proteins, or a de-regulation of the kinase activity caused by 
an over-expression of TKs, the activation of oncogenes or the loss of tumor 
suppressors. In addition mutations may lead to a constitutive activation of a kinase 
activity. 
Angiogenesis research is based on the assumption that preventing the growth of 
new blood vessels will impair the viability of tumor cells. The aim of 
antiangiogenic therapy is to stabilize the disease and keep tumorigenesis in check, 
rather than eradicating tumor mass, as in the case of the endpoints of 
chemotherapy and radiotherapy. Out of the several hundreds of molecules with 
anti-angiogenic activity in experimental models, about one hundred of these have 
entered clinical testing in cancer patients, and around 10 of these so far have 
become approved for clinical use. Despite the existence of many important 
pathways for the angiogenic process, VEGF ligands and receptors still constitute 
the main target for anti-angiogenic therapy used in clinical practice. The current 
strategies to inhibit VEGF signaling can be divided into those that bind VEGF 
ligands and therefore block their interaction with the receptors (antibodies, 
peptides, ribozymes and soluble receptors), and those that target the receptors in a 
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direct way (antibodies or small molecules tyrosine kinase inhibitors). Table 3 and 
Figure 13 summarize some of the principal anti-angiogenic molecules that 
currently are being used in clinical trials to target VEGF signaling.
98,99
 
 
 
Table 3. Angiogenesis inhibitors in advanced clinical trials. 
 
Therapeutic agent Type of inhibitor Specific Targets Clinical development 
Bevacizumab mAb VEGF Approved in 2004 (CC), 
in 2006 (NSCLC), in 2008 
(BC), in 2009 
(RCC,Glioblastoma) 
Ramucirumab mAb VEGFR-2 Phase II/III 
MF-1/MC-18F1 mAb VEGFR-1 Phase I 
CDP791 PEG di-Fab 
conjugate 
VEGFR-2 Phase II 
VEGF-trap/aflibercept Fusion protein VEGF-A and PlGF Phase II/III 
VEGF-AS Oligonucleotide VEGF-A, VEGF-C, VEGF-
D 
Phase I 
SU11248/sunitinib RTKI VEGFR1-3, PDGFR, c-kit, 
Flt-3 
Approved in 2006 (GIST 
and RCC) 
Bay43-9006/sorafenib RTKI VEGFR2-3, PDGFR, Raf-1, 
Flt-3, c-kit 
Approved in 2005 (RCC), 
in 2008 (HCC) 
Pazopanib RTKI VEGFR1-3, PDGFR, Flt-3, 
c-kit 
Approved in 2009 (RCC) 
AG013736 RTKI VEGFR1-3, PDGFR, c-kit Phase II/III 
ZD6474/vandetanib RTKI VEGFR1-3, EGFR, RET Phase II/III 
AZD2171/cediranib RTKI VEGFR1-3, c-kit Phase II/III 
Brivanib alanitate RTKI VEGFR2, FGFR-1 Phase II/III 
AMG706/motesanib RTKI VEGFR1-3, PDGFR, c-kit, 
RET 
Phase II/III 
ABT869/linifanib RTKI VEGFR1-3, PDGFR, flt-3 Phase II/III 
AV-951/tivozanib RTKI VEGFR1-3, PDGFR Phase II/III 
PTK787/vatalanib RTKI VEGFR1-3, PDGFR, c-kit Phase II 
AE941/Neovastat Shark cartilage 
component 
VEGF/VEGFR binding, 
MMP2, MMP9 
Phase II/III 
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Figure 13. VEGF signaling inhibitors and their targets.  
 
However, with exception for drugs targeting VEGF ligands or receptors, the vast 
majority of novel anti-angiogenic molecules have failed to confirm the 
encouraging preclinical results when tested in clinical trials. Furthermore, the 
initial concept to radically ‘‘starve’’ the tumor by stripping the blood supply has 
been modified, as aggressive angiogenesis inhibition may aggravate tumor 
metabolism and promote metastatic spread.
100,101 
In 2001 Jain proposed an alternative goal for anti-angiogenic therapy aimed at 
correcting the abnormal structure and functionality of tumor vessels, rendering 
them more accessible for delivery of chemiotherapeutic drugs. Targeting VEGFA 
signaling induces a “transient normalization” of the tumor vasculature in various 
tumor models, restoring some of the functional and morphological changes 
characteristic of tumor vessels. 
By now, it has become clear that the efficacy of angiogenesis inhibition depends 
on the cellular context, the dose and the timing of drug delivery.
 
Anyway we have always to remember that, when using such therapies in the long-
term treatment of cancer or other diseases that are associated with pathological 
angiogenesis, it will be  important to preserve pathways that are important for the 
survival of blood vessels in healthy tissues. 
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Targeted therapy 
 
Chemotherapeutic agents do not specifically target tumor cells, but rather interfere 
with cell division or inhibit enzymes involved in DNA replication or metabolism. 
These drugs therefore also damage the normal dividing cells of rapidly generating 
tissues, such as bone marrow, gut mucosa and hair follicles. Cancer chemotherapy 
is limited by a lack of specificity, resulting in the damage not only of cancer cells, 
but also normal cells. This creates a narrow therapeutic index. 
Targeted therapy, introduced in recent years, tries to rise the therapeutic index in 
cancer treatment because it is directed against cancer-specific molecules and 
signaling pathways. Tyrosine kinases are especially important targets because 
they play an important role in the modulation of growth factor signaling. 
The growth of solid tumors is dependent on their capacity to induce angiogenesis, 
the ability of blood vessels to supply themselves with oxygen and nutrients. 
Considering the possibility of interrupting a tumor’s supply of oxygen and 
nutrient, great interest has been given in the targeting of tumor vasculature and 
much effort has been directed towards the development of anti-angiogenic agents. 
 Tumor blood vessels are distinct from normal blood cells, so they can become a 
good target for cancer therapies. Anti-angiogenic drugs may act by inhibiting the 
synthesis of angiogenic proteins by cancer cells, neutralizing the angiogenic 
proteins or directly inducing endothelial cell apoptosis. These inhibitors include 
therapeutic antibodies and small molecules both capable of targeting angiogenic 
growth factor (such as VEGF) or angiogenic growth factor receptors (such as 
VEGFR). 
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Limitations and challenges of the Antiangiogenic 
therapy 
 
After the success of VEGF-pathway inhibitors in clinic, with hundreds of clinical 
trials currently underway in multiple cancer indications and pathological stages, 
and dozens of other VEGF and other angiogenic-pathway-targeted agents now in 
experimental or clinical testing, an urgent issue is understanding why the majority 
of patients stop responding - or do not respond at all - to such drugs, and how such 
limitations can be overcome. The extent of refractoriness varies from one cancer 
to another, differs between micro- and macrometastatic disease, and differs for 
various types of VEGF blocker.  
It is true that angiogenesis inhibitors targeting the vascular endothelial growth 
factor (VEGF) signaling pathways are affording demonstrable therapeutic efficacy 
in mouse models of cancer and in an increasing number of human cancers. The 
introduction of anti-angiogenic therapy results in transitory improvements, in the 
form of tumour stasis or shrinkage and in some cases increased survival. 
Inevitably, however, the tumours begin to grow again and the disease progresses, 
after a fleeting period of clinical benefit that is typically measured in months. In 
both preclinical and clinical settings, indeed, the benefits are at best transitory and 
are followed by a restoration of tumour growth and progression. 
Several mechanisms have been proposed to explain the phenomenon of resistance, 
which is related to changes in the tumor cells, endothelial cells or other stromal 
cells. 
Actually emerging data support a proposition that there are two modes of 
unconventional resistance: evasive resistance, an adaptation to circumvent the 
specific angiogenic blockade, and intrinsic or pre-existing indifference. 
Several studies have highlighted the possibility that VEGFR inhibitors can 
promote an invasive metastatic switch, in part by creating an increasingly hypoxic 
tumor microenvironment. The evolving hypothesis is that angiogenic tumours can 
adapt to the presence of angiogenesis inhibitors, variously acquiring the means to 
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functionally evade the therapeutic blockade of angiogenesis. In contradistinction 
to traditional concepts of drug resistance being acquired by mutational alteration 
of the gene encoding a drug target or by alterations in drug uptake and efflux, 
evasive resistance is largely indirect: alternative ways to sustain tumour growth 
are activated but the specific therapeutic target of the anti-angiogenic drug 
remains inhibited. The current experimental evidence, which is not yet definitive, 
suggests that there are at least four distinct adaptive mechanisms that manifest 
evasive resistance to anti-angiogenic therapies: first, activation and/or 
upregulation of alternative pro-angiogenic signaling pathways within the tumour 
with revascularization. Although VEGF-mediated signaling is the predominant 
stimulator of angiogenesis in cancer, parallel angiogenic pathways also drive 
tumor growth. Activation of these pathways may overcome inhibition of anti-
angiogenic tyrosine kinase inhibitors. Besides VEGF blockade inhibits sprouting 
angiogenesis, but may not be as efficient in suppressing other modes of tumor 
vascularization, relying on vessel co-option, vasculogenic mimicry or vessel 
splitting.  Second, recruitment of bone marrow-derived pro-angiogenic cells 
which can obviate the necessity of VEGF signaling, thereby effecting reinitiation 
and continuance of tumour angiogenesis; third, increased pericyte coverage of the 
tumour vasculature, serving to support its integrity and attenuate the necessity for 
VEGF-mediated survival signaling; and fourth, activation and enhancement of 
invasion and metastasis to provide access to normal tissue vasculature without 
obligate neovascularization.
102 
We envision a second mode of resistance to anti-angiogenic therapy, one for 
which the experimental clues are more diffuse but the rationale is nevertheless 
persuasive: intrinsic, pre-existing non-responsiveness of a tumour.  
 Such a clue involves the clinical trials of the currently approved VEGF pathway 
inhibitors. Although the trial designs did not typically involve frequent serial 
monitoring that could document intrinsic resistance, it seems likely that some of 
the non-responding patients fall into this category of no discernible response, with 
their tumours evidently ‘growing through’ the therapy. Although this resistance 
could reflect rapid adaptation and the onset of evasive resistance, we expect that 
pre-existing resistance will prove to be in force in some cases. Its basis could be in 
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tumours that, by virtue of their particular developmental ontogeny, have already 
activated one or more of the aforementioned evasive resistance mechanisms, not 
in response to therapy but rather in response to the selective pressures of their 
microenvironment during pre-malignant development and malignant progression.  
The operative definition of this mode of pre-existing resistance is the absence of a 
discernable (even transitory) beneficial effect of an angiogenesis inhibitor, even 
when the subject’s tumour(s) is serially analyzed. There is no tumour shrinkage 
(that is, no partial or complete responses in the clinical parlance), no cessation of 
tumour growth (stasis), nor even retardation in growth rate; neither is there quality 
of life benefit, nor increased survival. In short, the patient (or the tumour-bearing 
animal) is intrinsically refractory to the anti-angiogenic therapy, so disease 
progression continues unabated. 
 Therefore, although the therapy based on VEGFR inhibitors has frequently 
demonstrated delayed tumor progression, leading to progression-free survival and 
overall survival benefits compared with standard chemotherapy, a significant 
number of patients either do not respond to antiangiogenic agents or develop 
resistance to them (figure 14).  
There is no compelling clinical evidence that antiangiogenesis treatment will 
make disease worse or decrease survival,
103
 but it remains a major question as to 
why such robust gains in progression-free survival (PFS) seen in the majority of 
completed phase III trials with bevacizumab and chemotherapy, or VEGFR TKIs 
as monotherapy, have not frequently corresponded to robust gains in overall 
survival. 
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Figure 14. Variable efficacy of VEGF pathway-targeted therapies: exposing the gap between 
preclinical and clinical testing. 
 
 
 
Furthermore it is crucial that the complexity of the signaling pathways that 
promote or regulate angiogenesis is translated into the clinical situation of the 
patients for the appropriate antiangiogenic therapy. Therefore research on the 
genetic basis of the tumour response to anti-angiogenic treatment will have 
important implications for the development of angiogenesis based biomarkers and 
the optimization of anti-angiogenic therapy. Tumour vascular imaging and 
determination of short-term response may provide the necessary data to develop 
and validate such markers.  
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Receptor Tyrosin Kinase Inhibitors (RTKIs) 
 
Monoclonal Antibodies (MAbs) 
The first chimeric therapeutic antibody, Rituximab, was generated in the late 
1980s
104,105
, and was approved in 1997 for the treatment of B-cell non-Hodgkin’s 
lymphoma. Mabs have been found to have great therapeutic potential for various 
pathological conditions, and their use has evolved into an active field in cancer 
research. The use of MAbs is a promising approach to overcome the difficulties in 
differentiating tumor cells from normal ones because they could be designed to 
selectively target tumor cells and trigger various responses. These agents can 
either directly kill cells by bearing toxic material or instigating the destruction of 
cells in other ways, such as activating immune system, blocking receptors, or 
exfoliating growth factors.  They can prevent the binding of the ligand or lead to 
receptor degradation.  
The extracellular ligand binding domain of the RTK is well suited to the binding 
of antibodies. Antibody binding to either the receptor or the ligand can disrupt 
ligand/receptor interaction and activation of the receptor. For this reason MAbs 
don not need to be internalized in the tumor cell to exert their action. 
 Although the exact mechanism of antibody therapy is not fully understood, it has 
been proven to be efficacious in the clinical setting. It was hypothesized that in 
addition to the growth inhibitory effect by binding their specific targets on the 
surface of tumor cells, these antibodies probably also provoked antibody-
dependent cell mediated cytotoxicity (ADCC). Hence, a majority of the antibodies 
currently in clinical use are IgG1 subtype. Monoclonal antibodies seem to work 
best when combined with other modalities such as chemotherapy. Furthermore, 
these monoclonal antibodies are either chimeric (-ximab), humanized (-zumab), or 
fully human antibodies (-mumab) to minimize immune response.
106 
As angiogenesis is essential to tumor growth, the family VEGF/VEGFR has been 
extensively studied and, nowadays, the most clinically advanced angiogenesis 
inhibitor is Bevacizumab (Avastin; Genentech Inc.), an intravenously 
administered humanized monoclonal antibody against VEGF that also directly 
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inhibits VEGFR on the tumor cells. FDA approval of Bevacizumab was first 
granted on the 26
th
 of February 2004 after a successful phase III trial for treatment 
of metastatic colorectal cancer, in combination with chemotherapy. Several other 
clinical trials are currently under way studying the use of this MAb in the 
treatment of RCC, metastatic breast cancer, and cervical cancer.
107 
When given in 
combination with chemotherapy, Bevacizumab prolongs the survival of patients 
with lung, colon and breast cancer. Bevacizumab has been also approved for non-
squamous-cell lung carcinoma (NSCLC), metastatic renal cell carcinoma and 
glioblastoma multiforme. It has been suggested that anti-VEGF treatment 
transiently ‘normalizes’ the tumour blood vessels, which results in more efficient 
delivery of the chemotherapeutic drug. 
Presently Bevacizumab is being used in nearly 1000 clinical trials, and, despite 
promising results, its effects in certain types of cancer are modest or even 
irrelevant, with a distinct toxicity profile. It is important to realize that, although 
the effects of Bevacizumab in progression free survival have been impressive, the 
clinical benefit in term of overall survival are still modest and it is obvious that 
anti-angiogenic therapy will have to be further refined.
 
Other antibodies and other immunologic strategies targeting the VEGFR ligands 
are currently under study. On the other hand few agents to date have specifically 
inhibited one or more of the extracellular domains of a VEGFR. A PEGylated di-
Fab fragment targeting specifically VEGFR-2, CDP791, was studied in a phase 1 
clinical trial and showed tolerable toxicities with no observed DLTs (dose-
limiting toxicities).
108
 IMC-1121, a chimeric antibody against VEGFR-2, has also 
been evaluated in early clinical trials.
109
 Unfortunately, half of the patients 
exposed to IMC-1121 developed antichimeric antibodies and as such, clinical 
development of IMC-1121 was halted. Since favorable results from this drug were 
evident, the chimeric antibody was fully humanized to form IMC-1121B 
(Ramucirumab), which is now the most clinically advanced direct and specific 
inhibitor of VEGFR-2. Efficacy from phase 1 and 2 studies is impressive when 
compared to other agents in its class, Ramucirumab appears to be more effective 
at causing tumor responses or stability of tumor size for extended periods in 
populations of patients that have been heavily pretreated.  
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Ramucirumab is currently tested in around 30 clinical trials, including phase 2 
studies, for a spectrum of cancer diagnoses and phase 3 for breast cancer, gastric 
cancer or gastroesophagel junction adenocarcinoma and HCC. Based on early 
clinical trials, this antibody has shown activity in patients previously treated with 
other anti-angiogenic agents, indicating a more efficient anti-tumor response with 
direct targeting of VEGFR-2. 
Another approach for anti-angiogenesis therapies is to inhibit the adhesive 
interactions between endothelial cells and the surrounding extracellular matrix 
(ECM). The integrin αβ3 is expressed at high levels in tumor vasculature and 
wound-healing tissues, but at extremely low levels in normal blood vessels.
110 
The 
integrin αβ3 is also highly expressed on tumor cells in various tissues. Therefore, 
the inhibition of this integrin may have anti-tumor and anti-angiogenic effects.
111
 
Vitaxin, a humanized MAb antagonizing this integrin, inhibits endothelial cell 
adhesion and proliferation. Unfortunately, despite the good results shown in vitro 
and in vivo, most phase I clinical trials have failed to demonstrate Vitaxin to be 
efficacious in the treatment of human cancer.
112 
Regarding EGFR family, three monoclonal antibodies, Cetuximab, Panitumumab 
and Trastuzumab, have been approved by the FDA for clinical use. Actually the 
EGFR is frequently activated or overexpressed in a large percentage of tumors 
and targeting EFGR was explored for the treatment of a number of human 
malignancies including lung, head and neck, and colon.
113-117
 
In colorectal cancer Cetuximab has been shown to provide survival benefit, when 
used alone or combined with Irinotecan. Moreover the addition of Cetuximab to 
chemotherapy improves survival in EGFR positive metastatic NSCLC patients.
116-
117
 Trastuzumab, a humanized antibody against HER2/Neu, a member of the 
human EGFR superfamily, has been used successfully to treat breast cancers
118 
and significantly increased tumor response rate (RR) and overall survival (OS) 
time when combined with cytotoxic agents such as Paclitaxel or Carboplatin.
119,120
  
Although these three monoclonal antibodies have changed the natural history and 
outcomes of the three high incidence tumors (lung, breast and colon), the 
development of resistance to these agents poses a new challenge in the cancer 
treatment, and to overcome such resistance, several new monoclonal antibodies 
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targeting EGFR family are in the pipeline (Matuzumab, Ertumaxomab, 
Nimotuzumab).
121-123 
 
 
Small molecules RTK inhibitors 
As before mentioned, several tyrosine kinase receptors, VEGFR in particular, play 
crucial roles in the angiogenesis of tumors and may, therefore, serve as reasonable 
targets for chemotherapy. In the 1990s, a major step in targeted therapeutics was 
the appearance of Imatinib (Glivec, Gleevec, Novartis), an agent that specifically 
targets Bcr-Abl, the tyrosin kinase fusion protein causing chronic myelogeneous 
leukemia (CML).
124,125 
This drug was the first selective tyrosine kinase inhibitor 
(TKI) approved in 2001 for the treatment of CML.
126 
In recent years several small-molecule drugs have been manipulated in clinical 
trials and even approved by FDA. Small-molecule inhibitors have the advantage 
of being orally available as well as more promiscuous in target inhibition and also 
less expensive. Based on these therapeutic advantages, many tyrosine kinase 
inhibitors (TKIs) have been developed and subjected to clinical trials.
127,128 
Unlike monoclonal antibodies (mAbs), that can only act on molecules expressed 
on the cell surface or on secreted molecules, TKIs can translocate through plasma 
membranes.  
Small-molecules inhibitors are largely hydrophobic and can easly enter the cell 
where they can interact with the cytoplasmic domain of cell surface receptors and 
intracellular signaling molecules. 
MAbs and TKIs have different targets and different mechanism of action: MAbs 
lead to the receptor internalization and lead to its down-regulation; besides they 
have the advantage that they could evoke an immune answer. 
TKIs, on the other hand, block the ATP binding site and prevent the activation of 
the intracellular signaling pathway. TKIs compete with ATP that is present in 
great amount in the cell and so they have to be administered in large doses.  
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While MAbs are single-target agents because they recognize the specific univocal 
binding site, TKIs can bind to different TKs because the structure of ATP binding 
site is highly preserved among the different families of TKs. 
The multi-target approach has emerged as a new paradigm for the use of the new 
kinase inhibitors.
129 
More specific single-target agents might not have significant 
effects on cancer complexity and highly specific inhibition of only one target has 
often been associated with modest response rates. Bevacizumab, for example, has 
proved to be an effective drug, and studies testing growth factor receptors-
targeting antibodies are promising, but drug resistance often develops likely due 
to targeting a single tumorigenic pathway. Indeed extended blockade of a single 
growth factor may result in tumor revascularization, dependent on other 
proangiogenic factors. In the multi-target approach, instead, such agents are able 
to simultaneously target the tumor and supportive cells. With regard to the 
development or resistance caused by overexpression of key factors of signaling 
pathways, drug-efflux systems or signaling bypass owing to mutations, resistance 
is unlikely to occur with multi-target agents. Multi-target inhibitors may affect 
multiple parallel downstream signaling pathways or enhance the inhibition of one 
specific shared signaling pathway.  
As a result of the similarity shared by VEGFR-1, -2, and -3, VEGFR inhibitors 
often target more than one member of the VEGFR family. This lack of selectivity 
among VEGFRs may be an advantage, since both VEGFR-1 and VEGFR-2 must 
be simultaneously inhibited to prevent tumor metastasis.
130
 Their poor selectivity 
among  different TK families seems to offer different opportunities in cancer 
treatment. Several independent biological pathways that are vital for tumor 
proliferation and metastasis can be disrupted by these compounds. Additionally, 
during VEGF inhibition, the hypoxic environment can drive a shift from VEGF 
dependent signaling to other proangiogenic pathways. For this reason, the use of 
multitargeted inhibitors should be of great therapeutic benefit.  
On the other hand, inhibition of multiple targets may lead to increased drug 
toxicity, since the target molecules might also be expressed on normal tissues. 
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Most of the RTKIs include compounds that bind to the kinase domain and 
compete for binding with the substrate, ATP. They target the ATP binding site in 
its active conformation, in which the activation loop is phosphorylated.  
Binding of ATP to a kinase is characterized by the formation of hydrogen bonds 
from the adenine ring to the ATP-binding cleft of the kinase.  
 
Conceptually, the binding site of ATP can be divided into five regions (Figure 
15)
131,132 
: 
 
Figure 15. Representation of the five main regions of the ATP binding site. 
 
Adenine region. It is an hydrophobic region that accomodates the purine ring of 
ATP, which joins the lobes through the formation of two hydrogen bonds with the 
polypeptide chain, in which are involved the nitrogen atom N1 and the amino 
group in the 6 position. This region is also called the "hinge" region. In addition to 
these polar interactions, the purine ring also engages non-polar interactions with 
hydrophobic residues located at the N- and C-terminal lobes. The region of 
adenine’s binding is not characterized by large amino acid variability and 
therefore the interaction with this site doesn’t provide useful elements for 
selectivity towards specific protein kinases. 
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Sugar Region. The riboside portion of ATP takes place in this area. The 2'-OH 
group forms a hydrogen bond with a polar residue located at the beginning of the 
C-terminal lobe (generally Ser, Asp, Glu or Gln). 
Phosphate region. This region accepts the triphosphate group and is mainly 
composed of a glycine-rich flexible loop, and an alpha helix structure that 
properly orients the phosphate group of ATP for catalysis. In most crystal 
structures of ATP-kinase, a hydrogen bond between the α and β phosphate groups 
of ATP and a residue of lysine has been found. The γ-phosphate group instead 
interacts with an arginine residue. 
Buried region: ATP does not occupy this region, which constitutes one of the 
main source of structural and sequence diversity among the members of the kinase 
superfamily. The buried region consists in a lipophilic pocket variable in shape 
and dimension, opposite to the sugar region. At the entrance of this region, in 
several kinases, there is an important residue called gatekeeper that creates 
obstruction and blocks the binding to the task.  On the other hand, in other kinases 
the gatekeeper is not present and these differences may be used to create selective 
TKIs. 
Solvent accessible region. The shape of solvent accessible region depends on the 
presence or absence of a glycine residue, which can cause a conformational 
change of the protein between the hinge region and the initial portion of the C-
terminal tail.
 
As the previous region, it is not occupied by ATP and can be 
exploited to rise ligand affinity towards the protein. 
RTKIs typically make hydrogen bonds to the Adenine region and hydrophobic 
interactions around the purine-like portion of the molecule. (Figure 15)
133 
Tyrosine kinase inhibitors can be classified into two main groups according to 
their binding mode to the receptor. Type I inhibitors, the ones of major interest, 
bind specifically to the adenine-binding or ATP site of kinases in the active form. 
Type II inhibitors bind to the ATP site in an additional hydrophobic back pocket, 
an allosteric site found in the inactive form of the kinase. Different conformations 
are observed in the active and inactive states of tyrosine kinases at the beginning 
of the activation loop, which is constituted of the highly conserved triad Asp-Phe-
Gly (DFG). In the active state the kinase adopts a ‘DFG-in’ conformation, 
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whereas in the inactive state it adopts a ‘DFG-out’ conformation (figure 16). The 
binding site normally targeted in the structure-based drug design of small-
molecule kinase inhibitors is composed of a front ATP-binding pocket and a 
hydrophobic back pocket formed by the DFG-out conformation.
 
In the front 
pocket, the two key amino acid residues that participate in H-bond interactions 
with the adenine ring of ATP are Glu917 and Cys919, which are located in the 
hinge area of the binding site. The two key amino acids in the back pocket that 
participate in H-bond interactions are Glu885, locating in the αC-helix, and 
Asp1046, a part of the DFG-motif in the activation loop. Usually most VEGFR-2 
inhibitors form hydrogen bonds with these key amino acid residues. 
In addition there is a third type of inhibitors known as “covalent” inhibitors that 
bind to cysteines at specific sites of the kinases. 
Sulfur in the cysteine residue is an electron-rich atom that reacts with an 
electrophilic group of the inhibitor. In this way the  inhibitors  irreversibly bind to 
the cysteine residue and block the binding of ATP, preventing the activation of the 
kinase. 
 
 
 
 
Figure 16.The binding site in the VEGFR-2 kinase domain, with key residues participating in H-
bonds highlighted (a) DFG-in conformation showing the ATP-binding site (red circle) and two salt 
bridges from Lys868 (green dotted lines); (b) DFG-out conformation showing the allosteric pocket 
(blue circle) behind the ATP site. 
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Selectivity of tyrosine kinases inhibitors, toxicities 
and combining agents 
 
The high sequence similarity in the ATP-binding site among the members of the 
kinase family often results in inhibitors exhibiting poor selectivity and undesired 
side effects that limit their clinic use. These considerations led to the search for 
more selective inhibitors in an attempt to minimize the risk of side effects. 
However, the risk of a lower efficacy due to the redundancies in signaling 
pathways, has recently increased, as before mentioned, the interest in multitarget 
drug discovery (MTDD) based on the belief that modulating more than one target 
can provide superior efficacy and safety profiles compared to single target drugs. 
Currently, there are two contrasting MTDD philosophies. The first one involves 
combining agents that are selective for a single target to achieve an additive or 
synergistic effect. The second one involves discovering agents that are 
simultaneously capable of addressing two or more targets. 
It is reasonable to expect that inhibitors of multiple kinases have a broader 
efficacy than a single-targeted inhibitor. For example VEGF and PDGF pathway 
both play important roles in angiogenesis and so, a multi-targeted kinase inhibitor 
that blocks VEGFR as well as PDGFR signaling, is expected to be more effective 
than an inhibitor that targets only one of these pathways. Furthermore, 
downstream signaling pathways of RTKs include not only tyrosine kinases but 
also serine/threonine kinases. For this reason, combining TKIs with 
serine/threonine inhibitors might be a good strategy, as well as combining TKIs 
with the anti-VEGF monoclonal antibody Bevacizumab. 
Another strategy to combine anti-angiogenic agents involves the use of TKIs in 
association with other cancer therapeutics, for example conventional cytotoxic 
chemotherapy. It is hypothesized that anti-angiogenic agents can induce vessel 
normalization of the structurally and functionally abnormal tumor vasculature.
134
 
This may result  in improved delivery of cytotoxic drugs to the tumor and could 
enhance the efficacy of chemotherapy or radiation therapy.
135
 Furthermore, 
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combining anti-angiogenic agents with chemotherapy potentially delays the 
development of resistance to anti-angiogenic drugs as well as to chemotherapy.
136
 
Many clinically useful drugs are now known to have multiple activities, but most 
of these multitarget drugs (MTDs) were discovered serendipitously and their 
mechanisms of action were only established retrospectively. The deliberate and 
prospective design of multikinase inhibitors (MKIs) with specific multiple activity 
profiles is an emerging approach in drug discovery.  
On the other hand inhibitors should be highly selective to minimize treatment-
induced toxicities. Toxicity is another issue associated with the use of VEGFR 
inhibitors. Adverse event profiles are generally acceptable and can be classified in 
on-target adverse events, caused by VEGFR inhibition, and off-target adverse 
events. 
Selective inhibitors may induce toxicities since their target kinases are not 
differentially expressed by endothelial cells. Angiogenesis inhibitors are expected 
to target activated tumor endothelium and not the normal vasculature because 
most blood vessels remain quiescent during adulthood. However, under 
physiological conditions, growth factor signaling in endothelial cells seems 
important for their survival and for the maintenance of vascular integrity. 
Inhibitors of angiogenesis are capable of affecting signaling pathways in 
endothelial cells and might elicit toxicities as a result of decreased endothelial cell 
renewal capacity. Moreover, we have to meditate about the fact that one kinase is 
able to activate several downstream signaling pathways and, the inhibition of this 
kinase, may cause the turning off of a whole spectrum of signaling pathways, with 
the resulting reduction in specific biological outcomes. For example bleeding 
complications and wound healing problems may be caused by a disturbance of the 
close interactions between platelets, which seem to be affected by TKI.  
Off-target adverse events are more frequent with multitargeted-kinase inhibitors
 
and are due to the simultaneous inhibition of other kinases different from 
VEGFRs. Off-target effects are more dependent on the characteristics of patients, 
and the stage of the disease.
 
However, VEGFR inhibitors are generally less toxic than conventional 
chemotherapeutic agents, with the most common adverse effects being 
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thromboembolic events, bleeding, wound healing complications, congestive heart 
failure, gastrointestinal perforation, and hypertension.  
The most common clinically relevant side effects of Bevacizumab and other anti-
angiogenic drugs include renal toxicity.  
Particular attention must therefore be devoted to the toxicity evaluation of 
therapeutic protocols using associations of VEGFR inhibitors and conventional 
cytotoxic agents. 
 
In conclusion the aim for the medicinal chemist working in the MKI field should 
be to strike the right balance between the nonselectivity (promiscuity) that may be 
required for efficacy and the selectivity that is required for safety.
137 
• Selective Tyrosine Kinase Inhibitors (TKI) are usually inhibitors of the EGFR 
family, including compounds like Gefitinib, Erlotinib and Lapatinib (figure 17). 
 
 
 
 
Figure 17. Chemical structures of the TKIs gefitinib, erlotinib and lapatinib. 
 
 
Erlotinib and Gefitinib are specific inhibitors of EGFR. Gefitinib was initially 
approved by FDA to treat NSCLC in the second line setting and later removed 
from market because of lacking survival benefit. Erlotinib remains the second or 
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third line treatment for NSCLC. Clinical data have shown that lung cancers 
showing EGFR mutations are sensitive to EGFR TKIs.
138-140
 
By means of crystallography the designed structures of TKIs were bound to the 
target receptor and the interactions between drug and target have been determined. 
In particular N1 atom of the quinazoline of Erlotinib establishes a H-bond with 
the NH group of Met769 and a water molecule operates as a link to create an H-
bond between N in position 3 of the quinazoline and the OH group of Thr766 
(figure 18). 
 
 
Figure 18. Interaction points between Erlotinib and its target.  
 
 
Unfortunately, after a short time treatment, these inhibitors exhibit the 
development of resistance, that can be caused by different mechanisms such as an 
increased production of target, mutations of the target-protein, a reduced up-take 
of the drug. 
In the perspective of creating multi-target inhibitors GlaxoSmithKline has 
developed Lapatinib, a less specific tyrosine kinase inhibitor than erlotinib and 
gefitinib. It inhibits both EFGR and HER2/Neu. Currently, lapatinib is approved 
for treating HER2/Neu positive metastatic breast cancer. In addition, lapatinib can 
cross the brain-blood barrier and is effective in treating brain metastases.
141-143
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• Small molecule TKIs of the VEGFR family are generally multikinase inhibitors 
(MKIs), and they inhibit both VEGFR-1 and VEGFR-2 in vascular endothelial 
cells. Among ATP site-directed inhibitors of VEGFR, there are several drugs, 
approved or still in clinical trial:
144,145 
 
 Sorafenib  
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Sorafenib tosylate (trade name Nexavar, codeveloped and comarketed by Bayer 
and Onyx Pharmaceutical) is an orally available byarilurea multitargeted kinase 
inhibitor. It inhibits VEGFR-2 and -3, PDGFRβ (platelet-derived growth factor 
receptor), c-kit and Raf.
146 
Importantly, it is the only approved drug shown to inhibit Raf, which is a critical 
component of the Ras pathway, a fundamental enzymatic cascade for cell 
division. Sorafenib was approved by U.S. FDA in 2005 for the treatment of 
advanced renal cell carcinoma (RCC) and in 2007 for the treatment of 
hepatocellular carcinoma (HCC).
147
 All the drugs reported in this section have 
been approved for RCC but only sorafenib for HCC. Probably the positive clinical 
trial results that led to sorafenib’s approval for HCC are due to the inhibitory 
activity of this drug on Raf. Indeed, overexpression of Raf and its pathway are 
frequently observed in HCC.
148,149
 However, further efforts to understand the 
complete role of sorafenib in thetreatment of HCC are still necessary.
 
The anti-viral and immunosuppressive activities of Sorafenib constitute additional 
mechanisms of action. 
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Sunitinib 
 
 
Sunitinib malate (SU11248), trade name Sutent, by Sugen-Pfizer, is a multikinase 
indol-2-one inhibitor targeting VEGFR-1 and VEGFR-2, PDGFRβ, and other 
kinases, including FLT3, which has been shown to be involved, especially in 
mutated forms, in acute leukemia.
150
 It also inhibits c-Kit, hyperactivated by 
mutations in gastrointestinal stroma tumor (GIST).  
Sunitinib is characterized by a 5-fluoro-substituted indolinone structure, bearing a 
diethylaminoethyl group that confer good solubility. The co-crystal X-ray 
structure of the catalytic domain of the FGF (Fibroblast Growth Factor) receptor 
with several oxindoles suggests that the compound bind in the ATP pocket with 
the indolin-2-one core participating in key H-bond donor/acceptor capacities with 
specific residues of the hinge region of VEGFR-2.  
Sunitinib was approved in 2006 by the FDA for the treatment of advanced 
metastatic RCC and of Imatinib-resistant or Imatinib-intolerant gastrointestinal 
stromal tumors (GISTS) and it is actually in phase III development across 
multiple tumor types.
151
 
 
 Pazopanib 
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Pazopanib hydrochloride (5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methyl-amino]-2-
pyrimidinyl] amino]-2-methyl-benzensulfonamide) (GW-786034), trade name 
Votrient, by GlaxoSmithKline, is a potent second generation, orally available, 
pan-VEGFR inhibitor ( it inhibits VEGFR-1, -2, and -3). Its chemical structure is 
quite unusual among kinase inhibitors, bearing a 2,4-pyrimidinediamine core 
substituted by an indazole ring and a 2-methylbenzenesulfonamide moiety.
 
Pazopanib also inhibits PDGFRα/β and c-Kit.  
Another important class of angiogenesis inhibitors is the one of 
Anilinophtalazines. These compounds resulted selective for human VEGFR. 
The anilinophtalazine derivative Valatinib is one of the most potent and selective 
first-generation VEGFR kinase inhibitors, with IC50 of 110, 43, 195 nm against 
VEGFR-1, -2, -3 respectively. 
 
 Valatanib 
 
 
Valatinib succinate (PTK787/ZK 222584) is an oral angiogenesis inhibitor 
selected through high-throughput screening for its ability to block VEGF 
receptors. It also inhibits other kinases including PDGFRβ and c-kit, but at higher 
concentrations. This compound is currently in phase III trials for metastatic 
colorectal cancer. 
 Valatanib was docked in a model of ATP binding site of VEGFR-2, constructed 
using the available X-ray structures of the domain of FGF receptor 1. 
According to Authors’ hypothesis, Valatanib does not form direct hydrogen bonds 
with the peptide backbone of the hinge region as ATP and many reported kinase 
inhibitors do, but rather occupies the hydrophobic regions of the binding site. The 
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aniline moiety
152
 is located in a hydrophobic pocket, while the phthalazine bicycle 
makes hydrophobic contacts with other amino acids. Although none direct 
hydrogen bond with the hinge region is established, the aniline NH group forms 
water-mediated hydrogen bonds with specific residues of the hinge region of 
VEGFR, and the inhibitor pyridil nitrogen is assumed to form a hydrogen bond 
with Lys 1060, a residue of the kinase activation loop.
153 
In the contest of the same structural class of Gefitinib (anilinoquinazolines) 
appropriate modifications of the substituents have led to the identification of 
Vandetanib. 
 
 Vandetanib  
 
 
Vandetanib, (ZD6474), trade name Caprelsa, previously called Zactima, produced 
by AstraZeneca, is an orally available anilinoquinazoline derivative bearing a 
water-solubilizing basic side chain. Vandetanib is an ATP mimetic small 
molecule, orally available, with inhibitory activity on different intracellular 
signaling pathways: VEGFR-2, EGFR and RET. The RET (rearranged during 
transfection) proto-oncogene encodes a trans-membrane TK for the glial cell line-
derived neurotrophic factor family of ligands, which is involved in the regulation 
of cell growth, differentiation, and survival. 
In April 2011, vandetanib became the first drug to be approved by the FDA for 
treatment of late-stage (metastatic) medullary thyroid cancer in adult patients who 
are ineligible for surgery.
154
 This therapeutic activity is likely caused by inhibition 
of RET,  hyperactivated by mutations in medullary thyroid cancer.
155 
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Vandetanib joins two actions with a dual pharmacological profile, exhibiting 
potent agonist activity toward VEGFR-2 and, to a lesser extent, to EGFR. The 
clinical development of vandetanib is being progressed, as in vivo tests have 
demonstrated the ability to inhibit, in a dose-dependent way, the growth of a wide 
range of cancers. Its administration in mice leads to inhibition of VEGF signal, of 
angiogenesis, of neuro-vascularization induced by the tumour, and the tumour 
growth. Vandetanib is undergoing phase I clinical testing in patients who have 
advanced solid tumours. Clinical activity of vandetanib in NSCLC is currently 
being tested in two large randomized phase III trials, in combination with 
docetaxel and with pemetrexed. 
Different clinical trials are evaluating the use of this inhibitor in association with 
some anticancer drugs such as Temozolomide (Temodal) and Bortezomib 
(Velcade) for the treatment of several types of tumor. 
 
 Axitinib 
 
 
Axitinib (AG013736), trade name Inlyta, is an indazole derivative developed by 
Pfizer as a mutikinase inhibitor. It is active on VEGFR-1, VEGFR-2, VEGFR-3, 
PDGFR, and c-Kit.
156 
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VEGFR inhibitors in clinical trials 
There are a good number of VEGFR and multi-targeted inhibitors that have 
entered clinical trials. 
The quinazoline and the quinoline moieties bearing C4 anilino or C4 oxy 
substituents and C6, C7 oxy substitents are present in several TK inhibitors, 
including vandetanib and gefitinib. Cediranib is a member of this family of drugs. 
 
 Cediranib  
 
 
Cediranib maleate (AZD2171) (tentative trade name Recentin), from 
AstraZeneca, is a 4,6,7-trioxyquinazoline, a highly potent, second generation, 
orally available inhibitor of VEGFRs, showing IC50 values of 5, 1, and 3 nM 
toward VEGFR-1, -2, and -3, respectively. It is also active toward PDGFRβ and 
c-Kit with similar potencies and possesses good selectivity over a panel of other 
tyrosine and serine/threonine kinases.
157
 This inhibitor reduces VEGF-induced 
angiogenesis in vivo and shows activity in mice implanted with human tumor 
xenografts. It is currently in several phase 2/3 trials, alone or in combination with 
other antineoplastic agents, for the treatment of various solid tumors and 
leukemias, particularly acute myeloid leukemia (AML).
 
Results from a phase 2 clinical trial using cediranib monotherapy at a dose of 45 
mg/day for recurrent glioblastoma showed encouraging proportions of 
radiographic response and 6-month progression-free patient survival, with 
manageable toxicity.
158
 Unfortunately, it has been successively reported that 
recurrent glioblastomas relapse after initial response to cediranib treatment. 
Probably the tumor escapes antiangiogenic therapy by switching to VEGFR-
independent pathways. However, it has been very recently determined that a 
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judicious application of antiangiogenic therapy in glioblastomas may normalize 
the structure and function of the tumor vasculature, promoting an improved blood 
perfusion. These findings offer direct clinical evidence in support of the 
hypothesis that vascular normalization can increase tumor drug perfusion and help 
to improve glioblastoma patient survival.
159
 Results from a phase 2 clinical trial 
indicated that cediranib monotherapy demonstrates significant evidence of 
antitumor activity in patients with advanced RCC. The adverse event profile is 
consistent with previous studies of cediranib 45 mg/day and includes diarrhea, 
hypertension, and fatigue.
160
 Cediranib monotherapy has modest single-agent 
activity in malignant pleural mesothelioma after platinum-based therapy. This 
study provides a rationale for further testing of cediranib plus chemotherapy in 
mesothelioma patients,
161
 whereas the compound is not an effective treatment in 
patients with unresectable or metastatic HCC, due to its high toxicity in this type 
of patients.
162 
Cediranib has been tested in phase I and phase II clinical trials, either as a single 
agent or in combination with other agents in solid tumors, showing a significant 
antitumor activity and a good tolerability profile. Cediranib is currently being 
evaluated in phase III trials for the first-line treatment of metastatic colorectal 
cancer and in a phase II study as second-line treatment. 
 
 Cabozantinib 
 
 
 
Cabozantinib (XL184, BMS-907351), invented at Exelixis, later developed by 
Bristol-Myers Squibb and then returned to Exelixis in 2010, is a quinoline 
derivative bearing a cyclopropane-1,1-dicarboxylic acid amide substituent. It is a 
multikinase inhibitor that targets VEGFR-2, MET, and RET. The drug also 
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inhibits Kit, FLT3, and Tek with IC50 values in the low nanomolar range in 
enzymatic assays. Preclinical studies demonstrate that cabozantinib potently 
inhibits multiple receptor TKs in various cancer cell lines and animal xenograft 
models, with significant oral bioavailability and blood−brain barrier penetration. 
Cabozantinib is also a promising agent for inhibiting tumor angiogenesis and 
metastasis in cancers with deregulated VEGFR, MET, and RET signaling. For 
these reasons it is a potential candidate for the oral treatment of medullary thyroid 
cancer, glioblastoma, and NSCLC.
163
 The compound is being tested in several 
phase 1/2 trials for different malignancies and in phase 3 trials in patients with 
medullary thyroid and prostate cancer.
164-166
 Cabozantinib was granted orphan-
drug status by the FDA in 2011. 
 
 Foretinib  
 
 
 
Foretinib (GSK1363089, XL880) was synthesized at Exelixis and then licensed 
by GSK in 2007. It is a cabozantinib derivative in which the 7-methoxy group of 
the quinoline ring has been substituted by a solubilizing basic side chain. It is a 
multitargeted inhibitor that is especially active on VEGFR and MET and shows 
IC50 values of 0.8, 6.8, and 2.8 nM against VEGFR-1, VEGFR-2, and VEGFR-3, 
respectively, and of 0.5 nM on MET. It also inhibits PDGFRs and the 
angiopoietin-1 receptor Tie-2, it shows modest activity on FGFR and EGFR, and 
is inactive against 50 serine/threonine kinases. In human umbilical vein 
endothelial cells (HUVEC), it reduces VEGFR-2 phosphorylation with an IC50 of 
16 nM.88 Foretinib reduces invasive tumor growth in different models of ovarian 
cancer by affecting several critical tumor functions. This provides the rationale for 
its further clinical development for the treatment of ovarian cancer.
167
 The 
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significant antitumor activities in patient-derived HCC xenograft models justifies 
its clinical investigation in patients with advanced HCC.
168
 Foretinib is being 
tested in phase 1−2 clinical trials on solid malignancies.  
 
 Tivozanib  
 
 
Tivozanib (KRN951, AV-951) was originally synthesized at Kirin Brewery, now 
Kyowa Hakko Kirin, then licensed to AVEO in 2007, which in turn licensed the 
compound to Astellas in 2011. It is a quinoline derivative bearing a urea moiety 
substituted with an isoxazolyl group. The urea function is often present in kinase 
inhibitors, since it is a suitable group for hydrogen binding interactions with 
amino acids of the kinase catalytic cleft. Tivozanib is a potent inhibitor of 
VEGFR-1, VEGFR-2, and VEGFR-3, showing IC50 values of 0.21, 0.16, and 
0.24 nM, respectively, and nanomolar activity values on PDGFRβ and c-Kit. It 
displays antitumor activity in a variety of human tumor xenografts, such as lung, 
breast, colon, ovarian, pancreas, and prostate cancer.
169
 Tivozanib is undergoing 
clinical trial investigation for the treatment of several solid tumors.
170,171
 Phase 2 
results suggest that tivozanib is active and well tolerated in patients with advanced 
RCC.  
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 Lenvatinib 
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Lenvatinib (E7080)  also possesses an urea moiety, whereas the C6 methoxy 
group present in the previously reported quinolines has been replaced with an 
amide group. The compound produced by Eisai Co. is a potent dual inhibitor of 
VEGFR-2 (IC50 = 4.0 nM) and of VEGFR-3 (IC50 = 5.2 nM). In preclinical 
assays lenvatinib suppresses lymph node and lung metastases of human breast 
tumor- Treatment with lenvatinib potently inhibits the proliferation of malignant 
pleural mesothelioma cell lines. The compound also shows activity on human 
sarcoma xenografs.
172
 It is being tested in phase 1−2 clinical trials against solid 
tumors, including HCC, melanoma, and thyroid cancer of medullary, papillary, 
and follicular subtypes.
173
  
 
 Dovitinib 
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Dovitinib, developed by Novartis/Chiron, is a benzymidazolhydroquinolinone 
multitargeted inhibitor active on VEGFR-1, -2, -3, FGFR, PDGFRβ, c-Kit, and 
FLT3 with IC50 values in the low nanomolar range. The compound binds to the 
active and so-called “in” conformation of the enzyme in an ATP-competitive 
fashion and forms three hydrogen bonds to the hinge region (to Glu917-CO, 
Cys919-NH, and Cys919-CO). Moreover, it makes a pattern of van der Waals 
interactions with other amino acids, including Val916, which is the gatekeeper 
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residue of the catalytic site, and with some residues in the purine pocket. The 
good pharmacokinetic profile and the pharmacological activity in preclinical 
models have prompted further investigation on this compound.
174
 Dovitinib shows 
antiangiogenic activity in vivo and, when orally administered, inhibits tumor 
growth in colon cancer animal models in a dose dependent manner.
175
 Despite its 
preclinical activity on hematologic malignancies, at the moment dovitinib is in 
clinical trials for solid tumor treatment only.  
 
 Orantinib 
 
 
Orantinib (SU6668, TSU-68), synthesized by Sugen, is an indolin-2-one 
structurally similar to sunitinib
 
 but bearing an acid group on the pyrrole moiety. It 
is a soluble and orally bioavailable nanomolar inhibitor of VEGFR-2, PDGFRβ, 
and FGFR-1. In animal models it produces tumor vascular normalization because 
of its antiangiogenic effect. The compound is currently being tested in phase 1−2 
clinical trials for the treatment of solid tumors, especially HCC. It shows 
promising preliminary efficacy with a high safety profile in patients with HCC 
who had been heavily pretreated
176
 and satisfactory activity against breast cancer 
in combination with other antineoplastic agents.
177 
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 Nintedanib 
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Nintedanib (or intenanib) (BIBF 1120) is a 6-methoxycarbonyl-substituted 
indolinone reported by Boehringer Ingelheim Pharma GmbH & Co. and defined 
as a triple angiokinase inhibitor targeting VEGFR, PDGFR, and FGFR. It shows 
IC50 values of 104, 5, and 5 nM for VRGFR-1, -2, and -3, respectively, and of 38 
and 18 nM for FGFR-1 and PDGFRα, respectively, in enzymatic assays. The 
compound is an ATP-competitive inhibitor, as indicated by the homology model 
of a similar derivative in the VEGFR-2 kinase domain. The typical canonical 
hydrogen bonds are formed with the specific residues of the hinge region (Glu917 
and Cys919). In addition, the carbonyl oxygen of the C6 group can form an 
additional hydrogen bond with Lys868, probably accounting for the high potency 
of this family of compounds. Nintedanib shows antiproliferative activity on 
VEGF-related endothelial cells with additional efficacy on pericyctes and smooth 
muscle cells. However, no direct inhibition of tumor cell proliferation is observed. 
It is orally available and displays encouraging efficacy in in vivo tumor models 
while being well tolerated. It is currently in phase 3 clinical trials for the treatment 
of NSCLC.
178
  
By means of receptor-based virtual screening studies, several molecules have been 
docked into the crystallized structure of the VEGFR protein, leading to the 
identification of different classes of derivatives. 
A representative class of VEGFR inhibitors is that of the anthranilamides, 
designed on the hypothesis that an intramolecular hydrogen bond between the 
aniline moiety and the benzanilide carbonyl group would favour a conformation 
with a high similarity degree respect the previously discovered phthalazine class 
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(figure 19).
179
 Lead optimization studies within the anthranilamide series resulted 
in the identification of AAL993 as a highly potent and selective inhibitor of 
VEGFRs, with IC50 values of 130, 23 and 18 nM for VEGFR-1, -2 and -3, 
respectively. AAL993 shows good pharmacological properties and excellent 
bioavailability, in both rodents and dogs.
180,181 
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Figure 19. Evolution of the phthalazine class (PTK787 as an example) of VEGFR inhibitors to the 
anthranilamides, and the structure of AAL993 as a representative example of the latter. 
 
 
 
The X-ray crystal structure of AAL993 in complex with the catalytic domain of 
di-phosphorylated VEGFR-2 revealed that this molecule binds to and stabilizes 
the inactive conformation of the protein. The binding to the inactive conformation 
provides a reliable explanation for the observed selectivity of such compound. In 
fact, unlike the highly conserved ATP-binding (or active) conformation of TK, the 
inactive states of these enzymes often adopt distinct conformations. 
The analisys of the AAL993-VEGFR-2 complex showed how the inhibitor binds 
to the protein through three hydrogen bonds between: a) the pyridine N atom and 
the backbone NH of Cys919 in the hinge region of the protein, b) the 
anthranilamide C=O group and the backbone NH of Asp1046 of the conserved 
DGF motif, and c) the anthranilamide NH and the side chain carboxylate of 
Glu885 of the αC helix. The trifluoromethylphenyl moiety of AAL993 is 
accommodated within a lipophilic pocket defined by hydrophobic amino acids, 
while the phenyl ring of the anthranilamide moiety is sandwiched between the 
hydrophobic side chain components of Val914 and Lys868 (figure 20).
182 
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Figure 20 A-B. A) Model of VEGFR-2 kinase domain based on the X-ray crystal structure. The 
location of AAL993 in the ATP binding site is illustrated by the light green surface. B) Close-up 
view of AAL993 docked into the ATP binding site of VEGFR-2. Nitrogen atoms are shown in 
blue, oxygen in red, sulfur in yellow, and fluorine in green.
182 
 
Some additional anthranilamide derivates have been patented by Novartis, 
including ABP309 (figure 21), which was shown to be an active second-
generation VEGFR inhibitor. In ABP309, the pyridine moiety of the previous 
derivates, which is hydrogen bonded to the enzyme hinge region, has been 
substituted by a pyridone group.
183
 ABP309 is active against VEGFR-2, with an 
IC50 value of 37 nM, while is less potent against VEGFR-1 and VEGFR-3 (IC50 
of 810 and 330 nM, respectively) and it inhibits tumor growth in murine 
xenografts. Potent anthranilamide VEGFR inhibitors differently substituted at 
either the amide or the amino moiety were also published by Shering, and one of 
the more recent classes is represented by the pyridone 1 (figure 21), endowed with 
a 59 nM IC50 value against VEGFR-2. 
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Figure 21. Chemical structures of anthranilamide derivates characterized by the pyridone group. 
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VEGFR inhibitors recently reported 
  
A high number of VEGFR inhibitors have recently been reported, highlighting the 
interest of medicinal chemists from both academia and pharmaceutical companies 
in this class of therapeutic agents. Even if experience frequently shows a decrease 
of inhibitor activity when passing from in vitro to in vivo assays, preliminary data 
on the biological profile of some of these compounds are extremely interesting. 
Some of the new compounds are derived from minor chemical modifications of 
lead compounds already approved or in clinical trials. It is likely that the majority 
of the new inhibitors will prove to be less active than their parent drugs as the 
biological evaluation continues. On the other hand, the introduction of a small 
substituent on a suitable chemical scaffold can lead to surprising results. The most 
famous example is imatinib, the first kinase inhibitor approved for clinical use and 
the first drug of choice for chronic myeloid leukemia (CML) treatment. It is 
derived from an optimization process on phenylaminopyrimidine derivatives 
active as protein kinase C (PKC) and other kinases inhibitors. The introduction of 
a simple methyl group (often referred to as the “magic methyl”) at position 6 of 
the diaminophenyl ring abolished PKC inhibitory activity and retained, or even 
enhanced, activity against protein tyrosine kinases, thus giving rise to imatinib 
that is active on Abl, the TK etiologic agent of CML.
184
 It is impossibile to rule 
out a similar advance in the field of VEGFR/multitargeted inhibitors. 
Regorafenib, a close analogue of sorafenib, which bears only one fluorine atom 
more than its parent, appears to be doing surprisingly well in clinical trials, 
especially for metastatic colorectal cancer. It is very difficult to determinate a 
priori the complex nature of the interactions between a small molecule drug and a 
protein target, even using advanced techniques such as Xray crystallography or 
molecular modeling studies. So it is impossible to predict whether or not a very 
small change in a molecule will give rise to a large variation in its biological 
activity. It is important to point out that, besides the possible structural 
drug−target collaboration just mentioned, a small variation of chemical structure 
can lead to a different solubility or permeability and consequently to a different 
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biological behavior, especially when the compound in question is an apolar 
molecule, as several TKs inhibitors are. 
Among tyrosine kinases inhibitors, great interest has been directed towards the 
pyrimidines derivatives. 
 
Pyrimidine derivatives 
Many derivatives characterized by a variously substituted pyrimidine ring, either 
isolated or fused to form different heterocyclic structures, have been reported as 
interesting VEGFR inhibitors. 
 
Pyrrolo-pyrimidines 
AEE788 is a 7H-pyrrolo[2,3-d]pyrimidine synthetized by Novartis as a dual 
inhibitor of EGFR and VEGFR, which shows IC50 values of 2, 77, 59 nM towards 
EGFR-2, VEGFR-2 and VEGFR-1, respectively, in enzymatic assays.  
 
N
N
NH
H
N
N
N
 
AEE788 
 
In a cell based ELISA assay it was not particularly active towards VEGFR-2 
(IC50960 nM), but it inhibited the proliferation of VEGF-stimulated HUVECs 
(humanumbilical vein endothelial cell) and the VEGF-induced angiogenesis in a 
murine model. Orally administrated, AEE788 shows favourable pharmacokinetic 
properties and antitumor activity in different animal models of cancer. The drug 
has been evaluated in different phase I clinical trials in patients with advanced 
solid tumors and with recurrent glioblastoma, and is currently in phase II trials.  
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7-Aminopyrazolo[1,5-a]pyrimidines 
These compounds are substituted with a urea function and gave different VEGFR 
and PDGFR inhibitors. Several of these compounds were selective for VEGFR-2. 
Modeling and SAR studies suggest that these compounds bind in the ATP pocket 
of the enzyme with the 7- aminopyrazolo[1,5-a]pyrimidine core forming a 
bidentate hydrogen bonding interaction with the hinge region, in particular 
between the exocyclic amine and Glu917 backbone carbonyl and between the N1 
of the pyrazolopyrimidine and Cys919 NH. The N,N′-diarylurea occupies the 
hydrophobic pocket. 
Pyrazolo[1,5-a]pyrimidines with a 3-thienyl substituent, have been reported by 
Merck researchers as potent inhibitors of VEGFR-2. The optimization of the first 
series of compounds led to derivative 2, bearing a basic side chain on the 6-aryl 
ring that improves the pharmacokinetic properties. This molecule is selective for 
VEGFR-2, with an IC50 value of 7 nM, and inhibits VEGF-stimulated mitogenesis 
in HUVECs. 
NN
N
N
N N
S
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Thieno- and furo-pyrimidines 
Thieno-pyrimidines have been presented by Pfizer as potent dual inhibitors of 
VEGFR-2 and EGFR. Compound 3a possesses IC50 values of 2 and 7 nM towards 
the two TKs, respectively; interestingly, the similar thieno-pyridine (3b) is 250-
fold more selective towards VEGFR-2, showing IC50 values of 5 and 1250 nM 
against VEGFR-2 and EGFR, respectively.
185 
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N
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R
3a. X = N, R = CH2-N-piperidine-4-CONH2, R1 = H
3b. X = CH, R = CH2-N-morpholine, R1 = CH3  
 
Driven by a multidisciplinary approach combination (Structure-Based (SB) Three-
Dimensional Quantitative Structure–Activity Relationships (3-D QSAR), 
molecular modelling, organic chemistry and various biological evaluations, new 
thienopyrimidines, as inhibitors of KDR activity and human umbilical vein 
endothelial cell (HUVEC) proliferation, have been disclosed. More specifically, 
the compound below represents a new lead compound that inhibits VEGFR-2 and 
HUVEC at μM concentration. Moreover by the mean of an endothelial cell tube 
formation in vitro, 4 tartaric acid salt proved to block angiogenesis of HUVEC at 
μM level. 
 
 
 4 
 
 
Diaminofuro[2,3-d]pyrimidine 5 is a dual inhibitor of VEGFR-2 and PDGFR-β. 
The anti-angiogenic activity was assessed in the CAM (chicken embryo 
chorioallantoic membrane) assay, where 5 showed a 40 nM IC50 value. Moreover, 
the compound is more active than metotrexate in a B16 melanoma mouse model, 
and was also able to decrease lung metastases. Molecular modelling studies show 
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that the 4-aminopyrimidine moiety of ATP and 5 were initially superimposed. The 
4-NH2 along with the ring N3 of 5 make hydrogen bonds with the backbone 
carbonyl of Glu917 and the backbone NH of Cys919 in the hinge region, 
respectively; moreover, the 2-NH2 forms an additional H-bond with Cys919.
 
 
N
N O
NH2
H2N
CH3
 
5 
 
Pyrimido-pyrimidinones 
RO4383596 (6a) produced by Hoffmann-La Roche, is a multitargeted molecule 
that inhibits VEGFR-2, FGFR and PDGFR with IC50 values of 44, 29, 33 nM, 
respectively, while being between 10- and 3000-fold less potent against other 
TKs. In cell assays, it potently inhibits VEGF-stimulated HUVEC proliferation.
 
Compound 6b RO4396686, shows a biological  similar behaviour and 
significantly inhibits tumor growth. 
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6a RO4383596 R = H
6b RO4396686 R = F
 
 
Pyrimido-pyridones 
TKI-28 7 is a multitargeted TK inhibitor that shows IC50 in the low nanomolar 
range against VEGFR-2 (27 nM), EGFR, PDGFR-β, c-Kit and c-Src, while being 
inactive against VEGFR-1. The compound was found to possess anti angiogenic 
effects, with inhibition of EGF-, VEGF- and PDGF-stimulated cell proliferation, 
as well as decreased cell migration and tube formation in human microvascular 
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endothelial cells (HMECs), suggesting TKI-28 as a very promising anti-cancer 
and anti-angiogenic agent.
186
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Isolated pyrimidine ring derivatives 
The most active compound 8, bearing a 4-fluoro-2-methylindole on the oxygen 
atom at C-6 of the pyrimidine ring, has an IC50 value of 24 nM in enzymatic 
assays and shows antiproliferative activity against three different cancer cell lines, 
with IC50 values in the range 230-380 nM.
187 
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2,4-Disubstituted pyrimidines have been reported by Merck researchers as 
VEGFR-2 inhibitors; in particular, the 3,5- dimethylaniline derivative 9 inhibits 
the kinase with IC50 values of 6 and 19 nM in enzymatic and in cell assays, 
respectively.
188 
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A series of 4-aryl- 5-cyano-2-aminopyrimidines shows potent VEGFR-2 kinase 
inhibitory activity. The substituted cyano-pyrimidine JNJ-17029259 10, reported 
by Johnson and Johnson Pharmaceuticals, is a potent, orally available and 
selective inhibitor of the VEGFR family, showing IC50 values of 90, 21 and 12 
nM towards VEGFR-1, -2, and -3, respectively, about ten-fold lower activity 
towards PDGFR-β, FGFR and Flt-3, and no significant activity towards a huge 
panel of other tyrosine and serine/threonine kinases. Moreover, JNJ-17029259 
inhibits VEGF-induced HUVEC proliferation and migration with a 52 nM IC50 
value and possesses an interesting antiangiogenic activity as evaluated in an aortic 
ring assay (IC50=50 nM). The compound exhibits activity in delaying the growth 
of a variety of solid tumors in xenograft models, administered alone or in 
combination with conventional chemotherapeutic agents, such as paclitaxel and 
doxorubicin.
189 
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New Benzo- And Pyrido- Thiopyrano Fused 
Pyrimidines 
By means of receptor-based virtual screening studies, several series of chemical 
structures have been docked into the crystallized structure of the VEGFR protein, 
leading to the identification of several classes of derivatives.
 
The most performing leads, designed as ATP competitive compounds, proved to 
firmly bind to the catalytic site of the proteins, which has the peculiarity to be 
highly conserved throughout the whole class of tyrosine kinases. In particular, 
these products anchor to the backbone of the site exploiting hydrophobic 
interactions, strengthened by one or more hydrogen bonding groups, often 
heteroatoms. Moreover, other substituents, connected by different spacer chains, 
including amino and/or amide groups, can protrude toward two other distinct 
areas of the site, the solvent accessible region and the buried region. 
The research program performed in the laboratory where I worked for my thesis 
has always been devoted to the preparation and evaluation of new antiproliferative 
agents,
190-194
 polycyclic chromophores, as novel potential tyrosine kinase 
inhibitors. 
On the basis of previously described results, a series of benzothiopyran-fused 
pyrimidines of general formula I (figure 22), characterized by an aniline group in 
the 2-position, (compounds 12a-i ) has been recently synthesized.
195
 These latter 
were designed moving from the structures of the aniline substituted pyrimidines 
above reported.  
Actually it was hypothesized that these new products might share the 
pharmacophoric requirements suitable for an anchoring to the ATP binding site, in 
particular the aniline NH group and the pyrimidine N1 and N3 atoms. Moreover it 
seemed plausible to investigate if the thiopyrane sulfur atom might be directly 
implicated in additional H-bonding interactions with critical residues of the 
catalytic cleft. With the aim to perform critical SAR studies, the analogue 
derivatives 2-aryl (compounds 11a-i) and 2-benzylamino (compounds 13a-i) were 
also synthesized. In addition, the influence of electron donor or electron 
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withdrawing substituents (OCH3, Cl), into the heterocyclic system or on the 
pendant aryl group, was also assessed (figure 22).  
 
S
NN
Z
X
R1
               I
Z = - ; NH; NHCH2
X = H; OCH3; Cl
R1 = H; OCH3; Cl
 
Figure 22. General formula of  2-substituted-benzothiopyrano-fused pyrimidines (formula I). 
 
N Z X R1 n Z X R1 N Z X R1 
11a - H H 12a NH H H 13a NHCH2 H H 
11b - H OCH3 12b NH H OCH3 13b NHCH2 H OCH3 
11c - H Cl 12c NH H Cl 13c NHCH2 H Cl 
11d - OCH3 H 12d NH OCH3 H 13d NHCH2 OCH3 H 
11e - OCH3 OCH3 12e NH OCH3 OCH3 13e NHCH2 OCH3 OCH3 
11f - OCH3 Cl 12f NH OCH3 Cl 13f NHCH2 OCH3 Cl 
11g - Cl H 12g NH Cl H 13g NHCH2 Cl H 
11h - Cl OCH3 12h NH Cl OCH3 13h NHCH2 Cl OCH3 
11i - Cl Cl 12i NH Cl Cl 13i NHCH2 H H 
 
*
The 2-phenyl unsubstitited derivative 11a, as well as the unsubstituted anilino derivative 12a, 
were already described in literature,
196,197
 while the 8-methoxy-2-phenyl-5H-
benzo[3',2':5,6]thiopyrano [4,3-d]pyrimidine 11d, was previously prepared and published by our 
group. 
 
 
Subsequently, the synthesis of a series of pyridothiopyrano-pyrimidines analogs 
of general formula II was accomplished (figure 23). 
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Figure 23. General formula of  2-substituted-pyridothiopyrano-fused pyrimidines (formula II).  
 
N S
NN
Z
R
Z = - ; NH; NHCH2
R = H; OCH3; Cl
II
 
 
 
Recent Modifications: 
With the aim to further investigate the importance of the -NH group of the 2-
anilino substituted derivatives, it was also performed the synthesis of the 
omologous N-methyl anilino derivative 17. 
 
N S
NN
N
H3C
17  
 
Moreover, considering that many VEGFR inhibithors described in literature 
present a m-substituted aniline group inserted on the system of various fused 
pyrimidines, new benzothiopyrano- (12l-q) and pyridothiopyrano- (15d-f and 
16d-f) fused pyrimidines of general formula III, characterized by meta 
substituents on the 2-aryl moiety, were also prepared (Figure 24). In addition to 
m-OCH3 and m-Cl phenyl- substituents, the m-Br phenyl group, which had 
Comp. Z R 
14a - H 
14b - OCH3 
14c - Cl 
15a NH H 
15b NH OCH3 
15c NH Cl 
16a NHCH2 H 
16b NHCH2 OCH3 
16c NHCH2 Cl 
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already been found to affect the activity of described VEGFR inhibitors, was also 
inserted. 
 
Figure 24. General formula of  2-[(m-substituted)-aryl] benzo- and pyrido-thiopyrano fused 
pyrimidines (formula III). 
 
Y S
NN
Z
X
Y = CH; N
Z = - ; NH; NHCH2
X = H; OCH3; Cl
R = OCH3; Cl; Br
R
III
 
 
 
 
 
In a second period, following the previous works, some new benzothiopyrano- 
and pyridothiopyrano-fused pyrimidines in which the substituents in the meta 
position of the 2-aryl moiety were modified have been prepared. 
 
Y S
NN
Z
X
R
 
III 
 
Y = CH, N;   X = H, OCH3;   Z = NH, NHCH2,  R = CF3, F 
     18a-d: Y = CH;  X = H, OCH3;  Z = NH; R = CF3, F 
     19a-b: Y = CH;  X = H, OCH3;  Z = NHCH2; R = CF3 
     20a-c: Y = N;  X = H;  Z = NH, NHCH2; R = CF3, F 
 
In particular m-CF3 and m-F groups were inserted on the N-anilino or N-
benzylaminno moieties of the fused pyrimidines above described. (compounds 18-
Comp. Y Z X R 
12l CH NH H OCH3 
12m CH NH H Cl 
12n CH NH H Br 
12o CH NH OCH3 OCH3 
12p CH NH OCH3 Cl 
12q CH NH OCH3 Br 
15d N NH H OCH3 
15e N NH H Cl 
15f N NH H Br 
16d N NHCH2 H OCH3 
16e N NHCH2 H Cl 
16f N NHCH2 H Br 
 
Introduction to Experimental Section                                                               
89 
20) Actually, several described VEGFR-2 inhibithors are characterized by a m-
CF3 substituted phenyl moiety.
198 
Moreover, in order to verify the relevance of S atom in the 6 position of the 
heterocyclic compounds, the chromane derivatives 21a-c have been also 
synthesized. 
 
O
NN
Z
R
 
 
21a-c: Z = NH, NHCH2; R = CF3, F 
 
 
Biological evaluation: preliminary results    
 
The biological activity of the novel derivatives here reported, was evaluated  by a 
research group of the University of Padova.  
The capacity of targeting VEGFR-2 was assayed in vitro, the antiproliferative 
activity was evaluated in HUVEC and human tumor cell lines (HeLa, A-431 and 
MSTO-211H), and the antiangiogenic activity was confirmed in an ex vivo rat 
aortic ring assay. Combining modelling studies and biological assays, the 
inhibition profile of the tricyclic derivatives was rationalized. 
 
KDR inhibition assay 
The ability to inhibit the kinase activity of the VEGFR-2 (or kinase insert domain 
receptor, KDR), which is considered to exert a pivotal role in neo-angiogenesis, 
was determined by a biochemical assay performed with a recombinant human 
kinase insert domain receptor, using Semaxanib (SU5416) as reference 
compound. The preliminary results relative to the 2-anilino-substituted-5H-
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benzothiopyrano [4,3-d]pyrimidines 11a-i, 12a-q and 13a-i are reported in Tables 
4-6 and figures 25a-c. 
 
 
Table 4.        Table 5. 
 
 
 
 
 
 
Table 6. 
Comp. Z X R1 R2 
KDR 
inhib. (%) 
13a NHCH2 H H H n.d 
13b NHCH2 H OCH3 H 17 
13c NHCH2 H Cl H n.d 
13d NHCH2 OCH3 H H n.d 
13e NHCH2 OCH3 OCH3 H 13 
13f NHCH2 OCH3 Cl H n.d 
13g NHCH2 Cl H H n.d 
13h NHCH2 Cl OCH3 H 35 
13i NHCH2 Cl Cl H n.d 
 
Comp. Z X R1 R2 
KDR 
inhib. (%) 
11a - H H H n.d 
11b - H OCH3 H 31 
11c - H Cl H n.d 
11d - OCH3 H H n.d 
11e - OCH3 OCH3 H 11 
11f - OCH3 Cl H n.d 
11g - Cl H H n.d 
11h - Cl OCH3 H 41 
11i - Cl Cl H n.d 
 
 
Comp. Z X R1 R2 
KDR 
inhib. (%) 
12a NH H H H 83 
12b NH H OCH3 H 73 
12c NH H Cl H 71 
12d NH OCH3 H H 58 
12e NH OCH3 OCH3 H 60 
12f NH OCH3 Cl H 22 
12g NH Cl H H 21 
12h NH Cl OCH3 H 18 
12i NH Cl Cl H 80 
12l NH H H OCH3 92 
12m NH H H Cl 13 
12n NH H H Br 17 
12o NH OCH3 H OCH3 n.d 
12p NH OCH3 H Cl n.d 
12q NH OCH3 H Br n.d 
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Figure 25a. Percentage of the KDR tyrosine kinase activity inhibition of 2-phenyl- 11b, 2-anilino- 
12b, and 2-benzylamino- 13b, 8-methoxy-substituted derivatives. 
 
 
Figure 25b. Percentage of the KDR tyrosine kinase activity inhibition of 2-phenyl- 11e, 2-anilino- 
12e, and 2-benzylamino- 13e, 8-methoxy-substituted derivatives. 
 
 
Figure 25c. Percentage of the KDR tyrosine kinase activity inhibition of 2-phenyl- 11h, 2-anilino- 
12h, and 2-benzylamino-13h, 8-chloro-substituted derivatives. 
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The results obtained from the enzymatic assays allowed a generally high 
percentage of inhibition for the most part of the 2-anilino substituted derivatives 
(compounds of series 12), while both the addition of a methylene group 
(compounds of series 13) and the deletion of the amino spacer group (compounds 
of series 11) reduced the tyrosine kinase inhibition, thus clearly indicating a 
crucial role for the length of the side chain.  
In addition an important role of the substituents on both the chromophore and the 
aryl moiety was observed. As regards the 2-anilino-substituted derivatives 12, 
when the aryl moiety is unsubstituted (12 a,d,g), or bears a p-methoxy group (12 
b,e,h), the inhibition values are progressively reduced by the presence in the 8 
position of the chromophore of methoxy or chlorine substituents. Conversely, 
when a p-chloro aryl group is present (12 c,f,i) the highest value is shown by the 
8-chloro substituted compound 12i. In the group of m-substituted aniline 
derivatives, the preliminary results, referred to the 8 unsubstituted compounds 12 
l-n, indicate the methoxy group (comp. 12l) as the most suitable, while a halogen 
(both Cl and Br) seems to be detrimental.  
What is concerning the 2-phenyl (11 a-i) or 2-benzylamino (13 a-i) substituted 
derivatives, the now available results indicate the 8-chloro substituted analogues 
11h and 13h as the most active, and, what is puzzling, they show inhibition values 
higher than that of 12h. 
Finally, the drastic decrease in the KDR inhibition (2%) showed by the N-methyl 
substituted anilino derivative 17 can clearly indicate the key role played by the -
NH group on the 2 position. The results recorded by the evaluation of some 
isosteric pyridothiopyrano derivatives (Table 7 and figure 26), showed that the 
introduction of the pyridine heteroatom resulted successful, leading to an 
improvement in the enzymatic inhibition. Actually the 2-anilino substituted 
counterparts (compounds of series 15) confirmed to be endowed of a notable 
activity and among the tested compounds, the 2-(p-methoxy-anilino) substituted 
derivative (15b) produced the maximal (98%) inhibition of the tyrosine kinase 
activity. 
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Table 7. 
 
   
 
   
 
 
 
 
 
 
 
 
Figure 26. Percentage of the KDR tyrosine kinase activity inhibition of 2-(p-OCH3-phenyl)- 14b, 
2-(p-OCH3-anilino)- 15b, and 2-(p-OCH3-benzylamino)- 16b, substituted derivatives. 
 
Antiproliferative activity. The ability of new derivatives to inhibit cell growth 
was evaluated by means of an in vitro assay performed on human umbilical vein 
endothelian cells (HUVECs) and on cervix adenocarcinoma (HeLa), epidermoid 
carcinoma (A-431) and biphasic mesothelioma (MSTO-211H) human tumour cell 
lines. The results, expressed as IC50 values, i.e., the concentration (M) of 
 Comp Z R1 R2 
KDR 
inhib. 
(%) 
14a - H H n.d 
14b - OCH3 H 20 
14c - Cl H n.d 
15a NH H H 92 
15b NH OCH3 H 98 
15c NH Cl H 60 
15d NH H OCH3 88 
15e NH H Cl 21 
15f NH H Br 53 
16a NHCH2 H H 10 
16b NHCH2 OCH3 H 38 
16c NHCH2 Cl H 11 
16d NHCH2 H OCH3 n.d 
16e NHCH2 H Cl n.d 
16f NHCH2 H Br n.d 
SU5416    67 
Introduction to Experimental Section                                                               
94 
compound able to produce 50% cell death with respect to the control culture, are 
shown in Table 8. SU5416 (Semaxanib) was used as a reference compound. 
A good ability to exert antiproliferative effects on the HUVEC cells was shown 
by most part of the 2-phenyl and 2-anilino substituted pyrimidines 11a-i and 12a-
i, as demonstrated by their IC50 values, usually in the micromolar range (from 
0.35 to 16.4 M) and comparable or lower to that of SU5416. In contrast, the 2-
benzylamino substituted derivatives 13a-i always exhibited a lower cytotoxic 
capacity in this cell line. 
By comparing the antiproliferative effects exerted by analogous compounds, 
bearing the same aryl side group, a certain role seems to be played by the 
substituents in position 8 (X) and 4' (R1). Actually, within the sub-series 11a-i, the 
most active compounds are the unsubstituted (R1 = H) 11a, 11d and 11g, and the 
p-methoxy substituted (R1 = OCH3) 11b, 11e and 11h. Conversely, the insertion 
of a chlorine (R1 = Cl, compounds 11c, 11f and 11i), generally lowers the activity. 
As regards the role of the X group in the 8-position, a similar profile is displayed 
within each group of analogues, since the introduction of methoxy (11d, 11e 
versus 11a, 11b) or chlorine (11g, 11h versus 11a, 11b) enhances cytotoxic 
ability.) The lack of specific correlation between KDR inhibition ability and 
HUVECs antiproliferative capacity likely reflects that additional biological targets 
may play important roles in determining antiproliferative activity. 
The nature of the substituents R1 and X modulates the antiproliferative effects also 
in the group of 2-anilino substituted pyrimidines 12a-i. Actually, cytotoxic 
potency is usually improved by a methoxy on the phenyl ring (R1 = OCH3, 
compounds 12b, 12e versus 12a, 12d) or it is lowered if R1 is a chlorine (R1 = Cl, 
compounds 12c, 12f versus 12a, 12d). What is most puzzling is the effect of the 
halogen in the 8-position (X = Cl) of the heterocyclic scaffold. While 8-chloro 
substituted pyrimidines have null or scarce activity when R1 = H (compound 12g), 
or R1 = OCH3 (compound 12h), the 4'-chloro analogue 12i (R1 = Cl) is 
surprisingly the most potent compound in the whole series, in this assay on 
HUVEC cell lines. In this sub-series 12 a good correlation between KDR 
inhibition potency and HUVEC antiproliferative activity can be recognized, likely 
supporting this protein kinase as the main target of our anilino-pyrimidines. 
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The less performing sub-series 13a-i displayed comparable low cytotoxic 
potencies, independently of the presence of a hydrogen, a methoxy group or a 
chlorine in the 4' (R1) and/or 8 (X) positions, indicating that, in this class of 
analogues, the dependence of the cellular effects on such groups appears 
responsible only for slightly different biological activities. 
The above results might confirm the important role played by the NH spacer 
group, given that, only compounds 12a-i, featuring the 2-anilino side moiety, 
combine a significant antiproliferative effect on HUVEC cells with high inhibition 
rates in the KDR assay. 
In addiction, a notable effect might also be attributable to the p-methoxy 
substituent on the pendant phenyl ring, being 12 b,e the most active derivatives. 
The p-chlorine substitution seems detrimental, with the exception of 12i in which 
a good activity curiously appeared by introducing a chlorine atom on the 8-
position. 
The introduction of the pyridine heteroatom in the chromophore system led to an 
important improvement in cytotoxic activity, with IC50 values in the nanomolar 
range (15b). The crucial role for the length of the side chain was confirmed; 
moreover the activity was now expanded to the benzyl substituted homologues 
(16b,c). 
In order to highlight other cellular targets and prove that the compounds above 
described might be used in cancer treatment, the antiproliferative activity of the 
different series of compounds was evaluated on tumor human cell lines. The 
antiproliferative activity was assayed on HeLa (cervix adenocarcinoma), A-431 
(epidermoid carcinoma) and MSTO-211H (biphasic mesothelioma) cell lines. The 
results are expressed as IC50 values, i.e. the concentration (µM) of compound 
able to produce 50% cell death with respect to the control culture, treated with 
SU5416 (Semaxanib) as reference compound (Table 8). 
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Table 8. 
Y S
NN
Z
X
R2
R1
 
 
Comp. Y Z X R1 R2 KDR HUVEC HeLa A-431 MSTO-
211H 
11a CH - H H H 20 4.0 >20 >20 >20 
11b CH - H OCH3 H 31 12 >20 >20 >20 
11c CH - H Cl H 20 11.3 >20 >20 >20 
11d CH - OCH3 H H 20 2.9 >20 6.51.2 11.91.1 
11e CH - OCH3 OCH3 H 20 4.8 >20 >20 >20 
11f CH - OCH3 Cl H 20 >20 >20 >20 >20 
11g CH - Cl H H 20 2.3 >20 >20 >20 
11h CH - Cl OCH3 H 41 4.7 >20 >20 >20 
11i CH - Cl Cl H 20 15.3 >20 >20 >20 
12a CH NH H H H 75 2.4 10.22.1 >20 11.71.3 
12b CH NH H OCH3 H 75 0.45 0.70.5 0.960.25 1.080.04 
12c CH NH H Cl H 43 7.3 15.62.2 >20 11.51.5 
12d CH NH OCH3 H H 58 4.3 20.1 >20 15.01.6 
12e CH NH OCH3 OCH3 H 56 0.74 0.830.14 0.960.2 1.080.2 
12f CH NH OCH3 Cl H 22 >20 >20 >20 >20 
12g CH NH Cl H H 21 >20 >20 >20 >20 
12h CH NH Cl OCH3 H 18 16.4 2.10.2 5.80.4 20 
12i CH NH Cl Cl H 74 0.35 1.50.4 2.20.4 1.60.3 
12l CH NH H H OCH3 92 >20 n.d n.d n.d 
12m CH NH H H Cl 13 >20 n.d n.d n.d 
12n CH NH H H Br 17 12.3 n.d n.d n.d 
12o CH NH OCH3 H OCH3 n.d >20 n.d n.d n.d 
12p CH NH OCH3 H Cl n.d >20 n.d n.d n.d 
12q CH NH OCH3 H Br n.d >20 n.d n.d n.d 
13a CH NHCH2 H H H 20 >20 >20 >20 >20 
13b CH NHCH2 H OCH3 H 20 >20 >20 >20 >20 
13c CH NHCH2 H Cl H 20 12.3 >20 >20 >20 
13d CH NHCH2 OCH3 H H 20 >20 >20 >20 >20 
13e CH NHCH2 OCH3 OCH3 H 20 >20 >20 >20 >20 
13f CH NHCH2 OCH3 Cl H 20 >20 >20 >20 >20 
13g CH NHCH2 Cl H H 20 15.1 >20 >20 >20 
13h CH NHCH2 Cl OCH3 H 35 12 >20 >20 >20 
13i CH NHCH2 Cl Cl H 20 17 >20 >20 >20 
14a N - H H H n.d n.d n.d n.d n.d 
14b N - H OCH3 H 20 n.d >20 >20 >20 
14c N - H Cl H n.d n.d >20 >20 >20 
15a N NH H H H 92 n.d n.d n.d n.d 
15b N NH H OCH3 H 98 n.d 0,0840,022 0.120.02 0.130.02 
15c N NH H Cl H 60 n.d n.d n.d n.d 
15d N NH H H OCH3 88 0,39 0,780,44 1,570,25 1,080,45 
15e N NH H H Cl 21 4,39 8,300,26 9,402,35 6,672,35 
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15f N NH H H Br 53 3,11 5.101,84 9,062,21 4,031,04 
16a N NHCH2 H H H 10 n.d >20 >20 >20 
16b N NHCH2 H OCH3 H 38 n.d 2,70,2 >20 8,60,2 
16c N NHCH2 H Cl H 11 n.d 5,40,7 8,30,8 7,80.3 
16d N NHCH2 H H OCH3 12 1,46 0,450,05 3,630,35 9,503,54 
16e N NHCH2 H H Cl 5 5,55 0,450,15 4,760,86 8,602,74 
16f N NHCH2 H H Br 4 0,35 0,470,13 3,400,75 0,780,25 
SU5416      67 13,6 >20 >20 >20 
 
 
Our preliminary results seem to indicate a relationship between the inhibition of 
the enzymatic activity of the VEGFR-2 and the observed cytotoxic effects, as the 
lowest IC50 values are usually related to the highest inhibition % (12b, 12e, 12b). 
However, the exceptions to this general trend, e.g the lack of any antiproliferative 
activity of compound 11h (KDR inhib. 41%), or otherwise the notable activity 
exerted by compound 16c (KDR inhib. 11%), suggest the involvement of 
additional signalization pathways, that remain to be clarified.  
 
Anti-angiogenic activity evaluation. Angiogenesis assays are essential for the 
identification of potential pro-angiogenic agents as well as for the screening of 
pharmacological inhibitors As a part of a collaboration with the University of 
Valencia, angiogenic biological studies were performed to verify if the 2-anilino 
substituted derivatives (12b,e and 15b), which proved to effectively block the 
VEGFR-2 tyrosine kinase activity, were able to inhibit microvessel sprouting in 
an angiogenic process. 
To this purpose the activity of the selected compounds was tested in the ex-vivo 
“rat aortic ring assay”. Aortic explants were incubated for 7 days with compounds 
12b, 12e, and 15b, at different concentrations (10µM; 5µM; 1µM; 100nM) using 
DMSO as control, and the activity was compared with that exerted by SU5416. 
The samples were daily monitored and on the 7
th
 day, a final time fluorescence 
cell staining was performed (Figure 27). 
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Figure 27. Anti-angiogenic activity of compounds 12b, 12e, 15b at [10µM]; [5µM]; [1µM]; 
[100nM] compared with DMSO and SU5416 at the same concentration. All experiment were 
conducted in duplicate and at least on two different animals. 
 
The inhibition of the angiogenic sprouting by the selected compounds was 
confirmed in the aortic ring assay, and the use of different concentrations allowed 
us to identify the range in which the inhibition took place. In particular, the 
benzothiopyrano derivatives 12b and 12e, started to inhibit the process at 
concentrations ranging from 1 to 5µM, showing a profile similar to that of 
SU5416. The pyridothiopyrane derivative 15b, which totally inhibited the 
VEGFR-2 in the enzymatic assay, produced now a complete inhibition of the 
angiogenesis at a concentration lower than 1µM.  
 
Molecular Modeling Studies. Molecular docking calculations allowed to 
elucidate at molecular level the interaction pattern established by these 
compounds with the KDR domain of VEGFR-2 suggesting possible modifications 
to further enhance the inhibitory activity of these compounds. 
This model (figure 28) shows that the benzo-thiopyranic pyrimidinic scaffold is 
well inserted in the enzyme active site, with its nitrogen in position 3 and the 
DMSO 12e SU5416 12b 15b 
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adjacent exocyclic NH in position 2 establishing a double H-bond with the 
backbone NH and CO of Cys919 in the enzyme hinge region, respectively.  
 
 
Figure 28. Binding mode of compound 12b within the VEGFR-2 active site. The ligand is 
represented as green sticks while the protein as orange sticks and ribbons. H-bonds are depicted as 
dashed yellow lines. 
 
Molecular modeling studies performed on the tested compounds confirmed the 
importance of the 2-anilino-sobstituent on the pyrimidinic scaffold. Moreover 
these studies underlined that the sulfur atom of the thiopyranic system didn’t play 
a crucial role in the interaction with the receptor. In particular, it was possible to 
explain the molecular interactions between the compound that exhibited the best 
biological activity (12b) and the catalytic domain of VEGFR-2 (KDR). 
Compounds 12 demonstrated to have the necessary pharmacophoric requisites for 
the anchoring to the ATP binding site, These interactions explain why 12b and its 
closely related congeners are effective VEGFR-2 inhibitors and why the 2-aryl 
analogues (11a-i), by lacking the double H-bond interaction generally display 
lower inhibition percentages against the enzyme (Table 8). Moreover, the 
lipophilic benzothiopyranopyrimidine ring is well inserted in the hydrophobic 
ATP cleft where favorable contacts are established with Leu1035, Val899, Val916 
(gate-keeper residue), Val848, and Leu840. 
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In this context my thesis work concerned the synthesis of new polycyclic systems 
with potential antitumor activity. 
To this purpose, moving from the structures of the aniline substituted pyrimidines 
above reported, I tried to modify the original scaffold of the molecules, following 
the indications given by the previous modeling studies. 
In this regard, the sulfur atom of the tricyclic system was replaced by a N atome, 
thus obtaining the new 1,8-naphtyridinopyramidino heterocyclic chromophore of 
general formula IV. It seemed possible to hypothesize that an additional N atom 
might help the molecules to establish additional H-bonds or to get a more 
advantageous binding mode in the catalytic site. 
In the naphtyridino-pyramidine system, we decided to insert a CH3 group in the 8 
position to evaluate its potential role in the activity of the compounds.  
 
N N
NN
NH
H3C  
IV 
R = H, p-OCH3, p-Cl,  m-Cl,  
 
In the second part of my thesis work I carried out the synthesis of a new system of 
general formula V. This new system is characterized by a pyrimidoquinazolinic 
structure.  
In both systems the substituted anilino moiety was inserted, since it seemed to be 
an essential requisite for the anchoring in the ATP-site and the biological activity. 
More in particular, my thesis work concerned the preparation of new 
pyrimidoquinazoline derivatives, bearing a methoxy group in the meta position 
and a Chlorine both in the para and meta positionof the 2-aryl moiety: 
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N
N
NN
X
HN
R
 
V 
         X= NH2, CH3 
  R= m-OCH3, m-Cl, p-Cl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction to Experimental Section                                                               
102 
Synthesis of 2-anilino substituted pyrimido-
naphtyridines  
The procedure leading to the synthesis of the series of pyrimido-naphtyridines 
22a-d is described in scheme 1 and involved, as first step, the preparation of the 
already described 7-methyil-2,3-dihydro-(1,8)-napthyridin-4(1H)-one 23.
199
 This 
was obtained from the cyclization of N-(6-metil-2-pyrydil)β-alanine 24, whose 
synthesis was developed in the laboratory where I worked for my thesis. 
 
Scheme 1 
NH3C
NH
COOH
NH3C N
O
H
NH3C N
O
H
N
CH3
CH3
24 23 25
NH3C N
H
26
NN
NH2
N N
NN
NH
H3C
R
ii iii
 iv
  v
22a-d
a: R = H
b: R = p-OCH3
c: R = p-Cl
d: R = m-Cl
N NH2H3C
i
 
 
 
Reagents and conditions: i) β-propiolactone, H20; ii) H2SO4, 120 °C, 10 min; iii) DMF-DMA, 
refluxing toluene, 100 °C, 16 h; iv) guanidine hydrochloride, EtONa, refluxing Ethanol, 16h; v) p- 
or m-substituted phenyliodide, K2CO3, N,N’-dimethylethylendiamine, CuI, dioxane, 100 °C, 24h. 
 
The preparation of the intermediate 3-dimethylaminomethylen derivative 25 was 
accomplished, with good yields, by reaction of compound 23 with an excess of 
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dymethylformamide dymethylacetal (DMF-DMA) in refluxing toluene, for 16 
hours. 
Subsequently, the 3-dimethyilaminomethylen derivative 25 was allowed to react 
with guanidine hydrochloride in an ethanolic refluxing solution, in the presence of 
sodium ethoxide, obtaining the 2-aminopyrimidine derivative 26. 
The preparation of the desired naphtyridines was accomplished by reacting 26 
with iodobenzene, p-methoxy-iodobenzene, p-cloro-iodobenzene or m-cloro-
iodobenzene, in anhydrous dioxane, in the presence of K2CO3, N,N’-dimethyl 
ethylendiamine and CuI. 
The reaction mixture was heated at 100 °C and allowed to stir for 24 h. After 
cooling the suspension obtained was added with 15 ml of concentrated NH3 and 
with a saturated solution of NaCl (20 ml). 
The mixture was then extracted with ethyl acetate and the organic layer was 
evaporated under reduced pressure. The residue obtained was collected to give a 
crude residue which, purified by flash-chromatography using petroleum ether 
30°C-60°C/ Ethyl acetate = 2 : 8 as eluting solution, allowed to obtain the target 
naphtyridines 22 a-d (Table I). In these compounds, in addition to the insertion of 
the appropriate substituted phenil group, the aromatization of the napthyridinic 
system occured. 
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Synthesis of pyrimidoquinazolines 2-anilino 
substituted 
 
In the second part of this thesis work I synthesized the pyrimidoquinazolines 27a-
b, 28a-b and 29a-b. 
The synthetic pathway utilized in the preparation of all compounds 27-29 
involved, as first step, the preparation of the already described 2-amino-7,8-
dihydro-6H-quinazolin-5-one
200
 30 (Scheme 2). 
 
Scheme 2 
O O
O
i ii N
NH2N
O
N
CH3
CH3
O  
31 30 
 
 
Reagents and conditions: i) DMF DMA, 100 °C, 2h; ii) guanidine hydrochloride, EtONa, 
refluxing ethanol, 16h. 
 
To this purpose, the commercially available 1,3-cyclesandione
201
 was dissolved in 
an excess of dimethylformamide dimethylacetal (DMF-DMA) and the solution  
was heated at 100 °C (monitoring with tlc). After cooling, the obtained solution 
was added with ethyl ether and the resulting suspension was filtered. After 2h an 
orange solid was collected to give the corresponding 3-dimethylaminomethylen 
derivative 31, which was sufficiently pure to be directly used in the subsequent 
reaction.  
The preparation of compound 30 was accomplished by reacting compound 31 
with the binucleophile guanidine hidrochloride in an ethanolic refluxing solution, 
in the presence of sodium ethoxide
202
. The crude target compound was obtained 
as unique product (tlc) in good yields and purified by cristallization. 
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By reaction between 30 and the appropriate substituted aryliodide, in anhydrous 
dioxane, in the presence of K2CO3, N,N’-dimethylethylendiamine and CuI, the 
aniline-substituted derivatives 32 a-c have been obtained. (Scheme 3). 
 
Scheme 3 
i ii
32a-c 33a-c
a: R= m-OCH3
b: R= m-Cl
c: R= p-Cl
iii
27a: R= m-OCH3;  X= NH2
27b: R= m-OCH3;   X= CH3
28a: R= m-Cl;         X= NH2
28b: R= m-Cl;         X= CH3
29a: R= p-Cl;          X= NH2
29b: R= p-Cl;          X= CH3
30
N
N
O
H2N
N
N
O
HN
R
N
N
O
HN
R
N
27-29
N
NHN
R
NN
X
 
 
Reagents and conditions: i) p- or m-substituted phenyliodide, K2CO3, N,N’-
dimethylethylendiamine, CuI, dioxane, 100°C for 24 h; ii)  DMF-DMA, refluxing toluene, 100°C, 
24 h; iii) guanidine hydrochloride or acetamidine hydrochloride, EtONa, refluxing Ethanol, 16h. 
 
The reaction mixture was heated at 100°C and allowed to stir for 24 hours. After 
cooling, the suspension obtained was added with 15 ml of concentrated NH3 and 
with a saturated solution of NaCl. The mixture was extracted with ethyl acetate 
and the solution obtained was evaporated under reduced pressure to give a residue 
which, purified by flash chromatography using petroleum ether 60-80°C/ethyl 
acetate 2:8 as eluting system, afforded the aniline derivatives 32a-c.  
Finally the target compounds 27a-b, 28a-b and 29a-b were obtained from the 
appropriate dymethylaminomethylen derivative 33 a-c. 
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The preparation of the compounds 33a-c was accomplished, with good yields, by 
reacting compounds 32a-c with an excess of  dimethylformamide dimethylacetal 
(DMF-DMA) in refluxing toluene. After cooling the suspension obtained was 
evaporated under reduced pressure giving a residue which, after purification by 
filtration on a silica gel column, allowed to obtain the target compounds 33a-c. 
The desired pyrimidoquinazolines 27-29 were subsequently obtained by reacting 
3-dimethylaminomethylen derivatives 33a-c with the appropriate binucleophile 
guanidine or acetamidine hydrochloride, in an ethanolic refluxing solution, in the 
presence of sodium ethoxide. The reaction mixture was concentrated under 
reduced pressure and the obtained residue was purified by filtration on silica gel 
columns and allowed to get compounds 27-29 (Table II). 
 
All the target derivatives were obtained as unique products (tlc analysis) in good 
to modest overall yields. The proposed structures were confirmed on the basis of 
analytical and 
1
H-NMR spectral data, which relied on those of earlier studies.
 
The biological activity of the newly synthesized compounds will be evaluated 
thanks a long-lasting collaboration with a research group of the University of 
Padova. 
Generally, the antiproliferative activity of the compounds is assayed on HeLa 
(cervix adenocarcinoma), A-431 (epidermoid carcinoma), MSTO-211H (biphasic 
mesothelioma) cell lines and on HUVEC (human umbilical vein endothelial cell); 
the results are expressed as IC50 values, i.e. the concentration (M) of compound 
able to produce 50% cell death with respect to the control culture, treated with 
SU5416, taken as reference compound, due to its VEGFR-2 directed activity. 
Unfortunately the biological results of all compounds synthesized in this thesis 
work are not yet available. 
 
  
Table I  
Physical, Analytical and Spectral data of compounds 22a-d 
 
N N
NN
H3C
HN
R
 
N R Yield 
(%) 
m.p. °C 
 
1
H nmr ( ppm) Molecular 
formula 
Analysis (%) 
 
C H N 
22a H 19,9 > 220 2.71 (s, 3H, CH3); 7.08 (t, 1H, Ar-H); 7.36-7.42 
(m, 2H, Ar-H); 7.65 (t, 1H, Ar-H); 7.96-8.00 (m, 
2H, Ar-H); 9.01 (t, 1H, Ar-H); 9.36 (s, 1H, Ar-
H); 9.46 (s, 1H, Ar-H); 10.49 (s, 1H, NH scamb.)  
C17H13N5 
 
 
71.06 
70.80 
4.56 
4.45 
24.37 
24.11 
22b p-OCH3 15,6 
 
> 220 2.69 (s, 3H, CH3); 3.79 (s, 3H, OCH3); 6.99 (d, 
2H, Ar-H); 7.36 (d, 2H, Ar-H); 7.56 (d, 1H, Ar-
H); 8.53 (d, 1H, Ar-H); 9.32 (s, 1H, Ar-H) 
C18H15N5 68.13 
68.34 
4.76 
4.80 
22.07 
22.34 
22c p-Cl 17,3 > 220 2.70 (s, 3H, CH3); 7.45-7.62 (m, 6H, Ar-H); 8.56 
(d, 1H, Ar-H); 9.40 (s, 1H, Ar-H) 
C17H12ClN5 63.46 
63.12 
3.76 
3.71 
21.77 
21.45 
22d m-Cl 25 215-220 2.71 (s, 3H, CH3); 7.46-7.65 (m, 6H, Ar-H); 8.54 
(d, 1H, Ar-H); 9.43 (d, 1H, Ar-H) 
 
C17H12ClN5 63.46 
63.10 
3.76 
3.69 
21.77 
21.47 
  
Table II 
Physical, Analytical and Spectral data of compounds 27-29a-b 
 
N
N
NN
X
HN
R
 
N X R yield 
(%) 
m.p. °C 
 
1
H nmr ( ppm) Molecular 
formula 
Analysis (%) 
 
C H N 
27a NH2 m-OCH3 34,19 200 2.81-2.86 (m, 4H, CH2CH2); 3.73 (s, 3H, OCH3); 
6.42 (s, 2H NH2 scamb.); 6.56 (d, 1H, Ar-H); 7.19 (t, 
1H, Ar-H); 7.32 (d, 1H, Ar-H); 7.56 (s, 1H, Ar-H); 
8.10 (s, 1H, Ar-H); 8.95 (s, 1H, Ar-H); 9.97 (s, 1H, 
NH scamb.) 
C17H16N6O 63.74 
63.45 
5.03 
4.96 
26.23 
26.01 
27b CH3 m-OCH3 49,3 > 220 2.59-2.61 (m, 4H, CH2CH2); 2.96 (s, 3H, CH3); 3.74 
(s, 3H, OCH3); 6.59 (d, 1H, Ar-H); 7.19 (t, 1H, Ar-
H); 7.33 (d, 1H, Ar-H); 7.58 (s, 1H, Ar-H); 8.50 (s, 
1H, Ar-H); 9.08 (s, 1H, Ar-H); 10.06 (s, 1H, NH 
scamb.) 
C18H17N5O 67.70 
67.85 
5.37 
5.31 
5.01 
4.81 
28a NH2 m-Cl 30,8 210-215 2.82-2.92 (m, 4H, CH2CH2); 6.59 (s, 2H, NH2 
scamb.); 7.03 (d, 1H, Ar-H); .); 7.32 (t, 1H, Ar-H); 
7.75 (d, 1H, Ar-H); 7.99 (s, 1H, Ar-H); 8.13 (s, 1H, 
Ar-H); 8.99 (s, 1H, Ar-H); 10.26 (s, 1H, NH  scamb.) 
C17H17ClN6 59.91 
59.78 
5.03 
4.96 
24.66 
24.47 
  
28b CH3  m-Cl 58,5 180-185 2.62 (s, 3H, CH3); 2.97-2.99 (m, 4H, CH2CH2); 7.04 
(d, 1H, Ar-H); 7.33 (t, 1H, Ar-H);  7.74 (d, 1H, Ar-
H); 8.03 (s, 1H, Ar-H); 8.54 (s, 1H, Ar-H); 9.13 (s, 
1H, Ar-H); 10.32 (s, 1H, NH scamb.)  
C18H18ClN5 63.62 
63.51 
5.34 
5.41 
20.61 
20.37 
29a NH2 p-Cl 12 > 220 2.83-2.90 (m, 4H, CH2CH2); 6.52 (s, 2H, NH2 
scamb.); 7.35 (d, 2H, Ar-H); 7.84 (d, 2H, Ar-H); 8.12 
(s, 1H, Ar-H); 8.96 (s, 1H, Ar-H); 10.19 (s, 1H, NH 
scamb.) 
C17H17ClN6 59.91 
59.11 
5.03 
4.98 
24.66 
24.82 
29b CH3 p-Cl 24 220-225 2.59 (s, 3H, CH3); 2.94-2.96 (m, 4H, CH2CH2); 7.34 
(d, 2H, Ar-H); 7.83 (d, 2H, Ar-H); 8.50 (s, 1H, Ar-
H); 9.08 (s, 1H, Ar-H); 10.23 (s, 1H, NH scamb.)  
 
C18H18ClN5 63.62 
63.48 
5.34 
5.23 
20.61 
20.42 
  
 
 
 
Experimental section 
  
Materials and Methods 
 
Unless otherwise noted, all solvents and reagents for organic synthesis were 
obtained from commercial suppliers and were used without further purification. 
Reactions requiring anhydrous conditions were carried out under a dry N2 
atmosphere using anhydrous, freshly distilled solvents.  
Magnesium sulfate was always used as the drying agent.  
Evaporations were made in vacuo (rotating evaporator).  
Yields refer to chromatographically and spectroscopically (
1
H-NMR) 
homogeneous materials.  
Reactions were monitored by thin-layer chromatography (TLC) carried out on 
Merck 0.2 mm precoated silica gel aluminium sheets (60 F-254). Silica gel 60 
(230-400 mesh) was used for column chromatography.  
Nuclear magnetic resonance spectra (
1
H-NMR) were recorded in DMSO-d6 
solution on a Varian Gemini 200 spectrometer operating at 200 MHz, using 
(CH3)4Si (TMS) as the internal standard. 
Melting points were determined using a Reichert Köfler hot-stage apparatus and 
are uncorrected.  
Elemental analyses were performed by our Analytical Laboratory and agreed with 
theoretical values to within ± 0.4%. 
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N-(6-methyl-2-pyridil)β-alanine 24 
24 ml of water and 2,5 ml of β-propiolactone were added to 2-amino-6-methyl-
pyridine (5g) under agitation. After two days a white solid residue was collected 
and purified by crystallization from methanol, obtaining g 1,7 of the target 
compound 24 (yield: 25 %). 
m.p. :155-157°C    
 
7-methyl-2,3-dihydro-(1,8)-naphtyridin-4 (1H)-one 23
199 
N-(6-methyl-2-pyridil)β-alanine 23 (4,0 g; 0,122 moles), dissolved in 15 ml of 
H2SO4 concentrated, was heated at 120 °C for 10 minutes. After cooling, the 
solution was poured into ice and NH4OH 32% was added until it reached ph=8. 
Then the solution was extracted with CHCl3. The chloroformic layers were dried 
and evaporated under reduced pressure giving a solid residue which was purified 
by crystallization from Ethanol, obtaining g 0,1620 of 23 ( yield: 43%). 
m.p. : 154-156°C 
 
3-dimethylaminomethylen-7-methyl-2,3-dihydro(1,8)-naftiridin-
4(1H)-one 25 
An excess of DMF DMA (3,15 ml; 0,024 moles) was added to a stirred solution 
of  2,3-dihydronaphtyridone 23 (1,620 g; 0,0100 moles) in anhydrous toluene (10 
ml) and the mixture was refluxed for 16 h. After cooling, the obtained solution 
was evaporated under reduced pressure giving a solid residue which was treated 
with ethyl ether and collected, obtaining 1,802 g of 25 (yield: 89,6%). 
m.p.: 165-170°C 
1
H-NMR (DMSO-d6, ppm): 2.17 (s, 3H, CH3); 3.00 (s, 6H, N(CH3)2); 4.44 (s, 2H, 
CH2); 6.39 (d, 1H, Ar-H); 6.79 (s, 1H, NH scamb.); 7.32 (s, 1H, CH-N); 7.69 (d, 
1H, Ar-H). 
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2-amino-5H-8-methyl-[1,4]-naphtyridin-[3,2-c]-pyrimidine 26 
Guanidine hydrochloride (1,59g; 0,017 moles) was added, at room temperature, 
under a nitrogen atmosphere, to a stirred solution of sodium ethoxide (0,57 g; 
0,025 moles of sodium in 40 ml of anhydrous ethanol). The resulting suspension 
was stirred at room temperature for 15 minutes, then the opportune 
dimethylaminomethylen derivative 25 (1,802 g; 0,008 moles) was added and the 
reaction mixture was refluxed for 16h. After cooling, the resulting suspension was 
filtered and dried. The collected solid residue was then washed with water, filtered 
again and dried, obtaining 1,620 g of the target compound 26 (yield: 91,6%). 
m.p.: > 220°C 
1
H-NMR (DMSO-d6, ppm): 2.25 (s, 3H, CH3); 4.38 (s, 2H, CH2); 6.45 (s, 2H, 
NH2 scamb.); 6.48 (d, 1H, Ar-H); 6.75 (s, 1H, NH scamb.); 7.94 (d, 1H, Ar-H); 
8.00 (s, 1H, Ar-H). 
 
General procedure for the synthesis of 2-aniline-5H-8-methyl-
[1,4]-naphtyridin-[3,2-c]-pyrimidines 22a-d 
Compound 26 (0,300 g; 0,0014 moles) was added, at room temperature, under 
nitrogen atmosphere, to 0,2667 g of CuI (0,0014 moles) and 0,3864 g of 
anhydrous K2CO3 (0,0028 moles). 
Finally the appropriate substituted aryliodide (0,0028 moles), 0,15 ml of DMEDA 
(0,0014 moles) and 10 ml of anhydrous dioxane were added. 
The reaction mixture was heated at 100°C and allowed to stir for 24 hours. After 
cooling, the mixture was added with 15 ml of concentrated NH3 and with a 
saturated solution of NaCl (25 ml). The reaction mixture was extracted with ethyl 
acetate and the obtained solution was evaporated under reduced pressure giving a 
residue which was purified by flash chromatography using petroleum ether 30-
60°C/ethyl acetate 2:8 as eluting system, to give the target compounds 22a-d 
(Table I). 
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2-[(dimethylamino)methylen]-1,3-cyclesandione
201
31 
10,00 g (0,09 moles) of 1,3-cyclesandione were dissolved in 17,9 ml (0,135 
moles) of DMF-DMA. The resulting solution was heated at 100 °C for 2h, 
monitoring by tlc (petroleum ether: AcOEt = 2:8). After cooling the obtained 
solution was added with ethyl ether and the resulting suspension was filtered to 
give 14 g (0,084 moles) of the target compound 31 (yield: 93 %). 
m. p.: 117-120°C 
 
2-Amino-7,8-dihydro-6H-quinazolin-5-one
200
 30 
4,58 g (0,0048 moles) of guanidine hydrochloride were added, at room 
temperature, under a nitrogen atmosphere, to a stirred solution of sodium ethoxide 
(1,66 g; 0,07 moles of sodium in 80 ml of anhydrous ethanol). 
The resulting suspension was stirred at room temperature for 15 minutes. Then the 
dimethylaminomethyilen derivative 31 (4,00 g; 0,024 moles) was added and the 
reaction mixture was refluxed for 16h. After cooling the resulting suspension was 
filtered and the residue was dried obtaining a white solid, which was purified by 
crystallization from ethanol. 
We obtained 1,185 g of 30 (yield: 30,3 %). 
m. p.: 275-277°C 
 
General procedure for the synthesis of 7,8-dhydro-2-aniline-5-
(6H)-quinazolines 32a-c 
0,500 g (3,067 mmoles) of 30 were added, at room temperature, under nitrogen 
atmosphere, to 0,58 g (3,067 mmoles) of CuI and 0,85 g (6,150 mmoles) of 
anhydrous K2CO3. Then, the appropriate p- or m-substituted aryliodide (6,150 
mmoles), 0,33 ml of DMEDA (3,067 mmoles) and 10 ml of anhydrous dioxane 
were added. The reaction mixture was allowed to stir for 24 h. 
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After cooling the mixture was added with 15 ml of concentrated NH3 and with a 
satured solution of NaCl (20-25 ml). The reaction mixture was extracted with 
ethyl acetate and, the obtained solution, was evaporated under reduced pressure 
giving a residue which was purified by flash-chromatography using petroleum 
ether 30-60°C/ ethyl acetate = 2:8 as the eluting system, to give the target 
compounds 32a-c. 
 
32a: m.p.= 140-145°C  
yield: 29,8% 
1
H-NMR (DMSO-d6, ppm): 2.00-2.07 (m, 2H, CH2CH2CH2); 2.54 (t, 2H, 
CH2CH2CH2); 2.89 (t, 2H, CH2CH2CH2); 3.73 (s, 3H, OCH3); 6.61 (d, 1H, Ar-H); 
7.21-7.35 (m, 2H, Ar-H); 7.53 (s, 1H, Ar-H); 8.80 (s, 1H, Ar-H); 10.26 (s, 1H, 
NH exch.). 
 
32b: m.p.= 215-220°C 
yield: 29% 
1
H-NMR (DMSO-d6, ppm): 2.00-2.07 (m, 2H, CH2CH2CH2); 2.55 (t, 2H, 
CH2CH2CH2); 2.90 (t, 2H, CH2CH2CH2); 7.06 (d, 1H, Ar-H); 7.33 (t, 1H, Ar-H); 
7.71 (d, 1H, Ar-H); 7.96 (s, 1H, Ar-H); 8.82 (s, 1H, Ar-H); 10.46 (s, 1H, NH 
scamb.). 
 
32c: m. p. = 226-230°C  
Yield: 35,67% 
1H-NMR (DMSO-d6, ppm): 2.04-2.08 (m, 2H, CH2CH2CH2); 2.50 (t, 2H, 
CH2CH2CH2); 2.89 (t, 2H, CH2CH2CH2); 7.37 (d, 2H, Ar-H); 7.82 (d, 2H, Ar-H); 
8.80 (s, 1H, Ar-H); 10.42 (s, 1H, NH exch.). 
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General procedure for the synthesis of 6-dimethylaminomethylen-
2-aniline-7,8-dihydro-6H-quinazolin-5-ones 33a-c  
An excess of DMF-DMA (0,00686 moles) was added to a stirred solution of the 
appropriate 7,8-dhydro-2-aniline-5-(6H)-quinazoline derivative 32a-c (0,0046 
moles) in anhydrous toluene and the mixture was refluxed for 24h. 
After cooling, the obtained solution was evaporated under reduced pressure giving 
a solid crude residue of the target compounds 33a-c. The crude residue was 
purified by filtration on a silica gel (60/0,040-0,063 mm) chromatographic 
column, using Ethyl acetate as eluting solution. The materials recovered from the 
less mobile fractions (tlc) gave compounds 33a-c. 
 
33a: m.p.: > 220°C 
yield: 34,6 % 
1H-NMR (DMSO-d6, ppm): 2.02 (t, 2H, CH2CH2); 2.90 (t, 2H, CH2CH2); 3.74 (s, 
3H, OCH3, 6H, CHN(CH3)2); 6.62 (d, 1H, Ar-H); 7.17-7.36 (m, 2H, Ar-H); 7.54 
(s, 1H, Ar-H); 8.80 (s, 1H, Ar-H); 10.27(s, 1H, NH exch.). 
 
33b: m.p.: 220-225°C 
yield: 84% 
1H-NMR (DMSO-d6, ppm): 2.78 (t, 2H, CH2-CH2); 2.92 (t, 2H, CH2-CH2); 3.08 
(s, 6H, CHN(CH3)2); 6.95-7.903 (m, 1H Ar-H); 7.25-7.28 (m, 1H, Ar-H); 7.46 (s, 
1H, Ar-H); 7.66-7.69 (m, 1H, Ar-H); 7.96 (s, 1H, Ar-H); 8.70 (s, 1H, Ar-H); 
10,16 (s, 1H, NH exch.). 
 
33c: m.p.: 218-220°C 
yield: 58,8% 
1H-NMR (DMSO-d6, ppm): 2.86 (t, 2H, CH2-CH2); 3.07 (t, 2H, CH2-CH2); 3.26 
(s, 6H, CHN(CH3)2); 7.33 (d, 1H, Ar-H); 7.79 (d, 2H, Ar-H); 8.77 (s, 1H, Ar-H); 
10.836 (s, 1H, NH exch.). 
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General procedure for the synthesis of pyrimidoquinazolines 27a-
b 
Guanidine or acetamidine hychloride, respectively (0,000915 moles), was added, 
at room temperature, under a nitrogen atmosphere, to a stirred solution of sodium 
ethoxide (0,00137 moles of sodium in 3 ml of anhydrous ethanol). The resulting 
suspension was stirred at room temperature for 15 minutes, then compound 33a 
(0,457 mmoles) was added and the reaction mixture was refluxed for 16 h. After 
cooling, the resulting suspension was concentrated under reduced pressure and the 
obtained residue was purified by filtration on a silica gel chromatographic 
column, using ethyl acetate as eluting solution, to give compounds 27a-b. (Table 
II). 
 
General procedure for the synthesis of pyrimidoquinazolines 28a-
b 
Guanidine or acetamidine hychloride, respectively (0,00186 moles), was added, at 
room temperature, under a nitrogen atmosphere, to a stirred solution of sodium 
ethoxide (0,00279 moles of sodium in 3 ml of anhydrous ethanol). The resulting 
suspension was stirred at room temperature for 15 minutes, then compound 33b 
(0,00093 moles) was added and the reaction mixture was refluxed for 16 h. After 
cooling, the resulting suspension was concentrated under reduced pressure and the 
obtained residue was purified by filtration on a silica gel chromatographic 
column, using ethyl acetate as eluting solution, to give compounds 28a-b. (Table 
II). 
 
General procedure for the synthesis of pyrimidoquinazolines 29a-
b 
Guanidine or acetamidine hychloride, respectevely (0,00152 moles), was added, 
at room temperature, under a nitrogen atmosphere, to a stirred solution of sodium 
ethoxide (2,283 mmoles of sodium in 3 ml of anhydrous ethanol). The resulting 
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suspension was stirred at room temperature for 15 minutes, then compound 33c 
(0,7611 mmoles) was added and the reaction mixture was refluxed for 16 h. After 
cooling, the resulting suspension was concentrated under reduced pressure and the 
obtained residue was purified by filtration on a silica gel chromatographic 
column, using ethyl acetate as eluting solution, to give compounds 29a-b. (Table 
II). 
  
 
 
References 
References 
114 
1. G. Vlahovic, J. Crawford. Activation of Tyrosine Kinases in Cancer. The 
Oncologist, 2003; 8, 531-538. 
2. P. Blume-Jensen, T. Hunter. Oncogenic kinase signalling. Nature, 2001; 411, 
355-365. 
3. G.M. Pontieri, M. A. Russo, L. Frati. Oncogeni, 2008; Patologia Generale 3th 
Edition., PICCIN, 22:585-616. 
4. D Mathers, C.; Boschi-Pinto, C.; D Lopez, A.; JL Murray, C.. Cancer 
incidence, mortality and survival, Global Programme on Evidence for Health 
Policy Discussion Paper No. 13 World Health Organization, 2011. 
5. Ullrich A, Schlessinger J.  Signal transduction by receptors with tyrosine 
kinase activity. Cell, 1990; 61:203–212. 
6. Clayton. AH; Walker, F,; Orchard, SG.; Henderson, C.; Fuchs, D.; Rothacker, 
J.; Nice, EC.; Burgess, AW.  Ligand-induced dimer-tetramer transition during 
the activation of the cell surface epidermal growth factor receptor-A 
multidimensional microscopy analysis. J Biol Chem., 2005; 280:30392– 
30399. 
7. Ward, CW.; Lawrence, MC.; Streltsov, VA.; Adams, TE.; McKern, NM. The 
insulin and EGF receptor structures: new insights into ligand-induced receptor 
activation. Trends Biochem Sci., 2007; 32:129–137. 
8. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases.,Cell., 
2002; 109:275–282. 
9. Manash, K.P.; Mukhopadhyay, A. Tyrosine kinases-role and significance in 
cancer. Int J Med sci., 2004. 
10. Stevan, R.; Hubbard and Jeffrey H. Till, Proteine tyrosine kinase structure-and 
function. Annu. Rev. Biochem., 2000; 69:373–98. 
11. Blume, P.; Jensen, T.; Hunter T. Oncogenic Kinase Signaling. Nature, 2001; 
355-365. 
12.  Clayton, AH.; Walker, F.; Orchard, SG.; Henderson, C.; Fuchs, D.; 
Rothacker, J.; Nice, EC.; Burgess, AW. Ligand-induced dimer-tetramer 
transition during the activation of the cell surface epidermal growth factor 
receptor-A multidimensional microscopy analysis. J Biol Chem., 2005; 
280:30392–30399. 
References 
115 
13. Ward, CW.; Lawrence, MC.; Streltsov, VA.; Adams, TE.; McKern, NM. The 
insulin and EGF receptor structures: new insights into ligand-induced receptor 
activation. Trends Biochem Sci., 2007; 32:129–137.  
14. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases. Cell., 
2002; 109:275–282. 
15. Nolen, B.; Taylor, S.; Ghosh, G. Regulation of protein kinases; controlling 
activity through activation segment conformation. Mol Cell., 2004; 15:661–
675.  
16. Hubbard, SR. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat 
Rev Mol Cell Biol., 2004; 5:464–471. 
17. Till, JH.; Becerra, M.; Watty, A.; Lu, Y.; Ma, Y.; Neubert, TA.; Burden, SJ. 
Hubbard SR. Crystal structure of the MuSK tyrosine kinase: insights into 
receptor autoregulation. Structure, 2002; 10:1187–1196. 
18. Griffith, J.; Black, J.; Faerman, C.; Swenson, L.; Wynn, M.; Lu, F.; Lippke, J.; 
Saxena, K. The structural basis for autoinhibition of FLT3 by the 
juxtamembrane domain. Mol Cell., 2004; 13:169–178. 
19. Niu, XL.; Peters, KG.; Kontos, CD. Deletion of the carboxyl terminus of Tie2 
enhances kinase activity, signaling, and function. Evidence for an 
autoinhibitory mechanism. J Biol Chem., 2002; 277:31768–31773. 
20. Zhang, X.; Gureasko, J.; Shen, K.; Cole, PA.; Kuriyan, J. An allosteric 
mechanism for activation of the kinase domain of epidermal growth factor 
receptor. Cell., 2006; 125:1137–1149. 
21. Favelyukis, S.; Till, JH.; Hubbard, SR.; Miller, WT. Structure and 
autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct 
Mol Biol., 2001; 8:1058–1063. 
22. Furdui, CM.; Lew, ED.; Schlessinger, J.; Anderson, KS. Autophosphorylation 
of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. 
Mol Cell., 2006; 21:711–717.  
23. Ferrara, N. Vascular endothelial growth factor: basic science and clinical 
progress. Endocr Rev, 2004; 25:581–611. 
References 
116 
24. Hoeben, A.; Landuyt, B.; Highley, MS.; Wildiers, H.; Van Oosterom, AT.; De 
Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol 
Rev., 2004; 56:549–80. 
25. Lee, S.; Chen, T.; Barber, C.L.; Jordan, M.C.; Murdock, J.; Desai,  S.; Ferrara, 
N.; Nagy, A.; Roos, K.P.; Iruela-Arispe, M.L. Autocrine VEGF signaling is 
required for vascular homeostasis. Cell, 2007; 130 (4), 691–703. 
26. Robinson, CJ.; Stringer, SE. The splice variants of vascular endothelial growth 
factor (VEGF) and their receptors. J Cell Sci.., 2001; 114:853–65. 
27. Mignatti, P.; Rifkin, DB. Biology and biochemistry of proteinases in tumor 
invasion. Physiol Rev., 1993; 73:161–95. 
28. McDonald, N. Q.; Hendrickson, W. A. Cell, 1993; 73, 421–424. 
29. Muller, YA; Li, B; Christinger, HW; Wells, JA; Cunningham, BC; de Vos, 
AM. Vascular endothelial growth factor: crystal structure and functional 
mapping of the kinase domain receptor binding site. Proc Natl Acad Sci. USA, 
1997; 94:7192–7. 
30. Guttmann-Raviv, N; Kessler, O.; Shraga-Heled, N.; Lange, T.; Herzog, Y.; 
Neufeld, G. The neuropilins and their role in tumorigenesis and tumor 
progression. Cancer Lett., 2006; 231:1–11. 
31. Dvorak, HF. Angiogenesis: update 2005. J Thromb Haemost, 2005; 3:1835–
42. 
32. Waltenberger, J.; Claesson-Welsh, L.; Siegbahn, A.; Shibuya, M.; Heldin, CH. 
Different signal transduction properties of KDR and Flt1, two receptors for 
vascular endothelial growth factor. J Biol Chem., 1994; 69:26988–95. 
33. Carmeliet, P.; Ferreira, V.; Breier, G.; et al. Abnormal blood vessel 
development and lethality in embryos lacking a single VEGF allele. Nature, 
1996; 380:435–9. 
34. Ferrara, N.; Carver-Moore, K.; Chen, H.; et al. Heterozygous embryonic 
lethality induced by targeted inactivation of the VEGF gene. Nature, 1996; 
380:439–42. 
35. Olofsson, B.; Pajusola, K.; von Euler, G.; Chilov, D.; Alitalo, K.; Eriksson, U. 
Genomic organization of the mouse and human genes for vascular endothelial 
References 
117 
growth factor B (VEGF-B) and characterization of a second splice isoform. J 
Biol Chem., 1996; 271:19310–7. 
36. Salven, P.; Lymboussaki, A.; Heikkila, P.; et al. Vascular endothelial growth 
factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol., 
1998; 153:103–8. 
37. Tammela, T.; Enholm, B.; Alitalo, K.; Paavonen, K. The biology of vascular 
endothelial growth factors. Cardiovasc Res., 2005; 65:550–63. 
38. Joukov, V.; Pajusola, K.; Kaipainen, A.; et al. A novel vascular endothelial 
growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR 
(VEGFR-2) receptor tyrosine kinases. EMBO J, 1996; 15:1751–8. 
39. Lymboussaki, A.; Olofsson, B.; Eriksson, U.; Alitalo, K. Vascular endothelial 
growth factor (VEGF) and VEGF-C show overlapping binding sites in 
embryonic endothelia and distinct sites in differentiated adult endothelia. Circ. 
Res., 1999; 85:992–9. 
40. Karkkainen, MJ.; Haiko, P.; Sainio, K.; et al. Vascular endothelial growth 
factor C is required for sprouting of the first lymphatic vessels from 
embryonic veins. Nat Immunol., 2004; 5:74–80. 
41. Stacker, SA.; Stenvers, K.; Caesar, C.; et al. Biosynthesis of vascular 
endothelial growth factor-D involves proteolytic processing which generates 
non-covalent homodimers. J Biol Chem., 1999; 274:32127–36. 
42. Baldwin, ME.; Halford, MM.; Roufail, S.; et al. Vascular endothelial growth 
factor D is dispensable for development of the lymphatic system. Mol Cell 
Biol., 2005; 25:2441–9. 
43. Nakamura, Y.; Yasuoka, H.; Tsujimoto, M.; et al. Prognostic significante of 
vascular endothelial growth factorDin breast carcinoma with long-term 
follow-up. Clin Cancer Res., 2003; 9:716–21. 
44. Yasuoka, H.; Nakamura, Y.; Zuo, H.; et al. VEGF-D expression and lymph 
vessels play an important role for lymph node metastasis in papillary thyroid 
carcinoma. Mod Pathol., 2005; 18:1127–33. 
45. Funaki, H.; Nishimura, G.; Harada, S.; et al. Expression of vascular 
endothelial growth factor D is associated with lymph node metastasis in 
human colorectal carcinoma. Oncology, 2003; 64:416–22. 
References 
118 
46. Maglione, D.; Guerriero, V.; Viglietto, G.; Delli-Bovi, P.; Persico, MG. 
Isolation of a human placenta cDNA coding for a protein related to the 
vascular permeability factor. Proc Natl Acad Sci. USA, 1991; 88:9267–71. 
47. Maglione, D.; Guerriero, V.; Viglietto, G.; et al. Two alternative mRNAs 
coding for the angiogenic factor, placenta growth factor (PlGF), are 
transcribed from a single gene of chromosome 14. Oncogene, 1993; 8:925–31. 
48. Parr, C.; Watkins, G.; Boulton, M.; Cai, J.; Jiang, WG. Placenta growth factor 
is over-expressed and has prognostic value in human breast cancer. Eur J 
Cancer, 2005; 41:2819–27. 
49. Chen, CN.; Hsieh, FJ.; Cheng, YM.; et al. The significance of placenta growth 
factor in angiogenesis and clinical outcome of human gastric cancer. Cancer 
Lett, 2004; 213:73–82. 
50. Zhang, L.; Chen, J.; Ke, Y.; Mansel, RE.; Jiang, WG. Expression of placenta 
growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical 
and prognostic significance. World J Surg Oncol, 2005; 3:68. 
51. Carmeliet, P.; Moons, L.; Luttun, A.; et al. Synergism between vascular 
endothelial growth factor and placental growth factor contributes to 
angiogenesis and plasma extravasation in pathological conditions. Nat Med., 
2001; 7:575–83. 
52. Roskoski, Jr R. Vascular endothelial growth factor (VEGF) signaling in tumor 
progression. Critical Reviews in Oncology/Hematology , 2007; 62:179–213. 
53. Stuttfeld, E.; Ballmer-Hofer, K. Structure and function of VEGF receptors. 
IUBMB Life, 2009; 61, 915−922. 
54. Roskoski, Jr R. VEGF receptor protein–tyrosine kinases: Structure and 
regulation. Biochemical and Biophysical Research Communications, 2008; 
375:287–291. 
55. Koch, S.; Tugues, S.; Li, X.; Gualandi, L.; Claesson-Welsh, L.Signal 
transduction by vascular endothelial growth factor receptors Biochem. J,. 
2011; 437, 169−183. 
56. Kappert, K.; Peters, K. G.; Bo  hmer, F.; D.; Ostman, A. Tyrosine phosphatases 
in vessel wall signaling. Cardiovasc. Res., 2005; 65: 587−598. 
References 
119 
57. Olsson, A.K.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L. VEGF receptor 
signalling—in control of vascular function, Nat. Rev. Mol. Cell. Biol., 2006; 7: 
359–371. 
58. Autiero, M.; Waltenberger, J.; Communi, D.; Kranz, A.; Moons, L.; 
Lambrechts, D.; Kroll, J.; Plaisance, S.; De Mol, M.; Bono, F. Kliche, S.; 
Fellbrich, G.; Ballmer-Hofer, K.; Maglione, D.; Mayr-Beyrle, U.; Dewerchin, 
M.; Dombrowski, S.; Stanimirovic, D.; Van Hummelen, P.; Dehio, C.; 
Hicklin, DJ.; Persico, G.; Herbert, J.M.; Communi, D.; Shibuya, M.; Collen, 
D.; Conway, E.M.; Carmeliet, P. Role of PlGF in the intra- and intermolecular 
cross talk between the VEGF receptors Flt1 and Flk1, Nat. Med, 2003; 9:936–
943. 
59. Wiesmann, C.; Fuh, G.; Christinger, H.W.; Eigenbrot, C.; Wells, J.A.; de Vos, 
A.M. Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 
of the Flt-1 receptor, Cell, 1997; 91: 695–704. 
60. Christinger, H.E.; Fuh, G.; de Vos, A.M. Wiesmann, C.The crystal structure 
of placental growth factor in complex with domain 2 of vascular endothelial 
growth factor receptor-1, J. Biol. Chem,., 2004; 279: 10382–10388. 
61. Kimberly, F-W.; Kurtagic, E.; Nugent, M.A. Complex receptor-ligand 
dynamics control the response of the VEGF system. Bmc Systems bioloy, 
2011; 5:170. 
62. Maharaj, A. S.; Saint-Geniez, M.; Maldonado, A. E.; D’Amore, P. A. 
Vascular endothelial growth factor localization in the adult. Am. J. Pathol., 
2006; 168: 639−648. 
63. Kanno, S.; Oda, N.; Abe, M.; Terai, Y.; Ito, M.; Shitara, K.; Tabayashi, K.; 
Shibuya, M.; Sato Y. Roles of two VEGF receptors, Flt-1 and KDR, in the 
signal transduction of VEGF effects in human vascular endothelial cells. 
Oncogene, 2000; 19, 2138–2146. 
64. Carmeliet, P.; Moons, L.; Luttun, A.; Vincenti, V.; Compernolle, V.; De Mol, 
M.; Wu, Y.; Bono, F.; Devy, L.; Beck, H.; Scholz, D.; Acker, T.; Di Palma, 
T.; Dewerchin, M.; Noel, A.; Stalmans, I.; Barra, A.; Blacher, S.; 
Vandendriessche, T.; Ponten, A.; Eriksson, U.; Plate, K. H.; Foidart, J. M.; 
Schaper, W.; Charnock Jones, D. S.; Hicklin, D. J.; Herbert, J. M.; Collen, D.; 
References 
120 
Persico, M. G. Synergism between vascular endothelial growth factor and 
placental growth factor contributes to angiogenesis and plasma extravasation 
in pathological conditions. Nat. Med., 2001; 7: 575−583. 
65. Zhao, Q.; Egashira, K.; Hiasa, K.; Ishibashi, M.; Inoue, S.; Ohtani, K.; Tan, 
C.; Shibuya, M.; Takeshita, A.; Sunagawa, K. Essential role of vascular 
endothelial growth factor and Flt-1 signals in neointimal formation after 
periadventitial injury. Arterioscler., Thromb., Vasc. Biol., 2004; 24: 
2284−2289. 
66. Jackson, M. W.; Roberts, J. S.; Heckford, S. E.; Ricciardelli, C.; Stahl, J.; 
Choong, C.; Horsfall, D. J.; Tilley, W. D. A potential autocrine role for 
vascular endothelial growth factor in prostate cancer. Cancer Res., 2002; 62: 
854−859. 
67. Yang, A. D.; Camp, E. R.; Fan, F.; Shen, L.; Gray, M. J.; Liu, W.; Somcio, R.; 
Bauer, T. W.; Wu, Y.; Hicklin, D. J.; Ellis, L. M. Vascular endothelial growth 
factor receptor-1 activation mediates epithelial to mesenchymal transition in 
human pancreatic carcinoma cells. Cancer Res., 2006; 66: 46−51. 
68. Frank, N. Y.; Schatton, T.; Kim, S.; Zhan, Q.; Wilson, B. J.; Ma, J.; Saab, K. 
R.; Osherov, V.; Widlund, H. R.; Gasser, M.; Waaga- Gasser, A. M.; Kupper, 
T. S.; Murphy, G. F.; Frank, M. H. VEGFR-1 expressed by malignant 
melanoma-initiating cells is required for tumor growth. Cancer Res., 2011; 71: 
1474−1485. 
69. Roybal, J. D.; Zang, Y.; Ahn, Y. H.; Yang, Y.; Gibbons, D. L.; Baird, B. N.; 
Alvarez, C.; Thilaganathan, N.; Liu, D. D.; Saintigny, P.; Heymach, J. V.; 
Creighton, C. J.; Kurie, J. M. miR-200 Inhibits lung adenocarcinoma cell 
invasion and metastasis by targeting Flt1/ VEGFR1. Mol Cancer Res., 2011; 
9: 25−35. 
70. Kaplan, R. N.; Riba, R. D.; Zacharoulis, S.; Bramley, A. H.; Vincent, L.; 
Costa, C.; MacDonald, D. D.; Jin, D. K.; Shido, K.; Kerns, S. A.; Zhu, Z.; 
Hicklin, D.; Wu, Y.; Port, J. L.; Altorki, N.; Port, E. R.; Ruggero, D.; 
Shmelkov, S. V.; Jensen, K. K.; Rafii, S.; Lyden, D. VEGFR1-positive 
haematopoietic bone marrow progenitors initiate the pre-metastatic niche. 
Nature, 2005; 438: 820−827. 
References 
121 
71. Kendall, R.L.; Thomas, K.A. Inhibition of vascular endothelial cell growth 
factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. 
Sci.USA, 1993; 90: 10705–10709. 
72. Wu, F. T.; Stefanini, M. O.; Mac Gabhann, F.; Kontos, C. D.; Annex, B. H.; 
Popel, A. S. A systems biology perspective on sVEGFR1: its biological 
function, pathogenic role and therapeutic use. J. Cell. Mol. Med., 2010; 14: 
528−552. 
73. Fong, G.H.; Rossant, J.; Gertsenstein, M.; Breitman, M.L. Role of the Flt-1 
receptor tyrosine kinase in regulating the assembly of vascular endothelium. 
Nature, 1995; 376: 66–70. 
74. Hiratsuka, S.; Minowa, O.; Kuno, J.; Noda, T.; Shibuya, M. Flt-1 lacking the 
tyrosine kinase domain is sufficient for normal development and angiogenesis 
in mice. Proc. Natl. Acad. Sci. USA,1998; 95: 9349–9354. 
75. Hiratsuka, S.; Nakao, K.; Nakamura, K.; Katsuki, M.; Maru, Y.; Shibuya, M. 
Membrane fixation of vascular endothelial growth factor receptor 1 ligand- 
binding domain is important for vasculogenesis and angiogenesis in mice. 
Mol. Cell. Biol., 2005; 25: 346–354. 
76. McColl, B. K.; Baldwin, M. E.; Roufail, S.; Freeman, C.; Moritz, R. L.; 
Simpson, R. J.; Alitalo, K.; Stacker, S. A. and Achen, M. G. Plasmin activates 
the lymphangiogenic growth factors VEGF-C and VEGF-D. J. Exp. Med., 
2003; 198: 863–868. 
77.  Albuquerque, R. J.; Hayashi, T.; Cho, W. G.; Kleinman, M. E.; Dridi, S.; 
Takeda, A.; Baffi, J. Z.; Yamada, K.; Kaneko, H.; Green, M. G.; et al. 
Alternatively spliced vascular endothelial growth factor receptor-2 is an 
essential endogenous inhibitor of lymphatic vessel growth. Nat. Med., 2009; 
15: 1023–1030. 
78. J. Waltenberger, L.; Claesson-Welsh, A.; Siegbahn, M.; Shibuya, C.H. 
Different signal transduction properties of KDR and Flt1, two receptors for 
vascular endothelial growth factor. J. Biol. Chem., 1994; 269: 26988–26995. 
79. Matsumoto, T.; Bohman, S.; Dixelius, J.; Berge, T.; Dimberg, A.; Magnusson, 
P.; Wang, L.; Wikner, C.; Qi, J.H.; Wernstedt, C.; Wu, J.; Bruheim, S.; 
Mugishima, H.; Mukhopadhyay, D.; Spurkland, A.; Claesson-Welsh, L. 
References 
122 
VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in 
tumor angiogenesis. EMBO J., 2005;  24: 2342–2353. 
80. Shalaby, F.; Rossant, J.; Yamaguchi, T.P.; Gertsenstein, M.; Wu, X.F.M; 
Breitman, M.L.; Schuh, A.C. Failure of blood-island formation and 
vasculogenesis in Flk-1-deficient mice. Nature, 1995; 376: 62–66. 
81 Hughes, D.C. Alternative splicing of the human VEGFGR-3/FLT4 gene as a 
consequence of an integrated human endogenous retrovirus. J. Mol. Evol., 
2001; 53: 77–79. 
82. Aprelikova, O.; Pajusola, K.; Partanen, J.; Armstrong, E.; Alitalo, R.; Bailey, 
S. K.; McMahon, J.; Wasmuth, J.; Huebner, K. and Alitalo, K. FLT4 , a novel 
class III receptor tyrosine kinase in chromosome 5q33-qter. Cancer Res., 
1992; 52: 746–748. 
83. Ma kinen, T.; Veikkola, T; Mustjoki, S.; Karpanen, T.; Catimel, B.; Nice, E. 
C.; Wise, L.; Mercer, A.; Kowalski, H.; Kerjaschki, D.; Stacker, S. A.; Achen, 
M. G.; Alitalo, K. Isolated lymphatic endothelial cells transduce growth, 
survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO 
J., 2001; 20: 4762−4773. 
84. Su, J. L.; Yen, C. J.; Chen, P. S.; Chuang, S. E.; Hong, C. C.; Kuo, I. H.; 
Chen, H. Y.; Hung, M. C.; Kuo, M. L. The role of the VEGF-C/VEGFR-3 
axis in cancer progression. Br. J. Cancer, 2007; 96: 541−545. 
85. Achen, M. G.; Mann, G. B.; Stacker, S. A. Targeting lymphangiogenesis to 
prevent tumour metastasis. Br. J. Cancer, 2006; 94: 1355−1360. 
86. Dumont, D.J.; Jussila, L.; Taipale, J.; Lymboussaki, A.; Mustonen, T.; 
Pajusola, KP.; Breitman, M.; Alitalo, K. Cardiovascular failure in mouse 
embryos deficient in VEGF receptor-3. Science, 1998; 282:946–949. 
87. Xu, D., Fuster, M.; Lawrence, M.; and Esko, J. D. Heparan sulfate regulates 
VEGF165- and VEGF121-mediated vascular hyperpermeability. J. Biol. 
Chem., 2011; 286: 737–745. 
88. Stringer, S. E. The role of heparan sulphate proteoglycans in angiogenesis. 
Biochem. Soc. Trans., 2006; 34: 451–453. 
References 
123 
89. Fujisawa, H.; Kitsukawa, T.; Kawakami, A.; Takagi, S.; Shimizu, M. and 
Hirata, T. Roles of a neuronal cell-surface molecule, neuropilin, in nerve fiber 
fasciculation and guidance. Cell Tissue Res., 1997; 290: 465–470. 
90. Kawamura, H.; Li, X.; Goishi, K.; van Meeteren; L. A., Jakobsson, L.; Cebe-
Suarez, S.; Shimizu, A.; Edholm, D.; Ballmer-Hofer, K.; Kjellen, L. et al. 
Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and 
endothelial cell organization. Blood, 2008; 112: 3638–3649. 
91. Becker, P. M.; Waltenberger, J.; Yachechko, R.; Mirzapoiazova, T.; Sham, J. 
S.; Lee, C. G.; Elias, J. A. and Verin, A. D. Neuropilin-1 regulates vascular 
endothelial growth factor-mediated endothelial permeability. Circ. Res., 2005; 
96: 1257–1265. 
92. Pan, Q.; Chanthery, Y.; Liang, W. C.; Stawicki, S.; Mak, J.; Rathore, N.; 
Tong, R. K.; Kowalski, J.; Yee, S. F.; Pacheco, G. et al. Blocking neuropilin-1 
function has an additive effect with anti-VEGF to inhibit tumor growth. 
Cancer Cell, 2007 ;11: 53–67. 
93. Caunt, M.; Mak, J.; Liang, W. C.; Stawicki, S.; Pan, Q.; Tong, R. K.; 
Kowalski, J.; Ho, C.; Reslan, H. B.; Ross, J. et al. Blocking neuropilin-2 
function inhibits tumor cell metastasis. Cancer Cell, 2008;  13: 331–342. 
94. Hanks, S.K.; Quinn, A.M.; Hunter, T.The protein kinase family: conserved 
features and deduced phylogeny of the catalytic domains. Science, 1988; 
241:42–52. 
95. Kornev, A.P.; Haste, N.M.; Taylor, S.S.; Eyck, L.F. Surface comparison of 
active and inactive protein kinases identifies a conserved activation 
mechanism. Proc. Natl. Acad. Sci. USA, 2006; 103: 17783–17788. 
96. Coultas, L.; Chawengsaksophak, K.; Rossant, J. Endothelial cells and VEGF 
in vascular development. Nature, 2005; 438: 937–45. 
97. Folkman J.; Heymach J.; Kalluri RT. Tumor angiogenesis. In: Kufe, DW.; 
Bast Jr, RC.; Hite, WH.; Hong, WK.; Pollack, RE.; Weichselbaum, RR.; et al., 
editors. Cancer medicine. 7th ed. Hamilton, Ontario: B.C. Decker; 2006, p. 
157–91. 
98. Bridges, E.M.; Harris, A.L.The angiogenic process as a therapeutic target in 
cancer, Biochem. Pharmacol., 2011; 81: 1183–1191. 
References 
124 
99 Tugues, S.; Koch, S.; Gualandi, L.; Li, X. Vascular endothelial growth factors 
and receptors: Anti-angiogenic therapy in the treatment of cancer. Molec. Asp. 
of Med., 2011; 32: 88–111. 
100. Ebos, J.M.; Lee, C.R.; Cruz-Munoz, W.; Bjarnason, G.A.; Christensen, J.G.; 
Kerbel, R.S. Accelerated metastasis after short-term treatment with a potent 
inhibitor of tumor angiogenesis. Cancer Cell, 2009; 15 (3): 232–239. 
101. Paez-Ribes, M.; Allen, E.; Hudock, J.; Takeda, T.; Okuyama, H.; Vinals, F.; 
Inoue, M.; Bergers, G.; Hanahan, D.; Casanovas, O. Antiangiogenic therapy 
elicits malignant progression of tumors to increased local invasion and distant 
metastasis. Cancer Cell, 2009; 15 (3): 220–231. 
102. Bergers, G. & Hanahan, D. Modes Of Resistance To Anti-Angiogenic 
Therapy. Nat. Rev. Cancer, 2008; 592–603. 
103. Miles, D. et al. Disease course patterns after discontinuation of bevacizumab: 
pooled analysis of randomized phase III trials. J. Clin. Oncol., 2011; 29: 83–
88. 
104. Liu, AY; Robinson, RR.; Hellstrom, KE.; Murray, ED. Jr; Chang, CP.; 
Hellstrom, I. Chimeric mouse-human igG1 antibody that can mediate lysis of 
cancer cells. Proc Natl Acad Sci USA, 1897; 84: 3439-3443. 
105. Riechmann, L.; Clark, M.; Waldmann, H.; Winter, G. Reshaping human 
antibodies for therapy. Nature, 1988; 332: 323-327. 
106. Dy GK and Adjei AA. Systemic cancer therapy: evolution over the last 60 
years. Cancer, 2008;  113: 1857-87. 
107. Ranieri, G.; Patrono, R.; Ruggirei, E.; Montemurro, S.; Valerio, P.; Ribatti, D. 
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in 
cancer: from the biology to the clinic. Curr Med Chem, 2006; 13: 1845-1857. 
108. Ton, N.C.; Parker, G.J. ; Jackson, A. ;et al. Phase I evaluation of CDP791, a 
PEGylated di-Fab' conjugate that binds vascular endothelial growth factor 
receptor 2. Clin Cancer Res, 2007; 13: 7113–8. 
109. Posey, J.A.; Ng, T.C.; Yang, B.; et al., A phase I study of anti-kinase insert 
domain-containing receptor antibody, IMC-1C11, in patients with liver 
metastases from colorectal carcinoma. Clin Cancer Res, 2003; 9: 1323–32. 
References 
125 
110. Brooks, PC.; Clark, RA.; Cheresh, DA. Requirement of vascular integrin αvβ3 
for angiogenesis. Sciences, 1994; 264: 569-571. 
111. Mulgrew, K.; Kinner, K.; Yao, XT.; Ward, BK.; Damschroder, MM.; Walsh, 
B.; Mao, SY.; Gao, C.; Kiener, PA.; Coats, S.; Kinch, MS.; Tice, DA: Direct 
targeting of αvβ3 integrin on tumor cells with a mocolonal antibody, Abegrin. 
Molecular cancerTher, 2006; 5: 3122-3129. 
112. Dass, CR.; Tran, TM.; Choong, PF. Angiogenesis inhibitors and the need for 
anti-angiogenic therapeutics. J Dent Re, 2007; 86: 927-936. 
113. Koutras, AK; Kalogeras, KT; Dimopoulos, M;, et al. Evaluation of the 
prognostic and predictive value of HER family mRNA expression in high-risk 
early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. 
Br J Cancer, 2008; 99: 1775-85. 
114. Ruiz, M.; Floor, K.; Steinberg, S.; et al. Combined assessment of EGFR 
pathway-related molecular markers and prognosis of NSCLC patients. Br J 
Cancer, 2008. 
115. Bonner, JA.; Harari, PM.; Giralt, J.; et al. Radiotherapy plus cetuximab for 
squamous-cell carcinoma of the head and neck.. N Engl J Med, 2006; 354: 
567-78. 
116. Cunningham, D.; Humblet, Y.; Siena, S.; et al. Cetuximab monotherapy and 
cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. 
N Engl J Med, 2004; 351: 337-45. 
117. Pirker, R.; Szczesna, A.; von Pawel, J.; and al e. FLEX: A randomized 
multicenter, phase III study of cetuximab in combination with cis-
platin/vinorelbine (CV) versus CV alone in the first-line treatment of patients 
with advanced non-small cell lung cancer (NSCLC). Proc. Am J Oncol, 2008; 
26: abstract 3. 
118. Piccart-Gebhart, MJ. Adjuvant trastuzumab therapy for HER2-overexpressing 
breast cancer: what we know and what we still need to learn. Eur J Cancer, 
2006; 42: 1715-9. 
119. Gasparini, G.; Gion, M.; Mariani, L.; et al. Randomized Phase II Trial of 
weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line 
References 
126 
therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer 
Res Treat, 2007; 101: 355-65. 
120. Slamon, DJ.; Leyland-Jones, B.; Shak, S.;, et al. Use of chemotherapy plus a 
monoclonal antibody against HER2 for metastatic breast cancer that 
overexpresses HER2. N Engl J Med, 2001; 344: 783-92. 
121. Socinski, MA. Antibodies to the epidermal growth factor receptor in non 
small cell lung cancer: current status of matuzumab and panitumumab Clin 
Cancer Res, 2007; 13: 4597-601. 
122. Kiewe, P.; Hasmuller, S.; Kahlert, S.; et al. Phase I trial of the trifunctional 
anti-HER2 x antiCD3 antibody ertumaxomab in metastatic breast cancer. Clin 
Cancer Res, 2006; 12: 3085-91. 
123. Casaco, A.; Lopez, G.; Garcia, I.; et al. Phase I single-dose study of 
intracavitary-administered Nimotuzumab labeled with 188 Re in adult 
recurrent high-grade glioma. Cancer Biol Ther, 2008; 7: 333-9. 
124. Druker, BJ.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, GM.; Fanning, S.; 
Zimmermann, J.; Lydon, NB. Effects of a selective inhibitor of the Abl 
tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 1996; 561-
566. 
125. Lugo, TG.; Pendergast, AM.; Muller, AJ.; Witte, ON. Tyrosine kinase activity 
and transformation potency of bcr-abl oncogene products. Science, 1990; 247: 
1079-1082. 
126. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, 
imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug 
Discov., 2002; 1: 493-502. 
127. Casanovas, O., Hicklin, D. J.; Bergers, G.; and Hanahan D.. Drug resistance 
by evasion of antiangiogenic targeting of VEGF signaling in late-stage 
pancreatic islet tumors, Cancer Cell, 2005; 8: 299–309. 
128. Imai K.;and Takaoka, A. Comparing antibody and small-molecules therapies 
for cancer. Nature Reviews Cancer, 2006; 6: 714–727. 
129. Leary, A.; Johnston, S.R. Small molecule signal transduction inhibitors for the 
treatment of solid tumors. Cancer invest, 2007; 25: 347-365.  
References 
127 
130. Gille, J.; Heidenreich, R.; Pinter, A.; Schmitz, J.; Boehme, B.; Hicklin, D. J.; 
Henschler, R.; Breier, G. Simultaneous blockade of VEGFR-1 and VEGFR-2 
activation is necessary to efficiently inhibit experimental melanoma growth 
and metastasis formation. Int. J. Cancer., 2007; 120: 1899−908. 
131. Trumpp-Kallmeyer, S.; Rubin, J.R.; Humblet, C.; Hamby, J.M.; Showalter, 
H.D.H. Development of binding model to protein tyrosine kinases for 
substituted pyrido[2,3-d]pyrimidine inhibitors. Journal of Medicinal 
Chemistry, 1998; 41: 1752-1763. 
132. Cook, K.M.; and Figg W.D. Angiogenesis Inhibitors – Current Strategies and 
Future Prospects. CA Cancer J Clin., 2010; 60: 222–243. 
133. Garuti, L.; Roberti, M.; and Bottegoni, G. Non-ATP Competitive Protein 
Kinase Inhibitors. Current Medicinal Chemistry, 2010; 17: 2804-2821. 
134. Jain, RK. Normalizing tumor vasculature with anti-angiogenic therapy; a new 
paradigm for combination therapy. Nat Med., 2001; 7: 987-989. 
135. Jain, RK. Normalization of tumor vasculature: an emerging concept in 
antiangiogenic therapy. Science, 2005; 307: 58-62. 
136. Morphy, R. Selectively Nonselective Kinase Inhibition: Striking the Right 
Balance J. Med. Chem., 2010; 53: 1413–1437. 
137. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple 
ligands. Drug Discovery Today, 2004; 9: 641–651. 
138. Siegel-Lakhai, WS.; Beijnen, JH.; and Schellens, JH. Current knowledge and 
future directions of the selective epidermal growth factor receptor inhibitors 
erlotinib (Tarceva) and gefitinib (Iressa). Oncologist, 2005; 10: 579-89. 
139. Shepherd, FA.; Pereira, J., Ciuleanu, T., et al. Erlotinib in previously treated 
non-small-cell lung cancer. N Engl J Med, 2005; 353: 123-32. 
140. Lynch, TJ.; Bell, DW.; Sordella, R..; et al. Activating mutations in the 
epidermal growth factor receptor underlying responsiveness of non-small-cell 
lung cancer to gefitinib. N Engl J Med, 2004; 350: 2129-39. 
141. Reid, A.; Vidal, L.; Shaw, H.; and de Bono, J. Dual inhibition of ErbB1 
(EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer, 2007; 43: 481-9. 
142. Geyer, CE.; Forster, J.; Lindquist, D.; et al. Lapatinib plus capecitabine for 
HER2-positive advanced breast cancer. N Engl J Med, 2006; 355: 2733-43. 
References 
128 
143. Chang, JE.; Robins, HI.; and Mehta, MP. Therapeutic advances in the 
treatment of brain metastases. Clin Adv Hematol Oncol, 2007; 5: 54-64. 
144. Irby, R.B.; and Jiang, Y. Tyrosine Kinase Update: Role and Response in 
Cancer Therapy, Curr. Cancer Ther. Rev., 2011; 7: 155-166. 
145. Natoli, C.; Perrucci, B.; Perrotti, F.; Falchi, L; and Iacobelli, S.; on behalf of 
Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO), 
Tyrosine Kinase Inhibitors. Current Cancer Drug Targets, 2010; 10: 462-483. 
146. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R. A.; 
Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of 
sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug 
Discovery 2006, 5: 835−844. 
147. Woo, H. Y.; Heo, J. Sorafenib in liver cancer. Exp. Opin. Pharmacother., 
2012; 13: 1059−1067. 
148. Calvisi, D. F.; Ladu, S.; Gorden, A.; Farina, M.; Conner, E. A.; Lee, J. S.; 
Factor, V. M.; Thorgeirsson, S. S. Ubiquitous activation of Ras and Jak/Stat 
pathways in human HCC. Gastroenterology, 2006; 130: 1117−1128. 
149. Gedaly, R.; Angulo, P.; Chen, C.; Creasy, K. T.; Spear, B. T.; Hundley, J.; 
Daily, M. F.; Shah, M.; Evers, B. M. The role of PI3K/ mTOR inhibition in 
combination with sorafenib in hepatocellular carcinoma treatment. Anticancer 
Res., 2012; 32: 2531−2536. 
150. Schenone, S.; Brullo, C.; Botta, M. Small molecules ATP competitive 
inhibitors of FLT3: a chemical overview. Curr. Med. Chem., 2008; 15: 
3113−3132. 
151. Roskoski, R.; Sunitinib: a VEGF and PDGF receptor protein kinase and 
angiogenesis inhibitor. Biochem. Biophys. Res. Commun., 2007; 356: 
323−328. 
152. Harris, P. A.; Boloor, A.; Cheung, M.; Kumar, R.; Crosby, R. M.; Davis-
Ward, R. G.; Epperly, A. H.; Hinkle, K. W.; Hunter, R. N. , 3rd; Johnson, J. 
H.; Knick, V. B.; Laudeman, C. P.; Luttrell, D. K.; Mook, R. A.; Nolte, R. T.; 
Rudolph, S. K.; Szewczyk, J. R.; Truesdale, A. T.; Veal, J. M.; Wang, L.; 
Stafford, J. A. Discovery of 5-[[4-[(2,3-dimethyl-2Hindazol-6-yl) 
methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide 
References 
129 
(pazopanib), a novel and potent vascular endothelial growth factor receptor 
inhibitor. J. Med. Chem. 2008; 51: 4632−4640. 
153. Lee, J.H.; Canny, M.D.; De Erkenez, A.; Krilleke, D.; Ng, Y.S.; Shima, D.T.; 
Pardi, A.; Jucker, F. Proc. Natl. Acad. Sci. USA, 2005; 102: 18902. 
154. Commander, H.; Whiteside, G.; Perry, C. Vandetanib: first global approval. 
Drugs, 2011; 71: 1355−1365. 
155. Knowles, P. P.; Murray-Rust,  .; Kjaer, S.; Scott, R. P.; Hanrahan, S.; Santoro, 
M.; Ib  ez, C. F.; McDonald, N.  . Structure and chemical inhibition of the 
RET tyrosine kinase domain. J. Biol. Chem., 2006; 281: 33577−33587. 
156. Wedge, S. R.; Kendrew, J.; Hennequin, L. F.; Valentine, P. J.; Barry, S. T.; 
Brave, S. R.; Smith, N. R.; James, N. H.; Dukes, M.; Curwen, J. O.; Chester, 
R.; Jackson, J. A.; Boffey, S. J.; Kilburn, L. L.; Barnett, S.; Richmond, G. H.; 
Wadsworth, P. F.; Walker, M.; Bigley, A. L.; Taylor, S. T.; Cooper, L.; Beck, 
S.; Jurgensmeier, J. M.; Ogilvie, D. J. AZD2171: a highly potent, orally 
bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase 
inhibitor for the treatment of cancer. Cancer Res., 2005; 65: 4389−4400.  
157. Lindsay, C. R.; MacPherson, I. R.; Cassidy, J. Current status of cediranib: the 
rapid development of a novel anti-angiogenic therapy. Future Oncol., 2009; 5: 
421−432. 
158. Batchelor, T. T.; Duda, D. G.; di Tomaso, E.; Ancukiewicz, M.; Plotkin, S. R.; 
Gerstner, E.; Eichler, A. F.; Drappatz, J.; Hochberg, F. H.; Benner, T.; Louis, 
D. N.; Cohen, K. S.; Chea, H.; Exarhopoulos, A.; Loeffler, J. S.; Moses, M. 
A.; Ivy, P.; Sorensen, A. G.; Wen, P. Y.; Jain, R. K. Phase II study of 
cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine 
kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol., 2010; 
28: 2817−2823. 
159. Sorensen, A. G.; Emblem, K. E.; Polaskova, P.; Jennings, D.; Kim, H.; 
Ancukiewicz, M.; Wang, M.; Wen, P. Y.; Ivy, P.; Batchelor, T. T.; Jain, R. K. 
Increased survival of glioblastoma patients who respond to antiangiogenic 
therapy with elevated blood perfusion. Cancer Res. 2012; 72: 402−407. 
160. Mulders, P.; Hawkins, R.; Nathan, P.; de Jong, I.; Osanto, S.; Porfiri, E.; 
Protheroe, A.; van Herpen, C. M.; Mookerjee, B.; Pike, L.; Ju  rgensmeier, J. 
References 
130 
M.; Gore, M. E. Cediranib monotherapy in patients with advanced renal cell 
carcinoma: results of a randomised phase II study. Eur. J. Cancer, 2012; 48: 
527−537. 
161. Garland, L. L.; Chansky, K.; Wozniak, A. J.; Tsao, A. S.; Gadgeel, S. M.; 
Verschraegen, C. F.; Dasilva, M. A.; Redman, M.; Gandara, D. R. Phase II 
study of cediranib in patients with malignant pleural mesothelioma: SWOG 
S0509. J. Thorac. Oncol., 2011; 6: 1938− 1945. 
162. Alberts, S. R.; Fitch, T. R.; Kim, G. P.; Morlan, B. W.; Dakhil, S. R.; Gross, 
H. M.; Nair, S. Cediranib (AZD2171) in patients with advanced hepatocellular 
carcinoma: a phase II north central cancer treatment troup clinical trial. Am. J. 
Clin. Oncol., 2012; 35: 329−333. 
163. Yakes, F. M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.; Yu, P.; Qian, F.; Chu, 
F.; Bentzien, F.; Cancilla, B.; Orf, J.; You, A.; Laird, A. D.; Engst, S.; Lee, L.; 
Lesch, J.; Chou, Y. C.; Joly, A. H. Cabozantinib (XL184), a novel MET and 
VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and 
tumor growth. Mol. Cancer Ther. 2011; 10: 2298−2308. 
164. Zhang, Y.; Guessous, F.; Kofman, A.; Schiff, D.; Abounader, R. XL-184, a 
MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, 
glioblastoma multiforme and NSCLC. IDrugs, 2010; 13: 112−121. 
165. Bowles, D. W.; Kessler, E. R.; Jimeno, A. Multi-targeted tyrosine kinase 
inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs 
Today, 2011; 47: 857−868. 
166. Durante, C.; Russo, D.; Verrienti, A.; Filetti, S. XL184 (cabozantinib) for 
medullary thyroid carcinoma. Expert Opin. Invest. Drugs, 2011; 20: 407−413 
167. Zillhardt, M.; Park, S. M.; Romero, I. L.; Sawada, K.; Montag, A.; Krausz, T.; 
Yamada, S. D.; Peter, M. E.; Lengyel, E. Foretinib (GSK1363089), an orally 
available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, 
induces anoikis, and impairs ovarian cancer metastasis. Clin. Cancer Res., 
2011; 17: 4042−4051. 
168. Huynh, H.; Ong, R.; Soo, K. C. Foretinib demonstrates antitumor activity and 
improves overall survival in preclinical models of hepatocellular carcinoma. 
Angiogenesis, 2012; 15: 59−70. 
References 
131 
169. Nakamura, K.; Taguchi, E.; Miura, T.; Yamamoto, A.; Takahashi, K.; Bichat, 
F.; Guilbaud, N.; Hasegawa, K.; Kubo, K.; Fujiwara, Y.; Suzuki, R.; Kubo, 
K.; Shibuya, M.; Isoe, T. KRN951, a highly potent inhibitor of vascular 
endothelial growth factor receptor tyrosine kinases, has antitumor activities 
and affects functional vascular properties. Cancer Res., 2006; 66: 9134−9142. 
170. Eskens, F. A.; Planting, A.; Van Doorn, L.; Isoe, T.; Hayashi, K.; Hussain, S.; 
Ekman, L.; Burger, H.; Verweij, J. An open-label phase I dose escalation 
study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth 
factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with 
advanced solid tumors. J. Clin. Oncol., 2006; 24: 2034 ; Asco Meeting 
Abstracts. 
171. De Luca, A.; Normanno, N. Tivozanib, a pan-VEGFR tyrosine kinase 
inhibitor for the potential treatment of solid tumors. IDrugs, 2010; 13: 
636−645. 
172. Bruheim, S.; Kristian, A.; Uenaka, T.; Suo, Z.; Tsuruoka, A.; Nesland, J. M.; 
Fodstad, Ø. Antitumour activity of oral E7080, a novel inhibitor of multiple 
tyrosine kinases, in human sarcoma xenografts. Int. J. Cancer, 2011; 129: 
742−750. 
173. Gild, M. L.; Bullock, M.; Robinson, B. G.; Clifton-Bligh, R. Multikinase 
inhibitors: a new option for the treatment of thyroid cancer. Nat. Rev. 
Endocrinol., 2011; 7: 617−624. 
174. Renhowe, P. A.; Pecchi, S.; Shafer, C. M.; Machajewski, T. D.; Jazan, E. M.; 
Taylor, C.; Antonios-McCrea, W.; McBride, C. M.; Frazier, K.; Wiesmann, 
M.; Lapointe, G. R.; Feucht, P. H.; Warne, R. L.; Heise, C. C.; Menezes, D.; 
Aardalen, K.; Ye, H.; He, M.; Le, V.; Vora, J.; Jansen, J. M.; Wernette-
Hammond, M. E.; Harris, A. L. Design, structure−activity relationships and in 
vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a 
novel class of receptor tyrosine kinase inhibitors. J. Med. Chem., 2009; 52: 
278−292. 
175. Lee, S. H.; Lopes de Menezes, D.; Vora, J.; Harris, A.; Ye, H.; Nordahl, L.; 
Garrett, E.; Samara, E.; Aukerman, S. L.; Gelb, A. B.; Heise, C. In vivo target 
modulation and biological activity of CHIR-258, a multitargeted growth factor 
References 
132 
receptor kinase inhibitor, in colon cancer models. Clin. Cancer Res., 2005; 11: 
3633−3641. 
176. Kanai, F.; Yoshida, H.; Tateishi, R.; Sato, S.; Kawabe, T.; Obi, S.; Kondo, Y.; 
Taniguchi, M.; Tagawa, K.; Ikeda, M.; Morizane, C.; Okusaka, T.; Arioka, H.; 
Shiina, S.; Omata, M. A phase I/II trial of the oral antiangiogenic agent TSU-
68 in patients with advanced hepatocellular carcinoma. Cancer Chemother. 
Pharmacol., 2011; 67: 315−324. 
177. Toi, M.; Saeki, T.; Iwata, H.; Inoue, K.; Tokuda, Y.; Sato, Y.; Ito, Y.; Aogi, 
K.; Takatsuka, Y.; Arioka, H. A multicenter phase II study of TSU-68, an oral 
multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic 
breast cancer patients with anthracycline resistance. Breast cancer. Published 
Online: Mar 2, 2012. 
178. Roth, G. J.; Heckel, A.; Colbatzky, F.; Handschuh, S.; Kley, J.; Lehmann-
Lintz, T.; Lotz, R.; Tontsch-Grunt, U.; Walter, R.; Hilberg, F. Design, 
synthesis, and evaluation of indolinones as triple angiokinase inhibitors and 
the discovery of a highly specific 6- methoxycarbonyl-substituted indolinone 
(BIBF 1120). J. Med. Chem., 2009; 52: 4466−4480. 
179. Bold, G.; Altmann, K.H.; Frei, J.; Lang, M.; Manley, P.W.; Traxler, P.; 
Wietfeld, B.; Brüggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.;  Hofmann, 
F.; Martiny-Baron, G.; Mestan, J.; Rösel, J.; Sills, M.; Stover, D.; Acemoglu, 
F.; Boss, E.; Emmenegger, R.; Lässer, L.; Masso, E.; Roth, R.; Schlachter, C.; 
Vetterli, W.; Wyss, D.; Wood, J. Journal of Medicinal Chemistry, 2000; 43:  
2310-2323. 
180. Manley, P.W.;  Furet, P.; Bold, G.; Brüggen, J.; Mestan, J.; Meyer, T.; 
Schnell, C.R.; Wood, J.; Huth, A.; Krüger, M.; Menrad, A.; Ottow, E.; 
Seidelmann, D.; Siemeister, G.; Thierauch, K.H. Journal of Medicinal 
Chemistry, 2002; 45: 5687-5693. 
181. Manley, P.W.; Bold, G.; Brüggen, J.;Fendrich, G.; Furet, P.; Mestan, J.; 
Schnell, C.; Stolz, B.; Meyer, T.; Meyhack, B.; Stark, W.; Strauss, A.; Wood, 
J. Biochim. Biophys. Acta Proteins Proteomics, 2004; 1697: 17-27. 
References 
133 
182. Papakyriakou, A.; Katsarou, M.E.; Belimezi, M.; Karpusas, M.; Vourloumis, 
D. Discovery of Potent Vascular Endothelial Growth Factor Receptor-2 
Inhibitors. ChemMedChem, 2010; 5: 118-129. 
183. Bold, G.; Furet, P.; Manley, P.W. WO200452884, 2004. 
184. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, 
imatinib), a rationale developed, targeted anticancer drug. Nat. Rev. Drug 
Discovery, 2002; 1: 493−502. 
185. Munchhof, M.J.; Beebe, J.S.; Casavant, J.M.; Cooper, B.A.; Doty. J.L.; 
Higdon, R.C.; Hillermann, S.R.; Soderstrom, C.I.; Knauth, E.A.; Marx, M.A.; 
Rossi, A.M.; Sobolov, S.B.; Sun, J. Bioorg. Med. Chem. Lett., 2004; 14: 21. 
186. Guo, X.N.; Zhong, L.; Tan, J.Z.; Li, J.; Luo, X.M.; Jiang, H.L.; Nan, F.J.; Lin, 
L.P.; Zhang, X.W.; Ding, J. Cancer Biol. Ther., 2005; 4: 1125. 
187. Huang, S.; Li, R.; Connolly, P.J.; Xu, G.; Gaul, M.D.; Emanuel, S.L.; 
Lamontagne, K.R.; Greenberger, L.M. Bioorg. Med. Chem. Lett., 2006; 16: 
6063. 
188. Manley, P.J.; Balitza, A.E.; Bilodeau, M.T.; Coll, K.E.; Hartman, G.D.; 
McFall, R.C.; Rickert, K.W.; Rodman, L.D.; Thomas, K.A. Bioorg. Med. 
Chem. Lett., 2003; 13: 1673. 
189. Emanuel, S.; Gruninger, R.H.; Fuentes-Pesquera, A.; Connolly, P.J.; Seamon, 
J.A.; Hazel, S.; Tominovich, R.; Hollister, B.; Napier, C.; D'Andrea, M.R.; 
Reuman, M.; Bignan, G.; Tuman, R.; Johnson, D.; Moffatt, D.; Batchelor, M.; 
Foley, A.; O'Connell, J.; Allen, R.; Perry, M.; Jolliffe, L.; Middleton, S.A. 
Mol. Pharmacol., 2004; 66: 635. 
190. Da Settimo, A.; Marini, A. M.; Primofiore, G.; Da Settimo, F.; Salerno, S.; 
Viola, G.; Dalla Via, L.; Marciani Magno, S. Eur. J. Med. Chem., 1998; 33: 
685. 
191. Da Settimo, A.; Marini, A. M.; Primofiore, G.; Da Settimo, F.; Salerno, S.; 
Dalla Via, L.; Gia, O.; Marciani Magno, S. Farmaco, 2001; 56: 159. 
192. Dalla Via, L.; Gia, O.; Marciani Magno, S.; Da Settimo, A.; Primofiore, G.; 
Da Settimo, F.; Simorini, F.; Marini, A. M. Eur. J. Med. Chem., 2002; 37: 
475. 
References 
134 
193. Dalla Via, L.; Marini, A. M.; Salerno, S.; Toninello, A. Biochem. Pharmacol., 
2006; 72: 1657. 
194. Marini, A. M.; Da Settimo, F.; Salerno, S.; La Motta, C.; Simorini, F.; Taliani, 
S.; Bertini, D.; Gia, O.; Dalla Via, L. J. Heterocycl. Chem., 2008; 45: 745-
749. 
195. Dalla Via, L.; Gia, O.; Marciani Magno, S.; Marini, A.M.; Salerno, S.; Da 
Settimo, F.; Fornaciari, G.; Simorini, F.; La Motta, C.; Taliani, S.; Synthesis, 
Antiproliferative Activity And VEGFR-2 Inhibition of New Anilino-
Substituted Thiopyrano Fused Pyrimidines, XX National meeting on 
Medicinal Chemistry, September 12-16 2010 Abano Terme-Padova. 
196. Fravolini, A.; Martani, A. Bollettino, 1968; 26: 277. 
197. Jimenez, J.; Green, J.; Gao, H.; Moon, Y.; Brenchley, G.; Knegtel, R.; Pierard, 
F.; Preparation of aminopyrimidine derivatives as inhibitors of protein 
kinases. U.S. Pat. Appl. Publ., 2005. 
198. Bold, G.; Altmann, K.H.; Frei, J.; Lang, M.; Manley, P.W.; Traxler, P.; 
Wietfeld, B.; Brüggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.;  Hofmann, 
F.; Martiny-Baron, G.; Mestan, J.; Rösel, J.; Sills, M.; Stover, D.; Acemoglu, 
F.; Boss, E.; Emmenegger, R.; Lässer, L.; Masso, E.; Roth, R.; Schlachter, C.; 
Vetterli, W.; Wyss, D.;Wood, J. Journal of Medicinal Chemistry, 2000; 43: 
2310-2323. 
199. Carboni, S.; Da Settimo, A.; Bertini, B.; Ferrarini, P.L.; Livi, O.; Tonetti, I. Il 
farmaco, 1975; 30: 237.  
200. Lehmann, G.; Luecke, B.; Wehlan, H.; Hilgetag, G. 5-Oxo-5,6,7,8-
tetrahydroquinazolines, From Ger. (East) (1968) DD 62062 19680605. b) 
Mosti, L.; Menozzi, G.; Schenone, P. Reaction of 2 dimethylaminomethylene-
1,3-diones with dinucleophiles. III. Synthesis of 5-acylpyrimidines and 7,8-
dihydroquinazolin-5(6H)-ones. Journal of Heterocyclic Chemistry, 1983; 20: 
649-654. 
201. Schenone, P.; Mosti, L.; Menozzi, G. Reaction of 2-dimethylaminomethylene-
1,3-diones with dinucleophiles. I. Synthesis of 1,5-disubstituted 4-
acylpyrazoles. Journal of Heterocyclic Chemistry, 1982; 19: 1355-1361. 
References 
135 
202. Bruno, O.; Schenone, S.; Ranise, A.; Bondavalli, F.; Filippelli, W.; Falcone, 
G.; Motola, G.; Mazzeo, F. Antiinflammatory agents: new series of N-
substituted amino acids with complex pyrimidine structures endowed with 
antiphlogistic activity. Farmaco, 1999; 54: 95-100. 
 
 
  
 
